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Abstract 
The  elucidation  of  the  complex  array  of  cell  signalling  cascades  is  imperative  for  a  deeper 
understanding  of  cell  biology  in  both  physiological  and  patho-physiological  states.    Extensive 
biochemical characterisation of signalling networks has revealed the importance of post-translational 
modifications (PTMs), particularly phosphorylation.  Signalling via protein phosphorylation occurs across 
homeostatic  proliferative,  differentiative  and  anti-apoptotic  events.    Dysregulation  of  the  kinase 
signalling pathways as well as mutations in kinases involved in phosphorylation have been implicated in 
a number of pathologies such as cancer or immune deficiencies.  While it is estimated that 50% of all 
proteins are phosphorylated during their lifetime, phosphorylated proteins are present in relatively low 
abundance compared to their non-phosphorylated counterparts.  The rarity of phosphorylation, which 
occurs  on  serine,  threonine  and  tyrosine  residues,  has  prompted  the  development  of  sensitive 
approaches  to  improve  phosphorylation  characterisation.    Proteomic-based  strategies  offer  novel 
approaches to overcome the limitations of currently available strategies for phosphoprotein analysis.  
The  research  presented  within  describes  the  development  of  proteomic-based  methodologies  for 
phosphotyrosine  identification,  quantitation  and  characterisation.    These  methods  utilise  the  anti-
phosphotyrosine  Antibody  4G10  along  with  other  MS-compatible  approaches  for  phosphotyrosine 
enrichment prior to MS analysis.  Methods for more targeted phosphoprotein analyses involved coupling 
of 4G10 covalently to super para-magnetic beads or by affinity to super para-magnetic beads with 
protein  G  covalently  attached.    These  4G10-coupled  beads  successfully  enriched  tyrosine 
phosphopeptides derived from tryptic phosphoprotein digests for identification and characterisation of 
phosphopeptides using MALDI-TOF/TOF MS analysis.   
 
The  limited  capacity  of  the  magnetic  bead  approach  for  analysis  of  more  complex  samples 
necessetated  the  development  of  a  more  global  proteomic  strategy  for  tyrosine  phosphorylation 
analysis.    A  global  strategy  that  provides  not  only  qualitative  pTyr  information  but  also  shows 
quantitative  changes  that  occur  with  pTyr  signalling  is  imperative  for  detailed  signalling  cascade 
analyses.    The  global  approach  presented  here  utilised  the  4G10  Ab/bead  approach  as  well  as 
Hydrophilic  interaction  chromatography  (HILIC)  for  the  enrichment  of  pTyr  peptides  from  complex 
samples  isotopically-labelled  to  quantify  tyrosine  phosphorylation  after  LC-MALDI-TOF/TOF  MS 
analysis.    Aspects  of  this  approach  were  modified  to  improve  phosphopeptide  detection  and 
characterisation, including the development of a novel optimised matrix-deposition strategy for LC-
MALDI-TOF/TOF MS.  The strategy, termed EZYprep LC, allowed the effective use of the atypical 2,5-xii 
 
DHB matrix with phosphoric acid to improve phosphopeptide ionisation and subsequently identify and 
characterise more phosphorylation sites on phosphoprotein samples compared with LC-ESI-IT-MS/MS. 
 
Another aspect of the global strategy was the development of a modified isotope protein coded label 
strategy (modified ICPL).  The optimised ICPL approach ensured quantitative information from a larger 
sub-set of peptides after tryptic digest of complex samples.  The improved ability to quantify using this 
approach  was  highlighted  by  a  comparative  analysis  of  complex  cell  lysates  labelled  using  the 
conventional  ICPL  strategy  and  the  modified  ICPL strategy.   The  modified  ICPL  labelling strategy 
identified  more  proteins  and  provided  more  quantitative  information  that  the  conventional  ICPL 
methodology.  As such, the global phospho-tyrosine strategy, combined the modified ICPL labelling and 
4G10  Ab/bead  enrichment  with  peptide  fractionation  and  MALDI-TOF/TOF  MS  analysis,  was 
subsequently utilised to identify and quantify tyrosine phosphorylation occurring in insulin-stimulated 
insulin receptor A- and B-subtypes. 
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Magnetic  bead  based  covalent  affinity  Chromatography  for  binding  of  freely 
selectable proteins 
MB-IAC Prot G  Magnetic bead based immunoaffinity Chromatography on immobilised protein G 
MB-IMAC Fe  Magnetic bead-IMAC Fe  
MCP  Microchannel plate 
MOAC  Metal oxide affinity Chromatography 
Mr  Relative molecular mass 
MRM  Multiple reaction monitoring 
MS  Mass Spectrometry 
MS/MS  Tandem MS 
NaF  Sodium fluoride 
nLC  Nano-LC 
NP-40  Nonidet P-40 
NTA  Nitriloacetic acid 
OVA  Ovalbumin 
PA  Phosphoric acid 
PAGE  poly-acrylamide gel electrophoresis 
PBS  Phosphate buffered saline 
pI  Isoelectric point 
PM1  Protein mix 1 (1 pmol BSA, 1 pmol OVA, 2 pmol β-cas) 
pmol  Picomole 
PMSF  Phenylmethanesulfonylfluoride 
Pro-GP  4G10 affinity-coupled MB-IAC Prot G 
PSD  Post-source decay 
pSer  Phosphoserine 
PTEN  Phosphatase and tensin homolog 
pThr  Phosphothreonine 
PTKs  Protein tyrosine kinases 
PTMs  Post-translational modifications 
PTPs  Protein tyrosine phosphatases 
pTyr/pY  Phosphotyrosine 
PVDF  Polyvinylidene fluoride xx 
 
Q  Quadrupole 
QQQ  Triple quadrupole 
qTOF/QTOF  Quadrupole time of flight 
Rf/RF  Radio frequency 
RIPA  Radioimmunoprecipitation assay buffer 
RP  Reverse Phase Chromatography 
R-ve  IGF-1R-deficient mouse embryo fibroblast 
SA  sinapinic acid 
SAX  Strong anion-exchange 
SCX  Strong cation-exchange 
SD  Standard deviation 
SDS  Sodium dodecyl sulphate 
SEC  Size exclusion Chromatography 
SF1  Sheath fluid containing 0.05% PA/0.05% TFA/50% ACN 
SILAC  Stable isotope labelling by amino acids in cell culture 
SILE  Stable isotope labelling experiment 
SIMAC  Sequential elution from IMAC 
SRM  Single reaction monitoring 
t  Time 
TBST  Tris-buffered saline Tween-20 
TED  Tris(carboxymethyl)ethylenediamine 
TFA  Trifluoroacetic acid 
TiO2  Titanium Dioxide 
TIS  Timed ion selector 
TL  Thin-layer 
TLC  Thin-layer Chromatography 
TOF  Time-of-Flight 
U  Voltage 
v  Velocity 
WAX  Weak anion-exchange  
WCX  Weak cation-exchange 
YAG  yttrium aluminium garnet 
z  Charge 
β-cas  β-casein 







The  term  Proteomics,  initially coined  in  1996 by Wilkins  [1]  is  the  name  given  for  identifying  and 
characterising the proteome of an organism.  The proteome consists of the entire protein complement 
expressed by the genome of a given cell at a given time.  Identical organisms can have the same 
genome yet display an almost unrecognisable proteome.  The completion of the human genome project 
saw  the  realisation  that  a  deeper  understanding  of  the  proteins  involved  in  normal  function  and 
pathology was required as a certain level of gene transcription will not represent the same level of 
protein translation.  Compounding this complexity are the estimated 100 possible post-translational 
modifications involved in protein function and cell signalling.  Perturbations in cell signalling are known 
to be imperative for a variety of pathologies, drastically altering cellular protein levels.  The need for 
techniques  that  provide  both  qualitative  and  quantitative  information  is  required  to  decipher  the 
proteome.    These  can  be  categorised  into  four  main  aspects  –  protein  separation,  identification, 
characterisation and quantitation techniques. 
 
1.2 Protein separation strategies 
In terms of proteomic analysis, much emphasis has been placed on the development of strategies 
capable of resolving all proteins/peptides in a given proteome.  At present, no one separation strategy 
has the capability of achieving this.  This is due to the large protein concentration dynamic range of a 
given proteome.  As a result, multidimensional strategies using a combination of separation techniques 
have been utilised to obtain complete resolution of proteins present in a complex mixture [2].  These 
separation strategies can be categorised into electrophoretic and chromatographic methods. 
1.2.1 Two-Dimensional electrophoresis (2-DE) 
Gel electrophoresis is considered as one of the most common of the separation strategies used in 
proteome analysis.  This is due to its ability to separate a large component of the proteome in a 
reproducible and stable manner.  In particular, high resolution two-dimensional poly-acrylamide gel 
electrophoresis (First described by [3], 2-DE) has been utilised for multiple proteomic analyses.  It - 2 - 
 
involves the separation of proteins on the basis of isoelectric point (pI) in the first dimension, followed by 
molecular weight separation in the second dimension using poly-acrylamide gel electrophoresis (PAGE) 
[3, 4].  Using this method, one can simultaneously separate and resolve proteins over a wide isoelectric 
range (pH 3-11) and molecular weight range (from >10 kDa, <300 kDa).  As an added advantage, 
separation  using  this  technique  provides  a way  to  isolate  proteins  of  interest  in  a  manner  that  is 
compatible for downstream proteomic analyses.  As such, it is a method used routinely to study global 
analyses of a variety of cellular processes including protein synthesis,  glycolysis, gluconeogenesis, 
nucleotide and amino acid (AA) biosynthesis, lipid metabolism and stress responses [5-8].  Analyses of 
phosphorylation and other post-translational modifications for signal transduction pathways are also 
achievable with this separation strategy [7].  Phosphorylation, for example, changes the net charge of 
the protein and is often visualised on a 2-DE gel by a horizontal trail of protein spots [9].  In 1997, Unlu 
et. al [10] described Difference Gel Electrophoresis (DIGE), a method coupled to 2-DE that involves the 
labelling of two protein samples with spectrally resolvable fluorescent dyes referred to as Cy2, Cy3 and 
Cy5.    The  differentially-labelled  protein  samples  (Cy3,  Cy5)  are  combined  with  a  pooled  internal 
standard (equal amounts of both samples to be analysed that are labelled with Cy2) and simultaneously 
resolved using 2-DE.  Running both the internal standard and protein samples on one gel removes 
experimental variation and as such, enhances the accuracy of measuring changes in protein regulation 
between  the  samples  of  interest  (relative  to  the  pooled  standard).    The  subsequent  analysis  of 
differentially expressed protein spots from the gel using mass spectrometry (MS) enables researchers to 
obtain both qualitative and quantitative information on proteins of interest [11].  Despite the advantages 
of 2-DE DIGE for protein quantitation and identification, the method has some key limitations [7, 12, 13].  
Very  hydrophobic  proteins  (including  membrane  proteins)  and  basic  proteins  are  unable  to  be 
sufficiently resolved, nor are low abundant proteins [14] or proteins that are of high molecular weight 
[15].  Despite aspects of the methodology being improved (e.g. the introduction of pre-cast gels) it is 
difficult to automate and hence may not be considered as a high throughput proteomic strategy [16].  
Separation methods capable of addressing these limitations which would complement the robust 2-DE 
approach have been concurrently developed, including liquid chromatography [17]. 
 
1.2.1.1 High performance liquid chromatography (HPLC) overview 
It is estimated that over 30% of signal transduction pathways involved in protein products of the human 
and mouse genome are mediated by receptors  [18-20].  These pathways are initiated from direct 
physical contact between the receptors and their effector and regulatory molecular targets [18, 19].  
These membrane proteins play vital roles in a multitude of signal transduction pathways, providing a key 
link  between  the  external  environment  and  internal  cellular  processes  [21].    Changes  in  receptor - 3 - 
 
localisation,  expression,  and  post-translational  modifications  (PTMs)  have  been  shown  to  impact 
receptor functionality [22, 23].  Membrane proteins are difficult to resolve using 2-DE, mainly due to their 
increased hydrophobicity compared to cytosolic proteins.  Fractionation of a proteome into its sub-
cellular components can aid the overall resolution required for detailed analysis.  The use of Liquid 
chromatography (LC), in particular HPLC, either separately or in combination with gel electrophoresis, 
has become the mainstream methodology for complex proteome analysis [2, 24].  LC strategies are 
advantageous as both proteins and peptides can be separated using a variety of column chemistries 
(Table 1.1), including Reverse Phase (RP), size exclusion, ion-exchange chromatography (IEX), and 
affinity chromatography, whilst always in the liquid phase.  This is particularly important as sample loss 
is minimised by removal of protein/peptide extraction processes (from solid strategies – i.e. PAGE) and 
can be coupled directly to identification strategies, namely MS [24]. 
 
Property  Technique 
Size  Size Exclusion chromatography (SEC), 
Gel Filtration  
Charge  Ion-exchange chromatography (IEX), 
Chromatofocusing 
Bio-recognition (ligand specificity)  Affinity chromatography (AC) 
Hydrophobicity  RP chromatography, 
Hydrophobic Interaction chromatography (HIC), 
Hydrophilic Interaction Chromatography (HILIC) 
Table 1.1: Protein chromatographic separation strategies (adapted from [25]). 
 
The principle of protein/peptide LC separation involves the manipulation of either the mobile (solvent) 
phase or the stationary phase of the column.  The chemistry used to separate complex mixtures is 
dependent on class of proteins/peptides to be separated. 
 
1.2.1.2 Ion-exchange chromatography (IEX) 
When  considering  potential  separation  strategies,  it  should  be  considered  whether  the  strategy  is 
compatible  with  down-stream  methods,  such  as  mass  spectrometry  (MS).    IEX,  which  is  able  to 
effectively purify samples from undesirable solvents, concentrate diluted samples as well as separate 
components makes this strategy a popular first choice for protein LC separation  [25].  In fact, the - 4 - 
 
combination of strong cation exchange chromatography (SCX) and RP is the most widely used strategy 
for complex peptide mixtures, providing orthogonal separation characteristics [26, 27]. 
 
IEX exploits the natural charge state characteristics of proteins, which are dependent on the AA side-
chains in the sequence, as well as the carboxyl and amino termini, bound ions and PTMs.  The nature 
of ion-exchange groups as well as the sorbent they attach to is the main parameter used to separate 
complex mixtures using IEX [28].  Taking advantage of the unique relationship of a protein‟s net surface 
charge and pH, reversible interactions between charged molecules and IEX media are used to enrich, 
separate and subsequently elute molecules of interest [25, 29].  Alteration of pH such that it is higher 
than  the  isoelectric  point  will  result  in  a  protein  binding  to  positively-charged  IEX  media  (anion 
exchange), while a pH lower than the isoelectric point will result in a net positive charge, thus binding to 
negatively-charged  IEX  media  (cation  exchange)  [25,  28-30].    The stronger  the net  charge  of  the 
protein, the more strongly the protein will bind to the charged stationary phase.  One can optimise 
conditions such that proteins of interest can be enriched, providing the pH of the mobile phase is set 
such that the protein has an overall net charge.  Once bound, charged species of interest can be eluted 
using competing ions of the same charge in the mobile phase [25, 27, 29, 31].   
 
A variety of stationary phases are currently utilised for IEX, depending on the type of separation and the 
aims of the research to be completed.  Stationary groups whose charges are stable at any pH range, 
such as sulfonate groups (cation exchange) and tertiary or quaternary amines (anion exchange) are 
termed strong ion exchangers.  Utilising strong cation-exchange (SCX) or strong anion-exchange (SAX) 
is advantageous as interaction mechanisms are simplified, minimising the number of parameters that 
need to be optimised.  Both SCX and SAX have been successfully used for phosphopeptide enrichment 
[32-37].  However, the use of stationary phases whose charge state alters depending on pH, termed 
weak  (e.g.  weak  cation-exchange  [WCX],  weak  anion-exchange  [WAX])  can  be  advantageous  for 
improving retention and subsequent elution of particular proteins of interest [25-28, 31]. 
 
1.2.1.3 Size Exclusion Chromatography (SEC) 
SEC is another separation strategy that has been employed for protein analysis in complex samples.  It 
is  particularly  useful  for  samples  that  are  sensitive  to  alterations  in  conditions  such  as  pH  or 
temperature, separating solely on the basis of size.  In SEC, polymer beads with pores of different sizes 
are used to separate proteins.  The smaller the protein, the longer the path length, as smaller proteins - 5 - 
 
will enter the pores of the beads.  This results in the separation of proteins depending on size alone [25, 
29, 38].  Although SEC has been successfully used in research strategies alone [39-41], for proteomics 
it is generally used as part of a multi-dimensional separation strategy for proteins [42-44].  This is due to 
the fact that samples are generally diluted over the course of the separation in mobile phases that are 
not compatible with downstream processes such as MS [25]. 
 
1.2.1.3 Affinity chromatography (AC) 
Of the separation strategies that can be utilised, AC can ensure purification of molecules of interest from 
complex mixtures (as outlined in Figure 1.1).  The method exploits selective interactions, both biological 
and chemical, between molecules attached to a stationary phase and its partner to be enriched, which 
can then be reversed to release analytes of interest [25, 45, 46].  The type of affinity matrix used will 
depend on the class of proteins or peptides to be separated, such as lectin columns for glycoproteins or 
streptavidin columns for biotin-labelled proteins or peptides. 
 
 
Figure 1.1: An outline of AC utilising bound  Ab for antigen (Ag) enrichment 
from a sample mixture [adapted from [47]]. - 6 - 
 
This example of AC utilises bound Ab (on a solid support, in this case beads) to purify a 
targeted Ag that is contained in a complex mixture.  The mixture is loaded into a column 
and allowed to run over the Ab-conjugated beads.  Molecules that do not bind to the Ab 
pass through while the Ag of interest remains bound in the column.  After washing,  the 
Ag is eluted from the column into a new tube. 
 
In terms of protein enrichment, it is possible to not only enrich proteins exclusively on the basis of 
biological function or structure, but also enrich on the basis of modifications of proteins, including 
biological post-translational modifications (e.g. phosphorylation) [34, 48-61], recombinant modifications 
(e.g. poly-histidine tag) [25, 62-64] and chemical modifications (e.g. Biotin addition) [64, 65].  Affinity 
matrices with  covalently bound  substrates  (e.g.  small  peptides sequences  that  proteins  of  interest 
recognise) are also used to selectively purify proteins, providing the proteins of interest are in their 
biologically active conformation.  The ability to conjugate antibodies (Abs) or ligands for Abs, termed 
immuno-affinity chromatography, has resulted in this separation strategy being a popular technique for 
protein purification and enrichment [25, 45].  The use of Abs in immuno-affinity chromatography for 
protein purification utilises affinity matrices that either recognise the Fc region of Abs (i.e. Protein A or G 
covalently attached to beads) or form direct covalent interactions through amide bonds with the Abs [46, 
66, 67]. 
 
1.2.1.4 Reverse-Phase (RP) chromatography 
The most common separation strategy used in proteomics, RP chromatography will separate protein 
and/or peptide mixtures on the basis of peptide hydrophobicity, where an increasing concentration of 
organic solvent in the mobile phase is used to separate proteins or peptides bound to a stationary 
hydrophobic phase (e.g. silica with carbon chains attached).  A summary of the interaction that occurs in 
RP chromatography is shown in Figure 1.2 
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Figure 1.2: Schematic outlining the hydrophobic interaction between proteins 
with  a  hydrophobic  ligand on  a  stationary  support  (A).  Figure  1.2B outlines 
how  proteins  are  separated  using  an  increasing  polar  solvent  gradient 
[Adapted from [25, 68]]. 
 
As Figure 1.2 illustrates, proteins and the hydrophobic ligand in aqueous conditions (binding conditions) 
are surrounded by molecules (from the aqueous mobile phase) in a structured way.  Although the exact 
mechanism of RP is still debated, it is believed that when proteins bind to the immobilised hydrophobic 
ligand,  the  hydrophobic  region  of  the  protein  becomes  unprotected  from  water  molecules.    This 
reduction in the exposed hydrophobic region to water corresponds with a favourable increase in system 
entropy.    In  order  to  alter  the  polarity  of  the  solvent  and  thus  separate  proteins  with  varying 
hydrophobicity, a gradient of increasing organic solvent, such as acetonitrile (ACN) is applied, resulting 
in the less hydrophobic proteins losing affinity for the immobilised ligand, thus being released [25, 68-
71].  Multiple immobilised supports are available for hydrophobic separation of both protein and peptide.  
The stationary phase selected is dependent on whether separation is to occur on a protein or peptide 
level [25, 68]. In peptide separations stationary phases with pore sizes between 80-100 Angstroms are 
used,  whereas  in  protein  separation,  the  pore  size  of  the  stationary  phase  is  larger,  around  300 
Angstroms.   
 
The hydrophobicity of proteins and peptides is determined by a number of properties, including the AA 
sequence, and the tertiary and quaternary structure for proteins [68].  AAs are categorised into different 
groups based on their side-chain, namely acidic, basic, neutral, hydrophilic and hydrophobic [24].  The 
AA sequence of a peptide can subsequently be used to predict elution times of peptides during a 
gradient of organic solvent [24, 68].  The resolving ability of RP can be optimised by alteration of the 
mobile phase, namely in terms of ion-pairing reagents and pH.  A lowering of pH (generally around pH 





Base matrix Base matrix












protein- 8 - 
 
stationary phase when used in combination with an ion-pairing reagent [72-75].  The homologous series 
of volatile perfluorinated acids, such as TFA, are routinely used for RP-HPLC of peptide samples, 
particularly when coupled to MALDI-TOF/TOF MS [74, 76-78].  This is primarily due to its increased 
hydrophobicity over other ion-pairing reagents such as phosphoric acid (PA), thus not only acting as an 
effective ion-pairing reagent for basic residues but also improving peptide binding affinity to solid phase 
RP  supports.    The  volatile  nature  and  UV  transparency  of  TFA  at  low  concentrations  are  also 
advantageous.  The high volatility does not interfere with peptide protein ionisation in MS and the UV 
transperancy improves data output (by minising the baseline interference of ion-pairing reagents) using 
UV traces to determine separation efficiency [73, 74, 77, 78].  In contrast, PA is more hydrophilic than 
TFA, yet has been shown to be as sensitive as TFA for peptide separation.  In fact, its increased 
hydrophilicity has been shown to decrease overall peptide retention times; meaning better separation of 
complex samples [74, 77].  This is because slightly increasing the hydrophilicity of peptides will mean 
peptides will begin to elute earlier in the gradient, aiding effective separation of complex peptides using 
the same gradient [74]. 
 
In proteomics, large-scale analyses typically involve the use of two separation strategies prior to MS 
analysis, and here RP-HPLC is usually used as second strategy directly before MS analysis [26, 27, 79-
83].  This is due to the fact that RP-HPLC is able to not only de-salt, concentrate and separate proteins 
or peptides, but able to do so in mobile phases suited for MS downstream analyses.  Many proteomic 
strategies,  therefore,  involve  RP-HPLC  in  their  analysis  of  proteins  or  peptides  prior  to  MS  for 
identification of proteins/peptides in complex samples. 
 
1.3 Mass spectrometry: Protein identification and 
characterisation 
MS refers to the study of gas-phase ions and is used as an effective tool for the identification and 
characterisation of various molecules by measuring the mass-to-charge ratios (m/z, unit = Thompson 
[84]) of ions [25, 85-87].  These ions are formed as a result of a loss or gain of a charge from a neutral 
species,  directed  to  a  mass  analyser  via  electrostatic  forces,  separated  on  the  basis  of  m/z  and 
subsequently detected [85, 86]. Since the development of the first mass spectrometer (then called a 
parabola spectrograph) by Sir J.J Thompson, a number of major breakthroughs in MS has enabled this 
technology to be utilised universally for both chemical and biological analyses [86].  Mass spectrometers - 9 - 
 
typically consist of three major components; an ionisation source, a mass analyser and a detector 
(Figure 1.3) and these ultimately determine the capabilities and limitations of mass spectrometers.  
 
 
Figure 1.3: A diagram outlining the basic components of Mass Spectrometers 
[adapted from [25, 85, 86]. 
 
For the analysis of the proteome, MS has become the major hardware component, and this is due to the 
development of “soft-ionisation” MS techniques, referring to the conversion of intact analyte molecules 
(e.g. proteins and peptides) to corresponding ions  [87].  Two techniques in particular, electrospray 
ionisation  (ESI)  and  matrix  assisted  laser  desorption/ionisation  (MALDI)  have  developed  into 
indispensable tools both in research facilities and pharmaceutical companies across the globe involved 
in analytical biochemistry [86, 88].  These ionisation processes coupled with various mass analysers 
has seen  an  explosion  of  the  use  of  MS  in biochemical  studies.    These  analysers  are  based  on 
magnetic and/or electric field interactions with the charged ions that are produced at the ion source [87].  
Proteomic analyses typically utilise four types of mass analysers; quadrupole (Q), ion trap (quadrupole 
ion trap, QIT; linear IT, LIT or LTQ), time-of-flight (TOF) mass analyser, and Fourier-transform ion 
cyclotron resonance (FTICR) mass analyser [89, 90].  In addition, hybrid instruments including QQQ, 
QQ-LIT,  Q-TOF,  TOF-TOF  and  LTQ-FTICR  have  been  developed  to  combine  advantageous 
capabilities, proving particularly useful for tandem MS analyses, commonly known as MS/MS [89, 90].  
Discussing all mass spectrometer configurations is beyond the scope of this thesis. As a result, only ESI 
ion-trap (ESI-IT) and MALDI-TOF/TOF mass spectrometers will be discussed; the two configurations 
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1.3.1 ESI 
ESI was originally conceived in 1968 but not developed for the analysis of biomolecules until almost two 
decades later by Yashamita and Fenn [86, 91, 92].  An outline of the ESI process is shown in Figure 
1.4.  ESI involves the spraying of analytes (e.g. peptides) dissolved in an acidic, aqueous solution, 
creating highly charged droplets in the presence of an electric field [25].  This occurs through a small 
diameter needle, which has a high positive charge applied to it, resulting in a spray formation of solvent.  
The positively charged droplets (which received protons from the solvent) move away from the positively 
charged needle toward the negatively charged (relative to the needle) entry of the mass spectrometer 
[25,  85,  86].    As  this  occurs,  dry  nebulising  gas  and/or  heat  are  applied  to  the  droplets  under 
atmospheric  pressure,  resulting  in  the  desolvation  of  charged  ions.    As  the  size  of  the  droplets 
decreases, the Coulombic repulsion between the like-charges increases, such that it exceeds the forces 
of surface tension.  This results in the expulsion of charged ions from the droplet, which subsequently 
enters the mass spectrometer [25, 85, 86]. 
 
 
Figure 1.4: The formation of ions associated with ESI [adapted from [25, 85, 86]. 
In ESI, analytes dissolved in an acidified aqueous solvent are passed through a small 
diameter  capillary,  creating  a  mist  of  charged  droplets.    The  charged  droplets  travel 
toward the entrance to the mass analyser due to the presence of an electric field.  In this 
region,  a  dry  nebulising  gas  and/or  heat  is  applied  to  the  droplets  to  desolvate  the 
charged ions.  As the droplet size decreases, the Coulombic force between like charges 
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The ionisation of molecules using ESI results in the formation of ions with multiple charge states, due to 
the acidic conditions of the solvent [85].  For protein and peptide analysis in proteomic studies, this is 
particularly advantageous.  The formation of multiply charged protein ions allows deduction of the 
molecular weight of proteins that are larger than the mass range of the mass spectrometer.  For peptide 
analysis using ESI, the formation of multiply charged fragment ions using particular mass analysers for 
tandem MS/MS of peptides results in a larger amount of sequence information compared with only 
singly charged fragment ions.  Additional advantages of ESI for proteomic analyses are its compatibility 
with HPLC (particularly RP-HPLC) and high ionisation efficiency resulting in a high sensitivity, typically 
down to the low femtomole to attomole range [85, 86, 93-96]. 
 
1.3.2 Ion Trap (IT) mass analyser 
An IT (a three dimensional analogue of a quadrupole mass filter) consists of a ring electrode and two 
hyperbolic end caps, as outlined in Figure 1.5 [25, 85-87, 97-100]. 
 
 
Figure 1.5: The ion trap mass analyser [adapted from [25, 85-87, 99]]. 
 
De-solvated ions from an ESI source enter the IT through a focusing device, shown in Figure 1.5 as an 
Octopole lens system.  A radio frequency (rf) voltage is applied to the ring electrode, which creates a 
three-dimensional electric field.  In addition, the inside of the IT is filled with helium.  Entering ions begin 
to oscillate within the 3D field, and this oscillation is governed by both the rf voltage and the reduction in 
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occurs by the scanning of the rf voltage to excite the trapped ions and increase the amplitude of 
oscillations, resulting in the ejection of the ions out the IT to the detector [100]. As the rf voltage is 
scanned to higher frequencies, ions with larger m/z become excited and subsequently exit the trap [86, 
100].  This process is referred to as “mass-selective instability” as only ions with the selected m/z ratio 
are ejected from the IT [25, 85, 99, 100].  Mass Analysis using IT is particularly useful as it is possible to 
isolate  one  ion species  by  ejecting  all  others  from  the  trap  [86].    This  is  achieved  by applying  a 
waveform signal to the end cap electrodes.  The isolated ion species (precursor ion) are fragmented by 
collisional activation with helium molecules after the application of a small voltage (rf pulse) across the 
end cap electrodes.  The result of this collision between helium gas molecules and a selected ion 
species results in a conversion of kinetic energy to internal energy in the ion, resulting in fragmentation 
[85].  The fragments produced are then detected for analysis [25].  This fragmentation process, known 
as collision induced dissociation (CID), can be performed in real-time, allowing an extensive analysis of 
complex samples [25, 85, 86, 101].  Other advantageous properties of an IT analyser include its small 
size, its ability to be utilised for other MS/MS fragmentation strategies (e.g. MSn and Electron transfer 
Dissociation – ETD) as well as its ability to accumulate ions of interest to ultimately provide better signal 
and therefore better fragment information for analyte identification and characterisation. 
 
1.3.3 LC-ESI-MS/MS 
LC-ESI-MS/MS consists of a HPLC system coupled directly to an ESI source for analyte ionisation, 
which subsequently enters a mass analyser, in particular an ion-trap (IT) mass analyser, for tandem MS 
analysis.  This robust, high sensitivity as well as high throughput technology has seen LC-ESI-MS/MS, 
particularly nano-LC (nLC) ESI-MS/MS, become a powerful well established tool for proteomic research 
[102, 103].  Direct coupling of the LC to ESI-MS/MS allows analysis of complex biological samples, 
particularly protein samples digested with trypsin, that not only identify proteins and characterise the 
peptide  sequences,  but  also  supply  quantitative  information  between  sample  types  in  a  highly 
reproducible manner  [102-105].  As shown in Table 1.2, the size of particle size of the stationary 
packing material, the column inner diameter (I.D.) in conjunction with the flow rate ultimately determines 
the  sensitivity  of  the  LC-MS/MS  system.    Taking  this  into  consideration,  nano-LC  (nLC)  systems 
produce the highest sensitivity when analysing small sample amounts compared with the other available 
formats and this, coupled with ESI-MS/MS, has proven to be most applicable for low abundant sample 
analysis.  Despite the advantages of nLC-ESI-MS/MS for large-scale proteomic analyses, it does have 
some limitations, including a relatively low mass accuracy as a result of the limited number of ions that 
are able to be accumulated in the IT before distortion of ion distribution in the trap occurs due to space-
charge effects [102].  In addition, as samples are analysed in real-time, collection of redundant data can - 13 - 
 
occur and due to the nature of ESI, sample is used up during the analysis [103].  A major problem 
facing nLC-ESI-MS/MS analysis of complex peptide samples is that the number of peptides eluted after 
chromatographic separation often exceeds the maximal scan rate at which mass spectrometers can 
acquire MS/MS data, which results in a number of ions of interest being excluded from MS/MS analysis 
[103, 106, 107].  However, the development of other ionisation sources, such as matrix assisted laser 
desorption/ionisation  (MALDI),  as  well  as  mass  analysers,  like  TOF  mass  analysers,  provides 
researchers with multiple MS tools for complex sample identification and characterisation. 
 
Scale  Column I.D. [µm]  Column  volume 
(100  mm  length) 
[µL] 
Typical  flow  rate 
[µL/min] 
Gain in sensitivity 
Analytical  4600  1700  1000  1 
Narrow  2100  350  200  5 
Micro  1000  80  50  21 
Capillary  300  7  1 to 4  237 
Nano  75  0.5  0.2 – 0.5  3322 




The “soft ionisation” technique, MALDI, was first described for proteins in 1988 by Hillenkamp, Karas 
and Tanaka [86, 88, 111-114] .  Since then, it is now used for the analysis of proteins, peptides, and 
most  other  biomolecules,  including  carbohydrates,  lipids  and  oligonucleotides  [86].    The  ionisation 
process revolves around the use of a small chemical laser absorbing organic molecule (termed matrix).  
The matrix and sample are co-crystallised (in excess over sample) onto a metal surface (MALDI target 
plate), as outlined in Figure 1.6.  A laser (either an N2 or a yttrium aluminium garnet [YAG] pulse laser) 
is used to vaporise the sample/matrix crystal resulting in a gaseous plume.  Here, both sample and 
matrix are ionised for mass analysis (Figure 1.6). 
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Figure 1.6: The MALDI Ion source [adapted from [86, 115]]. 
The MALDI process involves the vaporisation of analyte embedded within a solid matrix 
using a laser under vacuum.  The result is the formation of a gaseous plume in which 
both analyte and matrix molecules are ionised.  These ions are subsequently accelerated 
toward the mass analyser by electric fields. 
 
Shown in figure 1.6 is an outline of the process of ionisation in a MALDI ion source.  Despite the 
widespread applications of MALDI, the fundamental mechanisms that lead to the formation of charged 
matrix and analyte molecules remains poorly understood [88, 116, 117].  Models explaining MALDI ion 
formation have been proposed [116, 118-121], yet the most accepted model is that termed the “lucky 
survivor” model proposed by Karas [116].  In this model, proteins and peptides become charged as they 
are incorporated into the matrix.  These charged species then undergo a process of re-neutralisation 
within desorbed matrix and analyte clusters [88, 116].  In the photoionisation process, electrons and 
protonated matrix species are formed.  Conditions in the gaseous plume favour electron neutralisation 
and proton neutralisation of negative-ion species due to the high rate of reaction and high density of 
positive ions, respectively [116].  The result is a dominant neutralisation process in which the only lucky 
survivors are singly charged ion species as these have a high significant probability of surviving [111, 
116].  This model explains the observation that mostly singly charged ions are detected following MALDI 
[88, 116, 122].  This model highlights the importance of the matrix not only for sample dilution and 
separation into solid phase, but also for absorbing the majority of the incident laser energy [88, 116].  
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cyano-4-hydroxycinnamic acid (CHCA) for peptides [123], sinapinic acid (SA) for proteins [124] and 2,5-
dihydroxybenzoic acid (DHB) with phosphoric acid for phosphopeptides [59, 125].  Irrespective of the 
type of matrix used to embed sample for MALDI, the resultant singly charged ions are accelerated 
toward a mass analyser for detection (Figure 1.6). 
1.3.5 MALDI-TOF/TOF MS 
A widely adopted technique utilises a MALDI ion source coupled to either one or a series of TOF mass 
analysers (MALDI-TOF or MALDI-TOF/TOF MS) to provide a highly resolved measurement of ionised 
samples at high sensitivity (down to the attomole range) in a high throughput capacity [126-129].  The 
TOF mass analyser is particularly suited to MALDI ion sources because they produce ions in pulse 
cycles and of masses greater than 1 mega Dalton (MDa).  TOF analysers are ideal as they are capable 
of measuring large ions [88].  TOF analysers determine the m/z ratio of ions by measuring the travel 
time through a field free drift region of the TOF tube.  Ions with a smaller m/z have a higher kinetic 
energy than ions with a higher m/z, due to the acceleration of ions at the ion source by electric fields 
[88].  Large ions with high mass to charge ratios (m/z) have a greater TOF value and strike the detector 
later than small ions (Hillenkamp, Karas et al. 1991; Suckau, Resemann et al. 2003).  Once through, the 
ion hits a detector, such as a microchannel plate (MCP).  The MCP converts ion hits to the detector face 
into electrical pulses [88, 129].  As such, a digital storage oscilloscope is used to plot the ion current 
signal versus the ion arrival time.  In axial TOF instruments, ions are accelerated by a given voltage [U] 
between the sample support and a nearby grid or open electrode, to a kinetic energy Ek before travelling 
down a flight path to the detector.  Thus, 
 
Ek = zeU, where z is charge and e is elementary charge. 
 
Ions with the same Ek have different velocities [v], depending on their mass [m].  Therefore, 
 
Ek = 1/2mv2. 
 
As v is defined by the length [L] of the drift region by the time [t] it takes the ion to travel through the drift 
region, 
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1/2m(L/t)2 = zeU. 
 
From this, the m/z of an ion can be determined; 
 
m/z = (2eU/L2)t2 [88, 129]. 
 
MALDI-TOF instruments are configured in two modes, linear and reflectron mode (Figure 1.7).  Linear 




Figure  1.7: The two  operational  modes  of  a  MALDI-TOF  mass  spectrometer. 
1.6A shows linear mode and 1.6B shows reflectron mode [adapted from [25, 85, 
88, 129]]. 
In  linear  mode  (A),  ions  produced  at  the  source  are  accelerated  at  V1  while  a  pulse 
voltage V2 is used to synchronise ions of the same mass leaving the source.  The ions 
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travel  over  a  linear  flight  path  to  the  detector.    In  reflectron  mode  (B),  variations  in 
kinetic energies of ions produced at the source are compensated using the ion mirror, or 
reflectron (V3), deflecting ions such that they enter the second drift region at the same 
time and velocity. 
 
Ions produced and subsequently analysed using MALDI-TOF usually have variations in their initial 
velocity.  This is due not only to their position in the plume following desorption but also their position 
within the solid matrix/analyte crystal [88].  These velocity variations result in ions of the same mass 
reaching the detector at slightly different times, resulting in a loss of resolution.  However, in linear 
mode, this is compensated by pulsed ion extraction, or delayed extraction (DE) [88, 130-133].  In DE, a 
pulsed voltage is applied after some time (typically nanoseconds) after ionisation.  Ions with a greater 
initial velocity will travel further from the sample surface.  The electrical field is then applied and this 
results in the faster ions having less electrical energy than ions with a lower initial velocity.  This 
“compensation of energy spreads” between ions with different initial velocities ensures the ions will 
reach an end-point at the same time.  Placing the detector at this end-point will result in an increase in 
resolution [88, 130-133].  Another option to compensate these kinetic energy variations is via the use of 
an ion mirror, or reflectron (Figure 1.7B), initially developed by Mamyrin [134].  The reflectron is a series 
of  ring  electrodes which  create  a constant  electric  field  near  their centre  through  a  linear voltage 
gradient [88].  Ions with a higher velocity will penetrate the reflectron further than corresponding ions 
(same m/z) with lower velocities.  These ions decelerate proportionally to their kinetic energies and 
leave the reflectron at the same time and velocity [88, 133]. 
 
During the ionisation process in MALDI, ions can undergo in-source decay (ISD) or post-source decay 
(PSD), generating fragments that are used to provide further information, such as the AA sequence of 
peptide  [88, 133].  ISD ions are produced as a result of the desorption/ionisation event and undergo the 
same acceleration through the TOF tube to the detector, however the intensities of the ions are usually 
too low for practical purposes  [88].  As such, PSD  decay is routinely used in MALDI-TOF MS to 
generate fragment ions for MS/MS spectra.  In PSD, precursor ions of interest undergo fragmentation 
within the drift-free region of the TOF tube [85, 88, 129, 135, 136].  This process is exploited for tandem 
MS analysis of ions. MALDI mass spectrometers with two TOF tubes are utilised to first select a 
precursor ion of interest (commonly referred to as a parent ion) using timed ion selectors (TIS), utilising 
deflecting voltages to isolate only ions of interest [129] which are also fragmented by PSD. 
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Metastable ion fragmentation is often unable to produce all fragment ions to effectively extract complete 
structural information of selected parent ions.  However, this can be improved by increasing the internal 
vibrational energy of molecules to induce more fragmentation [88].  This is achieved by the use of a 
collision cell, which can be placed between two TOF tubes in a MALDI-TOF/TOF mass spectrometer.  
Here, neutral gas molecules can be introduced to induce fragmentation of parent ions that have been 
isolated following TOF m/z separation and TIS selection.  This collision cell with fragment ions produced 
then acts as an ion source for the second TOF separation [88].  The effective generation of both MS 
and  MS/MS  data  using  MALDI-TOF/TOF  MS  has  seen  this  approach  become a  powerful  tool  for 
proteomic analyses. 
 
1.3.6 LC-MALDI-TOF/TOF MS 
In proteomics, LC coupled on-line to ESI MS/MS has been used extensively for shot-gun proteomic 
strategies, providing both qualitative (protein identification) and relative quantitation of peptide mixtures 
using peptide labelling strategies for over 10 years [102-104, 137-147].  However, the development of 
automated offline LC strategies for coupling to MALDI-TOF/TOF MS has provided an alternative for 
proteomic analyses, particularly as this allows for more information to be achieved from each matrix 
position on a MALDI target.  Although MALDI has certain advantages over ESI, including an increased 
dynamic range and higher resistance to salts, buffers and surfactants in samples  [148], one critical 
factor of MALDI-TOF/TOF MS/MS analysis is the quality of the matrix/analyte spot [149].  For MALDI 
MS analysis, the smaller the number of peptides on one spot, the greater the increase in sensitivity of 
the  analysis.    Too  many peptides on  one spot  results  in  ionisation  suppression  of  less  abundant 
peptides by highly abundant peptides [150, 151].  In addition, sample amount in each spot is finite, 
meaning only a limited number of MS/MS analyses can be acquired from the MALDI target as each 
desorption process accelerates sample loss [152].  The coupling of LC improves MALDI-TOF/TOF MS 
sensitivity by fractionating complex samples over a number of spots, increasing the number of peptides 
visible and subsequently improving MS/MS data for protein identification and characterisation.  The 
offline approach also allows the archiving of samples and a decrease in generation of redundant MS/MS 
data, as it is possible to analyse MS results for a more strategic parent ion selection [104].  As a result, 
LC-coupled  MALDI-TOF/TOF  MS  has  been  used  extensively  for  proteomic  analyses,  both 
independently and in conjunction with LC-ESI-MS/MS [17, 103, 104, 125, 148, 153-160]. 
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1.4 Quantitative LCMS-based proteomics 
Quantitative proteomic analysis holds great promise for the detection of novel drug targets for the 
prevention and treatment of diseases as it is possible to elucidate  changes in signal transduction 
between normal and diseased states [161].  2-DE quantitative strategies, such as DIGE or silver stain-
based gels have been invaluable for alterations in protein abundance between states however are 
unable  to  provide  a  complete  representation  of  the  proteome  due  to  limitations  in  resolution  and 
sensitivity.  In order to complement these gel-based strategies and thus quantify parts of the proteome 
not compatible with PAGE, a number of LC-MS based quantitative methods have been developed [102, 
161-165].    Generally  protein  or  peptide  quantitation  using  MS  is  performed  either  by  label-free 
approaches or by stable isotope labelling [163, 166, 167].  In terms of protein-specific quantitation, 
methods involving the use of synthetic standards to quantify endogenous peptides derived from the 
protein during MS have been developed.  Triple quadrupole (QQQ) mass spectrometers and multiple 
reaction monitoring (MRM) are particularly suitable tools [168].  For proteome-wide quantitation, many 
chemical labelling strategies have been employed due to the ability to utilise multiple MS configurations 
[169].  The developments now make it possible to label in vivo (i.e. stable isotope labelling by amino 
acids in cell culture – SILAC), chemically (e.g. isotope coded affinity tags – ICAT, isotope tagging for 
relative and absolute quantitation – iTRAQ, isotope-coded protein labels – ICPL) or enzymatically (e.g. 
16O/18O labelling) [163]. 
 
1.4.1 Cysteine specific isotopic labelling - ICAT 
Although MS has long been used in quantitative strategies for small molecule analyses, initial proteomic 
analyses utilised enzymatic modification by the incorporation of 18O atoms at the C-termini of peptides 
[170-175].  However, the development of ICAT in 1999 by Gygi [140] and co-workers provided a method 
to  simplify  complex  proteomic  samples  and  concurrently  provide  quantitative  information  between 
control and test samples.  The process involves the labelling of cysteine residues with a biotin-linked 
light or heavy isotopic label at either the protein or peptide level [140, 171, 176-178].  These labelled 
proteins and peptides can be selectively enriched using avidin affinity chromatography, thus reducing 
sample complexity approximately 10-fold [178, 179].  The remaining enriched labelled proteins are 
digested (for protein labelling) and labelled peptides are subsequently identified and quantified using 
LC-MS/MS [178, 179].  Although ICAT has been successfully used for quantitative analyses of the 
proteome [176, 177, 180], it does have some key limitations [171].  It has been previously reported that 
the avidin affinity purification steps for biotinylated peptides recover approximately 10% of the original 
peptides [181] and that not all cysteine-containing peptides with a biotin group could be captured [141].  - 20 - 
 
Although non-specific binding to avidin columns and multiple reactions at the same site have been 
reported with ICAT [171], one major limitation is the rarity of cysteine residues compared with other 
residues in a given proteome, being found to be absent from some protein sequences [13, 21].  Also, 
the  attached  biotin  group  results  in  reduced  ionisation  of  labelled  peptides,  which  subsequently 
decreases the overall sensitivity of the method [17].  Modifications to the ICAT methodology such as an 
additional biotin cleavage step [17] as well as alterations in the labelling technique [182] have improved 
ICAT quantitation however the rarity of cysteine limits the amount of quantitative data achieved upon 
complex proteome analysis.   
1.4.2 Amine specific isotopic labelling 
Amine-specific labelling strategies, including iTRAQ, SILAC and ICPL labelling, overcomes the major 
limitation of ICAT, as these modify free amino groups on both lysine residues and free N-termini.  This 
significantly increase the potential labelling sites that are available in protein sequences, resulting in 
higher sequence coverage and thus better quantitative information [13, 183]. 
1.4.2.1 Isobaric tags for relative and absolute quantitation (iTRAQ) 
The iTRAQ labelling strategy involves the use of up to an 8-plex set of amine reactive isobaric tags to 
derivatise peptide digests at both the N-terminus and lysine residues [17, 144, 145].  After labelling, the 
peptide samples are combined to minimise experimental variance and analysed by MS.  As the labelled 
peptides are isobaric, it is not possible to distinguish between labelled samples following MS analysis.  
Quantitation occurs at the MS/MS level via comparison of signature fragmentation ion (m/z = 112, 114-
118, 119, 121) intensity [144, 145].  The iTRAQ tags contain a moderately strong basic group (N-
methylpiperazine), which aids in improving peptide ionisation in positive ion mode MS analysis  [17].  
This is particularly useful for strategies utilising MALDI-MS, where it has been shown that peptides with 
a C-terminal arginine give stronger signal intensities compared with C-terminal lysine peptides [17, 184, 
185].  This has been attributed to the basicity of the guanidino functionality of the arginine side chain 
[184-188], and iTRAQ labelling of the lysine containing peptides improves ionisation by a similar effect 
[17].  Although this strategy is a highly sensitive quantitation approach [17, 103, 104, 137-139, 143, 144, 
146, 189-191], its key limitation, the poor detectability of the reporter ions in some types of mass 
spectrometers, has hampered its widespread use [163, 168, 192].  Compounding this is the fact that as 
quantitation can only be determined on the MS/MS level, MS/MS data must be acquired for all peptides 
in the sample.  This is particularly detrimental for MALDI-MS strategies as MS/MS data are limited by 
the robustness of the sample/matrix spot.  Thus, MS/MS analysis on low abundance peptides in the 
sample may not be possible after MS/MS of the highly abundance peptides has been acquired.  Thus, - 21 - 
 
labelling strategies that reduce the number of MS/MS scans by providing quantitative information on the 
MS level are required for large-scale proteome analysis. 
1.4.2.2 Stable isotope labelling of amino acids in cell culture (SILAC) 
In order to overcome labelling reaction issues that can occur with iTRAQ and ICAT, Ong and colleagues 
developed SILAC [171].  This strategy, termed in vivo labelling, involves introducing isotopic variants of 
amino  acids  via  protein  synthesis  of  cells  cultured  in  amino  acid-deficient  media.    This  approach 
removes affinity and chemical labelling steps and is compatible with most cell types, including primary 
cells [171].  For example, the test cells are cultured in medium containing arginine labelled with six 13C, 
whilst control cells are cultured in media with normal arginine.  As a result, all „heavy‟ (13C) arginine 
containing peptides are heavier than their normal „light‟ (12C) counterparts by 6 Da.  Once incorporated, 
the proteome from both the control and test cells can be combined for any downstream processing prior 
to MS [171, 193-196].  During MS analysis of combined samples, relative peak intensities between 
labelled and unlabelled pairs are quantitative, enabling the selection of only labelled peptides for MS/MS 
to reduce redundancy and to evaluate the effect of stimuli on a range of proteins using one experiment 
[197, 198].  SILAC has become the method of choice for many strategies analysing both proteome and 
PTM changes in cell systems [162, 171, 194, 197-208].  As cell culture is a requirement for SILAC, it is 
not applicable for samples that cannot be obtained through cell culture.  In addition, some cell types are 
unable to efficiently incorporate certain amino acids leading to incomplete labelling [193].  The SILAC 
process can also be quite time-consuming, involving a minimum of six cell passages to ensure complete 
incorporation [193].  The high number of passages may alter cell states, particularly for primary cells 
and care must be taken to minimise instances of interconversion between arginine and proline, which 
can affect quantitation efficiency [209].  The reliance of SILAC on cell culture has seen the development 
of an in vitro labelling strategy that is able to provide quantitative information at the MS level and is also 
suitable for virtually all sample types. 
1.4.2.3 Isotope protein coded label (ICPL) 
The  non-isobaric  technique  ICPL,  like  iTRAQ,  is  an  isotope-coded  tag  that  is  based  on  N-
hydroxysuccinamide (NHS) chemistry that target primary amino groups (Figure 1.8), namely protein N-
termini and lysine site chains [13, 163, 210-212]. 
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Figure 1.8: ICPL label molecular structure [Adapted from [13, 210, 213]]. 
The ICPL kit can contain up to four reagents.  (A) outlines the 1-(12C61H4)-Nicotinoyloxy-
succinamide  12C-Nic-Reagent  (Mr  =  105.0215  Da).  (B)  is  a  summary  of  the  reaction 
scheme  of  ICPL  labelling.  (C)  outlines  the  other  ICPL  reagents;  1-(12C62D4)-
Nicotinoyloxy-succinamide  2D-Nic-Reagent  (Mr  =  109.0715  Da),  1-(13C61H4)-
Nicotinoyloxy-succinamide  13C-Nic-Reagent  (Mr  =  111.0419  Da)  and  1-(13C62D4)-
Nicotinoyloxy-succinamide 13C2D-Nic-Reagent (Mr = 115.0919 Da).  All four reagents can 
be used simultaneously for quantitation experiments. 
 
A typical ICPL workflow will involve chemical labelling of proteins derived from control and test samples 
with „light‟ and „heavy‟ reagents, respectively.  Once labelled, the protein samples are combined and 
either fractionated on the protein level to reduce complexity or digested in-solution for subsequent 
fractionation prior to MS.  Since its introduction in 2005, different versions of ICPL reagent kits have 
been made available, enabling the quantitation of four samples simultaneously  [214].  As the ICPL 
reagents are non-cleavable, a permanent shift in the labelled peptide mass occurs, resulting in the 
detection of peptide pairs (for duplex) or groups (for triplex or 4-plex) after MS acquisition.  This method 
has been shown to improve the accuracy, sensitivity and dynamic range of existing methods [168, 210].  
ICPL  overcomes  the  disadvantages  of  other  labelling  strategies,  including  ICAT  (low  number  of 
potentially labelable residues), iTRAQ (poor detectability of the reporter ions in several types of mass 
spectrometers)  and  SILAC  (universally  labels  all  proteins  and  does  not  require cell  culture)  [163].  
Despite the adherent advantages, this particular labelling strategy has not been used as extensively as 
the other previously mentioned labelling techniques [13, 163, 168, 210, 211, 214].  The ability of this 
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information, including PTMs and isoforms, as well as its compatibility with all commonly used protein 
and peptide separation techniques will see this strategy being used more extensively [13]. 
 
1.5 Phosphorylation 
One  of  the  most  challenging  aspects  of  proteomic  research  is  the  quantitation,  identification  and 
characterisation of PTMs of proteins in a biological sample.  PTMs are enzymatic, covalent chemical 
modifications that occur after translation that potentially alter the physical or chemical properties of a 
protein.  This alteration can result in conformational, stability and/or activity changes, and can even 
result  in  alterations  in  cellular  location  of  a  protein  (e.g.  the  internalisation  of  a  receptor  into  the 
cytoplasmic domain) [215].  PTMs can be used in a dynamic fashion, where reversible modification of 
proteins in signalling cascades is used to regulate cellular processes.  Over 400 PTMs have been 
identified or are likely to be identified [215, 216]. 
 
Since the isolation of phosphoserine by Levene and Lipmann in 1932, phosphorylation has turned out to 
be one of the most biologically significant protein modifications [161].  As such, in proteomics, a large 
focus  has  been  placed  on  the  analysis  of  protein  phosphorylation.    Reversible  phosphorylation  is 
estimated to occur on 30% of the entire protein complement in mammalian cells at any point in time 
[217-219] and it has been speculated that 50% of all proteins are phosphorylated during their lifetime, 
yet  phosphorylated  proteins  are  present  at  relatively  low  abundance  compared  to  their  non-
phosphorylated  counterparts  [220].    For  example,  a  signal  from  the  plasma  membrane  can  be 
transmitted in the form of phosphorylation using a cascade of proteins until the signal reaches the 
nucleus.  Phosphorylation by kinases and dephosphorylation by phosphatases are tightly regulated 
events that play an important role in many cellular processes, such as cell proliferation, differentiation, 
migration and the prevention of cell death [59, 221].  Genomic analysis has revealed that ~2-3% of all 
eukaryotic genes are likely to encode protein kinases (estimated to be 478), whilst over 100 human 
protein phosphatases have been predicted [222-224].  The phosphorylation of a protein may result for 
example in a change in its intracellular localisation, its catalytic activity and/or its interaction with other 
proteins.  Over expression of so called oncogenes such as the epidermal growth factor receptor (EGFR) 
or loss of so called tumour suppressors like phosphatase and tensin homolog (PTEN) disturb the 
balance, which can lead to a number of pathologies such as cancer or immune deficiencies  [225, 
226](Condina et. al. In Press).  In eukaryotic cells, phosphorylation occurs primarily on serine (pSer), 
threonine (pThr) and tyrosine (pTyr) residues, estimated to be in the ratio of 1800:200:1 [221, 225, 226], 
with  phosphoserine  and  phosphothreonine  being  about  3000  times  more  abundant  than - 24 - 
 
phosphotyrosine [221, 227].  It has been predicted that over 1 x 105 phosphorylation sites may exist in 
the human proteome [228].  Due to the critical role of this PTM in both normal cellular processes and 
perturbed  signalling  in  multiple  pathologies,  the  identification  and  characterisation  of  protein 
phosphorylation is of paramount importance [59, 161, 225, 229]. 
 
1.5.1 Phosphoprotein detection 
To date, the identification of phosphorylation sites and evaluation of their function on proteins has been 
achieved through several standard procedures.  These include radioactive labelling with  32P-labelled 
ATP followed by 1D or 2D SDS-PAGE, thin-layer chromatography (TLC), HPLC or Edman Sequencing, 
site-directed mutagenesis or deletion experiments, chemical modification (particularly β-elimination of 
the phosphate moieties of serine/threonine phosphorylated proteins and peptides by alkali treatment 
and subsequent Michael-type addition of nucleophiles), Edman sequencing and the use of  general 
phosphospecific antibodies (Abs), [59, 161, 220, 230-232].  The more recent development of phospho-
specific  stains,  particularly  Pro-Q  Diamond,  in  conjunction  with  SDS-PAGE  has  facilitated 
phosphoprotein detection [233-240].  Although less sensitive than radioactive methods, their ease of 
handling is far more convenient [220].  Phosphoprotein visualisation can also be achieved by traditional 
western blot analysis of samples fractionated using 1D and/or 2D SDS-PAGE using phosphospecific 
Abs [241-245].  Western blot analysis can routinely detect very low amounts of phosphoprotein/s in a 
sample  (low  femtomole),  however  sensitivity  is  dependent  on  the  Ab  used  [246].    Hundreds  of 
commercially available phosphotyrosine Abs exist, such as 4G10, pY20, pTyr100, pY99 and pY66, all 
showing  varying  degrees  of  specificity  and  sensitivity  [225].    However,  these  phosphotyrosine 
antibodies  generally  have  low  cross-reactivity  to  un-phosphorylated  tyrosine  or  serine/threonine-
phosphorylated residues [247, 248].  In contrast, Abs for phosphoserine and phosphothreonine  are 
generally dependent on consensus sequences in addition to the phosphorylated residue, with steric 
hindrance decreasing effective Ab binding [220]. 
 
Analysis using a phospho-specific dye or western blot will only provide locations of phosphorylated 
proteins and not site-specific information.  Many approaches analysing phosphorylation at the protein 
level  will  target  either  specific  proteins  of  interest  or  the  entire  phosphoprotein  complement  using 
immuno-precipitation  (IP)  strategies  to  reduce  sample  complexity  [241,  249-251],  often  using 
phosphospecific antibodies [252, 253].  Enriched phosphoproteins can then be characterised by MS, 
typically after proteolytic digestion.  MS has thus become a powerful tool for the unbiased analysis of 
protein phosphorylation [102].  Providing the abundance of phosphopeptides is sufficient, successful 
characterisation of phospho-sites is achievable.  However, this is seldom the case as phosphopeptides - 25 - 
 
are known to be difficult to analyse by MS, particularly when analysing a mixture of phosphorylated and 
non-phosphorylated peptides.  This is due to a low ionisation efficiency of phosphopeptides (particularly 
multiply phosphorylated peptides) compared with non-phosphorylated peptides, resulting in ionisation 
suppression effects [59].  As phosphorylation site analysis remains a challenge for many laboratories, 
advances in phosphoproteomic technologies involving the enrichment of phosphopeptides have aided in 
the analysis of complex protein samples [161]. 
 
1.5.2 Phosphopeptide enrichment strategies 
A summary of the proteomic-based methods that have been developed for phosphopeptide enrichment 
prior to MS analysis is outlined in Figure 1.9.  Some methods outlined, particularly immobilised metal 
affinity chromatography (IMAC), SCX, SAX and immuno-affinity chromatography (e.g. using a phospho-
specific Ab for pTyr) can enrich at both the protein and peptide level.  Also, as shown, these methods 
can be used solely or in combination with other enrichment techniques to reduce sample complexity and 
thus maximise the probability of phosphopeptide detection. 
 
 
Figure 1.9: Enrichment strategies for phosphopeptides [Adapted from [59, 161, 
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A  variety  of  proteomic  based  techniques  have  been  developed  an  optimised  for 
phosphopeptide enrichment to improve subsequent identification and characterisation by 
MS.  These include IMAC, TiO2 enrichment, MOAC enrichment, SCX or SAX, HILC with 
IMAC,  calcium  phosphate  precipitation,  pTyr  Ab  enrichment,  Hydroxyapatite  (HAP) 
enrichment and multi-dimensional enrichment strategies such as sequential elution from 
IMAC (SIMAC). 
 
1.5.2.1 Immobilised metal affinity chromatography (IMAC) 
IMAC,  first  introduced  by  Porath  et.  al.  [255]  for  enrichment  of  histidine-  and  cysteine-  containing 
proteins interacting with IMAC resin, has become one of the most frequently used phosphoprotein and 
phosphopeptide enrichment strategy [59, 61, 161, 220, 225, 254, 256].  The technique is based on 
metal ions (e.g. Fe3+, Al3+, Ga3+, Ni2+, Co2+, Zr4+ or Mn2+) immobilised on a chromatographic or bead 
support.  These ions are chelated by either iminodiacetic acid (IDA) [255], nitriloacetic acid (NTA) [257] 
and Tris(carboxymethyl)ethylenediamine (TED) linkers [59, 61, 220, 225].  While divalent ions such as 
Ni2+, Co2+ and Mn2+ are better for proteins with a high density of histidines, the trivalent ions Fe3+, Al3+, 
Ga3+ and more recently the tetravalent Zr4+ have been shown to be better for phosphorylated protein 
and peptide enrichment [59, 61].  The process of enrichment is seemingly straight-forward, involving 
column  equibrilation,  binding,  washing  and  elution  and  has  been  successfully  utilised  in  multiple 
strategies at both the protein and peptide levels [34, 48-58, 60, 80, 191, 201, 202, 205, 207, 258-264].  
Despite  its  widespread  use,  the  method  as  a  stand  alone  approach  can  have  some  drawbacks, 
including non-specific binding of highly acidic peptides (peptides with aspartic acid or glutamic acid) and 
the strong binding of multiply-phosphorylated peptides.  As IMAC is based largely on ionic interactions, 
peptides rich in glutamic and aspartic acid residues are often co-purified [240].  Reduction of non-
specifically bound acidic peptides can be achieved by esterification of carboxylic acids to methyl esters 
[48, 50, 205, 259, 264].  However, care must be taken when performing this reaction to minimise side 
reactions, resulting in increased sample complexity [59, 220].  Once enriched, the isolated peptides can 
then be identified by MALDI-MS or LC-ESI-MS/MS as IMAC is compatible with MS.  In one such study, 
peptides were obtained from yeast protein extract and methylated to reduce non-specific binding of 
acidic non-phosphorylated peptides to IMAC resin.  This approach identified 216 phosphopeptides and 
324 phosphorylation sites [50].  Other studies have combined IMAC with pre-fractionation protocols in 
order to enhance the effectiveness of phosphopeptide identification, such as using calcium phosphate 
precipitation of phosphopeptides prior to IMAC [53]. 
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1.5.2.2 Titanium Dioxide (TiO2) phosphopeptide enrichment 
An alternative strategy for phosphopeptide enrichment, TiO2, is based on the selective interaction of 
water soluble phosphates with porous TiO2 microspheres [59, 265, 266].  Phosphopeptides bind under 
acidic conditions are and subsequently eluted (after washing to remove non-phosphorylated peptides) 
using alkaline conditions.  Although this is superior to IMAC in terms of non-specifically bound peptides, 
non-phosphorylated peptides often remain after TiO2 enrichment.  As such, recent studies have altered 
sample loading conditions to improve phosphopeptide binding and further reduce unspecifically bound 
peptides [261].  As with IMAC, this enrichment method is also compatible with MS and on-line columns 
have been developed to automate phosphopeptide enrichment, identification and characterisation [267, 
268].  Further developments of metal oxide affinity chromatography (MOAC) [269-273], such as the use 
of Al(OH)3-based technique by Wolschin et. al. [240] have aimed to further improve phosphopeptide 
binding and reduce non-specific binding. 
 
1.5.2.3 HILIC 
HILIC was first coined in 1990 to describe normal phase chromatography with mobile phases that are 
typically 10-40% aqueous  [274, 275].  Although originally described in the 1970s for carbohydrate 
analysis, only in the last 15 years has it been applied in a number of analyses, mainly due to its 
versatility  as  well  as  the  growing  need  for  chromatographic  materials  that  can  fractionate  polar 
compounds and are compatible with MS [26].  In HILIC, the stationary-phase material is sufficiently 
more polar than the mobile phase (i.e. compounds are loaded in a high organic mobile phase), resulting 
in  the  retention  of  polar  compounds  that  are  unable  to  be  retained  with  conventional  RP 
chromatography  [26,  275].    The  compounds  bind  by  hydrogen  bonding,  which  are  subsequently 
disrupted by decreasing the organic environment in the mobile phase.  Compounds subsequently elute 
according to their hydrophobicity, with the more hydrophobic peptides being eluted off first  [26, 80].  
HILIC is not only compatible with MS, it has shown to improve sensitivity for ESI-MS strategies [276, 
277].  Furthermore, studies on the separation of unphosphorylated peptides using HILIC, SCX and RP-
HPLC have indicated that a better orthogonal separation could occur between HILIC and RP-HPLC, 
making  HILIC  viable  for  the  multi-dimensional  separation  of  complex  samples  [278,  279].    As 
phosphorylated peptides are generally more polar than non-phosphorylated peptides, recent analyses 
of  the  phosphoproteome  have  utilised  HILIC  alone  [275]  or  in  conjunction  with  other  separation 
strategies [58, 80]. 
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1.5.2.4 Combined strategies for phosphopeptide enrichment 
Despite the highly sensitive strategies reported here for phosphoproteome analysis, obtaining complete 
phosphoproteome  characterisation  remains  a  challenging  task.    In  order  to  further  reduce sample 
complexity and subsequently improve phosphopeptide identification and characterisation, a number of 
enrichment methods have been combined.  For example, sequential elution IMAC (SIMAC), exploits the 
retention of multiply phosphorylated peptides by IMAC with the preference that TiO2 has on mono-
phosphorylated  peptides  [60].    The  process  involves  the  fractionation  of  multiply-phosphorylated 
peptides  and  mono-phosphorylated  peptides  by  first  enriching  complex  samples  over  IMAC.    The 
unbound fraction (including unbound phosphopeptides) is collected for TiO2 enrichment.  The eluates 
from both the IMAC and TiO2 are analysed separately to improve phosphopeptide characterisation [59, 
60].  Other combined enrichment strategies involve the use of calcium phosphate precipitation, SCX, 
SAX, and HILIC prior to more specific phosphopeptide enrichment including IMAC, TiO2, and SIMAC 
[34, 53, 58-60, 80, 202, 280]. 
 
1.6 Tyrosine phosphorylation 
Although tyrosine phosphorylation (pTyr) makes up only a small percentage of the phosphoproteome, 
protein-tyrosine kinases (PTKs) are amongst the most important oncogenes known to date [281].  Of 
the more than 90 PTKs, more than half have been implicated in various types of cancers [282, 283].  
This  is  due  to  the  biological  role  of  PTKs  in  cell  proliferation,  motility,  actin  re-organisation  and 
chemotaxis  [284].    For  instance,  unregulated  tyrosine  phosphorylation  has  been  shown  to  drive 
malignancy and tumour growth due to its involvement in proliferative and survival signal transduction 
pathways [229, 282].  PTKs, Protein-tyrosine Phosphatases (PTPs) and their substrates have been 
associated with many normal physiological processes, and perturbation of these events is implicated in 
other disease states, including immune deficiencies [221, 226, 281, 285, 286].  The major role of 
tyrosine phosphorylation, particularly in cancer, has seen the development of novel proteomic and 
therapeutic approaches to identify, characterise and target unregulated PTKs and PTPs as well as the 
pathways involved in tumour growth and survival [226, 229, 284]. 
 
1.6.1 Proteomic methods for phosphotyrosine detection 
The technical challenging nature of pTyr signalling analysis is attributed to the occurrence of tyrosine 
phosphorylation at an extremely low abundance within cells (often only a few hundred copy numbers 
per cell), the low stoichiometry for a given protein, the fact that pTyr represents only 0.05% of all 
phosphorylated amino acid content, and the labile nature of pTyr events during chemical processing - 29 - 
 
required for MS analysis [225, 280, 283, 287].  In addition, the rules of consensus do not work well with 
pTyr, with programs that utilise algorithms to predict pTyr sites not matching experimental outcomes 
[283]. 
 
Despite the rarity of phosphotyrosine in cellular protein extracts, a number of methods have been 
utilised to successfully characterise pTyr.  The availability of broadly reactive Abs that recognize pTyr 
residues have aided in the identification and characterisation of many PTK substrates involved in growth 
factor and cytokine signalling [228, 288-292].  These Abs have been employed in immunoprecipitation 
as well as western blotting experiments [252].  The immunoprecipitated proteins are separated by gel 
electrophoresis,  digested  in-gel  with  a  protease  and  analysed  by  MS.    In  general,  these 
immunoprecipitated proteins are identified without mapping their tyrosine phosphorylation sites [229].  
More recent pTyr analysis utilise protein specific Abs or pTyr specific Abs to batch purify prior to further 
enrichment  using  a  phosphorylation-based  strategy  [208,  225,  259,  264,  283,  293-296].    Global 
strategies have generally selected one pTyr specific Ab in enrichment strategies [208, 229, 243, 297] 
however a combination of pTyr Abs have been used to improve subsequent identification [264, 288, 
294].  To date, the majority of global pTyr analyses utilise pTyr-specific Abs at the protein level as after 
enrichment and digestion, both non-phosphorylated and phosphorylated peptides remain from the pTyr 
phosphoproteins.  As most strategies follow a “bottom-up” approach (dealing with peptides derived from 
proteins) [298], the analysis of both phosphorylated and non-phosphorylated peptides improves protein 
identification.  The use of pTyr Ab for protein IP can also enrich pTyr protein binding partners for 
identification, which aid in the characterisation of pTyr signalling cascades [225].  However, protein level 
enrichment will not distinguish between pTyr proteins and their binding partners without identification 
and quantitation of corresponding pTyr sites.  Also, the presence of non-phosphorylated peptides can 
result in ionisation suppression effects on phosphopeptides, minimising pTyr site characterisation.  As 
such, methods utilising pTyr specific Abs for direct pTyr enrichment at the peptide level [191, 229, 283, 
299-301], improve sensitivity by avoiding ion suppression through non-phosphorylated peptides.  Due to 
the extremely low abundance of pTyr in complex samples, various methodologies will utilise global 
phosphopeptide  enrichment  strategies  either  prior  to  or  after  pTyr  peptide  enrichment  using 
immunoaffinity  enrichment  [225].    The  combination  of  IMAC  with  pTyr  Ab  enrichment  has  been 
effectively used to characterise a larger set of pTyr sites [191, 264, 297, 301, 302]. 
 
1.6.2 Identification of phosphorylation sites by MS 
Proteomic  based  methodologies,  namely  enrichment  strategies  coupled  with  MS  analysis,  have 
provided a number of methods that are beneficial in identifying, quantifying and characterising pTyr - 30 - 
 
events  in  cell  systems  [59,  161,  164,  220,  225,  254,  281].    The  successful  identification  and 
characterisation of pTyr using MS is dependent on the consideration of phosphopeptide characteristics 
observed  during  the  ionisation  process.    In  addition  to  the  low  stoichiometry  of  phosphorylation 
compared with non-phosphorylated peptides in the sample, phosphopeptides generally have a lower 
ionisation efficiency (particularly in positive ion mode MS) and the labile nature of the phosphate group 
from  a  peptide  minimises  sufficient  backbone  fragmentation  for  phosphosite  characterisation.  
Proteolytic  digestions  of  proteins  often  produce  phosphopeptides  with  more  than  one  potential 
phosphorylation site, emphasising the need for full phosphosite characterisation [161].  As such, careful 
consideration  must  be  taken  when  determining  the MS  strategy  to  be  utilised  in  order  to  achieve 
sufficient information to identify and subsequently characterise pTyr sites. 
 
Many strategies developed for phosphotyrosine identification utilise 1D or 2D LC coupled with tandem 
MS analysis, using ESI or MALDI ionisation [51, 59, 200, 225].  Nano-LC coupled online with ESI 
tandem MS (nLC-ESI-MS/MS) and LC coupled offline with MALDI tandem MS (LC-MALDI-MS/MS) 
provide simple, sensitive and automated analyses of complex peptide samples, with each method 
having advantages for phosphorylation analysis. 
 
Despite the fragmentation suppression effects of the labile phosphate group, nLC-ESI-MS/MS is a 
technology capable of providing adequate phosphopeptide sequence coverage.  In addition, its high 
sensitivity allows for the effective analysis of samples over a large dynamic range, which is particularly 
useful  for  phosphoproteome  characterisation.    The  effectiveness  of  nLC-ESI-MS/MS  for  tyrosine 
phosphorylation analysis is dependent on the peak capacity of the gradient used for peptide separation 
and  the  electrospray  ionisation  efficiency.    When  separating  complex  peptide  mixtures  using  LC, 
phosphopeptides and non-phosphorylated peptides often co-elute.  As phosphopeptide ionisation is 
suppressed compared with non-phosphopeptides, these often are not selected for subsequent tandem 
MS  analysis.    Phosphotyrosine  enrichment  at  a  protein  and/or  peptide  level  minimises  sample 
complexity (in comparison to direct analysis of the entire proteome) and, is often combined with nLC-
ESI-MS/MS analysis.  nLC-ESI-MS/MS is also used as a number of methods can be implemented to 
improve phosphopeptide identification, such as the use of precursor ion scanning for phosphopeptide 
selection as well as automated switching between fragmentation techniques (i.e. CID and ETD) [59, 
161, 164, 220, 303-309]. 
 
CID fragmentation of phosphopeptides often results in the partial loss of phosphoric acid (H3PO4 – 98 
Da loss) as a result gas-phase β-elimination of the phospho-ester bond, with pSer and pThr peptides - 31 - 
 
whilst with pTyr peptides, a partial loss of 80 Da (HPO3) is more dominant.  As a loss of the neutral 
molecule is thermodynamically preferred, further fragmentation of the amino acid backbone is rarely 
observed in CID of phosphopeptides.  In order to overcome this inadequate phosphotyrosine peptide 
fragmentation,  strategies  which  utilise  characteristic  phosphopeptide  fragments  in  CID  have  been 
developed. An ion trap mass spectrometer and other MS3-capable instruments are able to trigger a MS3 
analysis if the precursor ion is showing a neutral loss of 49 Da or 40 Da for doubly charged or 32.66 Da 
or 26.66 Da for triply charged ions. In this experiment, the fragmentation of the phosphopeptide after 
gas-phase β-elimination of the phospho-ester bond on pSer and pThr peptides and loss of HPO3 for 
pTyr can provide peptide backbone fragmentation data which will elucidate the site of phosphorylation. 
 
A strategy for pTyr includes the pTyr immonium ion at m/z = 216.043 Da  as precursor selection criteria 
of peptides to be fragmented [231, 253, 310].  Precursor ion selection for the pTyr immonium ion 
increases the number of phosphotyrosine peptides that are selected for fragmentation, such that other 
co-eluting non-phosphorylated peptides do not interfere.  Although this strategy for pTyr analysis has 
been successfully used previously, it does require the use of specific MS configurations with high-
resolution and accuracy, such as a quadrupole TOF (qTOF) hybrid mass spectrometer, because other 
fragment ions such as b-ions NT or GS (both m/z = 216.098 Da) and y2-ion-NH3 DV (m/z = 216.069 
Da), etc. are likely false positives [310].  Yet other fragmentation strategies have been developed that 
are applicable to various MS configurations, such as ECD and ETD fragmentation. 
 
In 1998, McLafferty and co-workers introduced Electron Capture Dissociation (ECD) [311], a process 
where  low  energy  electrons  were  reacted  with  peptide  cations  in  the  magnetic  field  of  a  Fourier 
transform  ion  cyclotron  resonance  mass  spectrometer  (FT-ICR-MS).    This  resulted  in  electron 
attachment to protonated peptides, forming cations with an additional electron. The odd-electron cation 
rearrangement is followed by subsequent dissociation of the N-Cα bond and not the peptide bond like in 
CID.  The fragmentation of the N-Cα bond is independent of the amino acid itself and the modification of 
the amino acid.  As such, unlike conventional CID, ECD does not cleave chemical modifications from 
the peptide (instead inducing random cleavage along the peptide backbone, keeping PTMs intact) and 
is indifferent to either peptide sequence or length [303, 304].  However, ECD requires an FT-ICR mass 
spectrometer in order to „catch‟ electrons, instruments that are not readily available to many in the 
proteomics field. 
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In contrast, ETD utilises ion-ion chemistry.  Originally reported in 2004 [312], this fragmentation strategy 
utilises an electron donor to generate charged-reduced peptide radical ions, which are then fragmented 
at alternative positions on the peptide backbone compared with CID  [312, 313].  As with ECD, this 
fragmentation occurs solely on the peptide backbone (N-Cα bond cleavage) [59, 303, 304, 312, 314-
318], keeping PTMs (such as phosphorylation) intact.  In addition, this fragmentation strategy has been 
easily  implemented  in  a  number  of  MS  configurations,  making  this  an  interesting  strategy  for 
phosphotyrosine peptide analysis [59, 161, 254, 305].  This is because ETD utilises a RF quadrupole 
ion trapping device instead of an FT-ICR-MS for ion trapping and detection [312], and as RF ion trap 
mass spectrometers are low-cost, low-maintenance, and widely accessible compared with FT-ICR-MS, 
this fragmentation strategy is more applicable in the proteomics field.  Furthermore, the introduction of 
ETD on 3D ion trap mass spectrometers allows the collection of both the electron donor and peptide 
ions within the confines of the trap at the same time, improving charged-reduced peptide radical ion 
generation for subsequent ETD fragmentation of complex proteomic samples.  The introduction of ETD 
in mass spectrometer configurations like nLC-ESI-3D-IT-MS/MS allows for complex peptide sample 
analysis where a multi-dimensional approach consisting of consecutive sample analyses using CID 
followed  by  ETD  fragmentation  is  utilised,  which  improves  overall  protein  identification  and  PTM 
characterisation, particularly for phosphopeptides [303-309]. 
 
Although nLC-ESI-MS/MS strategies have been successfully used for phosphotyrosine analysis, the 
combination  of  LC-coupled  to  MALDI-TOF/TOF  MS/MS  analysis  can  be  advantageous  for 
phosphopeptide identification.  The developments of sample preparation methods for MALDI-TOF/TOF 
MS that enhance phosphopeptide ionisation make this a particularly useful tool for phosphoproteome 
analysis [200].  The added capability of this approach to characterise phosphorylation on large (>3 kDa) 
mono-  and  multi-phosphorylated  peptides  makes  this  an  attractive  and  useful  approach  for  global 
phosphorylation analysis [200, 319]. 
 
In order to enhance phosphopeptide ionisation using MALDI-TOF/TOF MS, matrix deposition strategies 
have been optimised, primarily using 2,5-dihydrobenzoic acid (DHB) with phosphoric acid (PA) added 
[51, 125, 320].  DHB has the added advantage of being more tolerant to salts/contaminants compared 
with other matrix strategies, such as α-cyano-4-hydroxycinnamic acid (CHCA).  Yet one critical factor of 
MALDI-TOF/TOF MS/MS analysis is the quality of the matrix/analyte spot [149].  The offline approach 
also means the archiving of samples and a decrease in redundant MS/MS data, as it is possible to 
analyse MS results before MS/MS data have to be acquired, which make a more strategic parent ion - 33 - 
 
selection possible [104].  Both nLC-ESI-MS/MS and LC-MALDI-TOF/TOF MS analyses have specific 
advantages for pTyr characterisation.  However, it has been shown that these two MS-based methods 
are complementary and have previously been used to provide more complete proteome coverage [103, 
156, 321, 322]. 
 
1.6.3 Quantitation of tyrosine phosphorylation 
Elucidation  of  perturbed  signalling  networks  requires  methods  that  can  accurately  quantify  and 
characterise  phosphorylation.    Although  traditional  biochemistry  approaches  such  as  32P  labelling, 
immunoblotting, and fluorescent labelling can be used to quantify changes in protein phosphorylation, 
MS-based approaches have increasingly become the method of choice [196, 225].  In regards to stable 
isotope labelling, a number of strategies have been adopted for pTyr quantitation analyses [191, 208, 
264, 280, 294, 295, 297, 301, 323].  These approaches utilise a labelling strategy (at either the protein 
or peptide level) in combination with a pTyr enrichment strategy.  In particular, SILAC [208, 280, 294, 
323], iTRAQ [191, 295, 301] and ICAT [297] have had the most wide-spread use in conjunction with 
either protein [208, 294, 297, 323] or peptide [191, 295, 301] pTyr enrichment (using pTyr specific Abs), 
with some strategies additionally utilising IMAC [191, 295, 301] or TiO2 [280] to further reduce sample 
complexity and thus improve pTyr quantitation and characterisation. 
 
1.7 Thesis Synopsis 
Despite  the  development  of  multiple  strategies  for  phosphopeptide  enrichment,  quantitation  and 
characterisation, as of 2003, fewer than 2000 phosphorylation sites were known of a possible 1 x 105 
potential  phosphorylation  sites,  with  only  a  fraction  being  phosphotyrosine  sites  [228].    Despite 
advances in both pTyr enrichment and MS strategies, pTyr characterisation remains a challenging task.  
The difficulty of tyrosine phosphoproteome analysis highlights the need for methodologies that are 
sensitive enough to not only enrich for phosphotyrosine peptides, but also provide sufficient MS/MS 
data for accurate mapping the site of phosphorylation.  The basis of my project involves the use of a 
phosphotyrosine specific Ab in conjunction with MALDI-TOF MS for the development of new methods to 
map tyrosine phosphorylation in biological samples.  The coupling of this Ab to para-magnetic beads will 
be utilised as a targeted approach for direct enrichment of phosphopeptides from pTyr proteins.  In 
order to map tyrosine phosphorylation in specific pathways in cell lines under stimulatory conditions, a 
more  global  approach  is  required.    The  comparative  quantification  of  low-abundant  tyrosine - 34 - 
 
phosphorylated proteins isolated from complex cell lysates will be analysed using isotopic labelling in 
conjunction with phosphopeptide enrichment strategies and LC-MALDI-TOF/TOF MS analysis. 
 
1.8 Aims 
The goal of the project was to develop and optimise sensitive  proteomic based strategies for the 
analysis of the phosphoproteome, with a particular focus on tyrosine phosphorylation.  The following 
aims were developed to achieve this goal: 
  To develop a targeted proteomic approach for phosphotyrosine analysis from protein samples 
(Chapter 2) 
  To develop an optimised LC-MALDI-TOF/TOF MS strategy for complex (global) sample 
analysis (Chapter 3) 
  To quantify and characterise global pTyr phosphorylation for complex cell samples using a 
proteomics based strategy incorporating ICPL, HILIC and pTyr enrichment prior to LC-MALDI-
TOF/TOF MS analysis (Chapter 4) 
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Chapter 2: Background 
The rarity of pTyr phosphorylation coupled with the technical challenging nature of analysing this PTM 
has highlighted the need for more sensitive approaches for pTyr detection.  Although a number of 
strategies have been developed to characterise the pTyr phosphoproteome, only a fraction of pTyr sites 
have been characterised.  The aim of the study presented here was the development of optimised 
approaches that specifically target pTyr. 
 
Many research strategies are focused on the characterisation of protein function and/or regulation in 
particular signalling cascades implicated in pathologies such as cancer.  Often, western blot analysis, 
32P labelling and phosphospecific stains are used to show phosphorylation of proteins of interest during 
signalling.  Although these methods can provide information as to what proteins are phosphorylated, 
they  are  unable  to  accurately  characterise  phosphorylation  sites  without  further  site-directed 
mutagenesis  experiments.    As  such,  the  development  of  a  target  proteomic  approach  capable  to 
identifying  and  characterising  tyrosine  phosphorylation  on  proteins  of  interest  would  aid  signal 
transduction research. 
 
The availability of broadly reactive pTyr specific Abs, such as 4G10, are able to be utilised to achieve 
adequate enrichment of pTyr proteins and peptides.  Proteins of interest can be recombinantly produced 
and subsequently in vitro phosphorylated or are purified from complex samples (by IP using protein 
specific Ab or pTyr specific Ab) and fractionated by 1D or 2D SDS-PAGE.  Bands corresponding to the 
protein of interest can then be excised and proteolytic in-gel digestion can be used prior to extraction of 
both phosphorylated and non-phosphorylated peptides. 
 
Super para-magnetic beads specially designed for MALDI analysis has been commercialised (Bruker 
Daltonics, Bremen, Germany).  The basis of my project involves the use of a phosphotyrosine specific 
Ab  in  conjunction  with  MALDI-TOF  MS  for  the  development  of  new  methods  to  map  tyrosine 
phosphorylation in biological samples.  The coupling of this Ab to these para-magnetic beads will be 
utilised  as  a  targeted  approach  for  direct  enrichment  of  phosphopeptides  from  phosphotyrosine 
proteins. 
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Chapter 3: Background 
The development of the sensitive super para-magnetic bead approach utilising 4G10 provides a simple 
straight-forward targeted proteomic approach for pTyr characterisation on relatively simple (<4 protein) 
sample digests.  The use of either Pro-GP and/or Cov-P beads in conjunction with more traditional 
biochemical techniques, namely IP and western blot analysis, will be able to identify proteins that have 
been phosphorylated after the implementation of test conditions as well as characterise the sites of pTyr 
without the need for site-directed mutatgenesis experiments or recombinant protein synthesis. 
 
Despite the advantages of the Pro-GP/Cov-P method described in Chapter 1, the method is limited as a 
targeted proteomic approach.  This is because the capacity of the 4G10 beads is small, requiring pre-
fractionation (e.g. SDS-PAGE) or IP experiments so only a small number of proteins are digested for 
pTyr phosphopeptide enrichment.  As such, if Pro-GP/Cov-P was to be used for more complex sample 
analysis,  a  serial  enrichment  strategy  involving  multiple  enrichment  steps  would  have  to  be 
implemented.  However, this type of strategy would be time consuming and may not be successful in 
characterising total pTyr phosphorylation of complex samples.  In addition, the substantial increase in 
sample handling prior to MS will increase pTyr loss and as pTyr abundance is low, the number of pTyr 
sites detected would be significantly decreased. 
 
The complexity of cell lysates with the low abundance of pTyr has prompted the development of multiple 
strategies  aiming  to  reduce  sample  complexity  for  successful  phosphopeptide  detection  and 
characterisation.  The coupling of HPLC and MALDI-TOF/TOF MS is one strategy that has been used 
successfully for phosphoproteomic analysis [156, 337-339].  Aspects of the approach can be modified to 
improve  phosphopeptide  recovery,  detection  and  characterisation,  particularly  in  regard  to  MALDI-
TOF/TOF MS. 
 
Prior to the analysis of a complex protein sample (i.e. cell lysates), the development of a LC-MALDI-
TOF/TOF MS strategy that has been optimised for phosphoproteome analysis was required.  Both the 
HPLC  and  MALDI  MS  aspects  of  the  method  would  have  to  be  optimised  to  ultimately  minimise 
phosphopeptide loss during HPLC fractionation and improve phosphopeptide ionisation and subsequent 
detection in MALDI-TOF/TOF MS analysis.   
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Chapter 4 Background: 
The ability of the proposed EZYprep matrix deposition strategy to improve DHB matrix application for 
LC-MALDI-TOF/TOF  MS  as  outlined  in  Chapter 3  now  provides an  optimised  way  to analyse  the 
phosphoproteome of complex samples utilising the advantageous properties of DHB with PA.  The low 
abundance of pTyr in complex samples highlights the importance of employing enrichment strategies as 
well as optimised MS approaches to improve pTyr characterisation.  The development of proteomic 
methods capable of providing not only qualitative pTyr information but also show quantitative changes 
that occur with pTyr signalling are imperative to provide a complete overview of the phosphoproteome. 
 
Although  the  method  using  Pro-GP/Cov-P  for  determination  of  the  pTyr  component  of  the 
phosphoproteome is very promising it is primarily a targeted approach in that the strategy has limited 
sample capacity making it less suitable for „large-scale‟ (global) sample analysis.  Tissue samples are 
often limited in both the amount and concentration of analytes, which can be attributed to a low number 
of cells present within the sample [127, 302, 372, 373].  As such, new methods, which display a higher 
stringency in terms of sensitivity and throughput, are essential to detect tyrosine phosphorylation sites 
[372]. 
 
The  research  presented  aimed  to  utilise  the  4G10  Ab/bead  approach  for  the  enrichment  of  pTyr 
peptides from complex samples.  This enrichment step is subsequently combined with HILIC to improve 
phosphopeptide  fractionation  and  resulting  samples  are  analysed  using  the  optimised  LC-MALDI-
TOF/TOF MS methodology outlined in Chapter 3.  Experiments are designed to isolate and identify the 
presence  and/or  changes  in  phosphotyrosine  sites  between cell  types  cultured  in  the  presence  of 
specific stimuli.  Quantitative analysis of pTyr between test samples is achieved by ICPL labelling of 
samples prior to pTyr enrichment.  Both MS and subsequent MS/MS data will be used to characterise 
pTyr residues and quantify changes in phosphorylation between samples.  This is potentially a highly 
sensitive approach that will not only identify phosphopeptides and the phosphorylation sites, but also 
will provide quantitative data relating to the level of expression. 
  




Phosphotyrosine  quantitation  and  characterisation  in  insulin 




Abbreviated Title: Insulin receptor phosphorylation analysis using proteomics 
Abbreviations: Ab, Antibody; HILIC, Hydrophilic Interaction Chromatography; FA, formic acid; FACS, 
Fluorescence activated cell sorting, IGF, insulin-like growth factor; IGFBPs, IGF-Binding proteins; IR, 
insulin receptor; ICPL, Isotope Protein coded Label; MAP, Mitogen-activated Protein, PTK, protein-
tyrosine kinase; PTP, protein-tyrosine phosphatases 
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Abstract for Chapter 4 
Despite the low abundance of phosphotyrosine in the mammalian proteome, the role of this PTM has 
been implicated in multiple signalling networks utilised in both normal and patho-physiological states.  
Its importance has resulted in research to not only identify and characterise tyrosine phosphorylation but 
also  quantify  expression  levels  in  multiple  cellular  processes.    Of  the  methodologies  utilised, 
phosphotyrosine protein and/or peptide enrichment coupled with MS has shown the greatest promise to 
provide a comprehensive outline of the tyrosine phosphoproteome.  The use of broadly-specific Abs for 
phosphotyrosine (e.g. 4G10) has been shown to enable sufficient enrichment of phosphoproteins and 
peptides for subsequent use in MS, as seen with the Pro-GP/Cov-P enrichment strategy previously 
described.  Although suitable for low complexity samples (e.g. recombinant proteins), a more extensive 
enrichment strategy coupled with an optimised MS approach would be required for global analysis of the 
tyrosine phosphoproteome.  As such, a multi-dimensional enrichment approach utilising HILIC coupled 
with phosphotyrosine peptide enrichment for subsequent analysis using EZYprep LC-MALDI-TOF/TOF 
MS analysis was utilised for the analysis of insulin-stimulated cell lysate to characterise phosphorylation 
for both IR-A and IR-B insulin receptor subtypes.  In addition, an optimised ICPL labelling strategy was 
utilised to quantify phosphorylation levels of the insulin receptor subtypes. 
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4.1 Introduction 
The insulin-like growth factor (IGF) system is composed of three ligands (insulin, IGF-I and IGF-II), their 
cognate receptors (IGF-IR, IGF-IIR and the insulin receptor isoforms A and B; IR-A, IR-B), and six high-
affinity IGF-binding proteins (IGFBPs) [374, 375].  The IGF system is critical in normal foetal and post-
natal growth and development, and has been implicated in multiple pathologies including cancer and 
diabetes due to its role in cell survival, metabolism and mitogenesis [376-381].  The critical role played 
by circulating IGFs in the development of cancer has resulted in a significant focus on characterisation 
of signal regulation in this system for the development of novel therapeutics. 
 
The insulin receptor (IR), a member of the tyrosine kinase growth factor receptor family, consists of two 
alpha and two beta subunits linked by disulfide bonds [382].  The extracellular alpha subunits contain 
the ligand-binding domain, whilst the transmembrane beta subunits contain an intracellular tyrosine 
kinase domain [383].  The two demonstrated isoforms of IRs differ as a result of alternative splicing of 
exon 11, with IR-A lacking the 12 amino acids normally encoded by exon 11 [376, 384, 385].  In normal 
cell pathology, the IR-B isoform is predominant in a number of insulin-responsive tissues, primarily 
mediating the metabolic effects of insulin [376, 384-386].  In contrast, IR-A is the predominant isoform in 
the foetus and is responsible for regulation of growth and development [376, 387].  However, it has also 
been shown to be the dominant receptor sub-type expressed in a variety of cancer cell types, and 
activation of this receptor isoform by IGF-II plays a significant role in cell proliferation, survival and 
migration [387-391]. 
 
The binding of insulin to either IR-A and IR-B results in the activation of two downstream signalling 
pathways, the Akt/PKB and MAPK pathways.  Both metabolic (predominantly Akt/PKB) and mitogenic 
(predominantly MAPK) signalling can be induced by insulin upon binding to both isoforms, however, IR-
A activation on cancer cells has been shown to lead to mitogenic responses including survival and 
growth  [387,  389-391].    The  over-expression  of  insulin  receptors  in  cancer  could  have  important 
implications in the progression of the disease, highlighting the importance of a deeper understanding of 
IR signalling. 
 
The  activation  of  either  metabolic  or  mitogenic  signalling  is  dependent  on  not  only  the  signalling 
pathway activated by the particular IR, but also contacts that are made between the ligand and the  
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receptor [392, 393].  Upon receptor ligation, auto-phosphorylation of the receptor occurs on tyrosine 
residues at specific regions of the receptor, including the catalytic domain and the C-terminal tail [394-
397].  Auto-phosphorylation of specific tyrosine residues results in a conformational change  which 
triggers the activation of intracellular signalling pathways  [382].  It has been hypothesised that the 
activation of downstream pathways is dependent on the phosphorylation of specific residues upon 
ligand binding [398].  IR-B binds insulin with a 2-fold higher affinity (based on inhibition of europium-
labelled insulin; IC50 1.4 ± 0.1 nM) than IR-A, but binds both IGFs with low affinity (366 ± 15 IGF-1, 68 ± 
11 nM IGF-II) [399]. In contrast, IR-A binds both IGF-1 (3-fold) and IGF-II (3.7-fold) with an affinity that is 
greater than the B-isoform (IC50 120.4 ± 34.1 nM and 18.2 ± 2.4 nM for IGF-I and IGF-II, respectively), 
highlighting the influence of the twelve amino acids encoded by exon 11 on ligand binding [399-402].  
Despite  this  difference  in  insulin  binding  affinity,  the  IR-B  subtype  undergoes  greater  auto-
phosphorylation and has a higher level of tyrosine kinase activity than IR-A [399, 403].  The differences 
between IR-A and IR-B in terms of expression, binding affinity to ligands and activation of signalling 
pathways suggest that the two isoforms perform different functions [401, 402]. 
 
To date, analysis of phosphorylation of the IR and substrates has been performed using 1D and 2D 
SDS-PAGE  and  peptide  sequencing  [392,  395-397,  404-407].    The  developments  in  MS  for 
phosphoproteome identification and quantitation has seen a number of strategies focus on the effects of 
ligands and inhibitors on phosphorylation of the IR and downstream signalling targets [203, 244, 283, 
301, 377, 408, 409].  Recent research on receptor tyrosine kinase phosphorylation has shown the 
activation of specific signalling pathways is dependent on the ordered phosphorylation of the receptor, 
which  may  be  similar  for  all  tyrosine  kinases,  including  IR  [398,  404,  410].    Therefore,  the  key 
differences  in  IR-A  and  IR-B  signalling  may  be  attributed  to  alterations  in  not  only  the  sites  of 
phosphorylation  but  also  the  duration  and  order  that  residues  are  phosphorylated.    A  sensitive 
proteomic-based strategy capable of quantifying and characterising phosphorylation (particularly pTyr 
phosphorylation) may identify the key regulators of IR signalling, depending on which IR isoform is 
activated. 
 
Here a global phosphoproteomic strategy that utilises isotopic labelling combined with phosphopeptide 
enrichment and LC-MALDI-TOF/TOF MS analysis for the comparative analysis of IR activation upon 
insulin binding is described.  Mouse IGF-1R-negative fibroblasts over-expressing the human IR-A (R-
veIR-A) or IR-B (R-veIR-B) cells [399] were stimulated with insulin prior to lysate collection.  Lysates from 
both cell types were labelled using an optimised ICPL strategy.  The digested samples were combined  
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and the phosphopeptides were enriched using HILIC and a 4G10 Ab column.  Both flow-through and 
eluted fractions were subsequently analysed using LC-MALDI-TOF/TOF MS, utilising EZYprep DHB 
matrix deposition for phosphopeptide fraction analysis.  This global phosphoproteomic strategy was 
undertaken to identify quantitative differences in tyrosine phosphorylation of the IR-A and IR-B receptor 
subtypes, and on tyrosine phosphorylation events in signalling cascades downstream of the receptors 
upon stimulation with insulin. 
  




Formic acid (FA, p.a., >98% purity) and Phosphoric Acid (PA, 50% w/w) were obtained from Fluka 
Chemie GmbH (Neu-Ulm, Germany).  DTT and iodoacetamide (IAM) were purchased from Sigma-
Aldrich (Castle Hill, Australia).  TFA was obtained from Applied Biosystems (Warrington, UK), whilst LC 
grade ACN was obtained from Merck (Darmstadt, Germany).  Ammonium bicarbonate was from BDH 
(Poole,  UK).    For  enzymatic  digestion,  modified  porcine  Trypsin  was  purchased  from  Promega 
(Madison,  WI,  USA).    CHCA  and  DHB  matrices  were  purchased  from  Bruker  Daltonics  (Bremen, 
Germany).  All aqueous solutions were prepared using deionised water with a resistance of less than 
18.2 MΩ.  All other reagents and solvents were of highest-grade analytical quality and were used 
without further purification.  Protein A (Prot A) sepharose beads were purchased from GE Healthcare, 
while anti-phosphotyrosine antibody (4G10) was purchased from Upstate Biotechnology.  The SERVA 




-veIR-B Cell lines and culture 
IGF-IR-deficient (R-ve) mouse embryo fibroblast lines engineered to express similar levels of human IR-
A and IR-B have been previously described [399, 411].  5.3 x 106 cells/T175 flask were serum starved 
for 4 hours in serum-free medium before being treated with 100 nM insulin for 10 mins at 37°C, 5% 
CO2.  Following stimulation, cells were washed twice with ice-cold PBS before being lysed in 1 mL lysis 
buffer containing 1% (vol/vol) Nonidet P-40, 150 mM NaCl, 50 mM Tris, pH 7.5, 1 mM EDTA, 0.25% 
sodium deoxycholate, 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM NaF and protease inhibitor 
cocktail (Sigma-Aldrich).  Flasks were incubated for 1 hour at 4°C and lysates were centrifuged at 
12000 x g for 10 mins at 4°C.  Each supernatant was transferred to a fresh tube.  Lysates were then 
either stored at -80°C for LDS-PAGE or a 5-fold excess of 100% ice-cold acetone was added and 
precipitated lysates stored at -80°C. 
 
4.2.3 LDS-PAGE and Western blotting 
Protein  concentration  was  determined  using  EZQ  quantitation  kit  (Invitrogen).  100  µg  lysate  from 
stimulated  and  control  R-veIR-A  and  R-veIR-B  cells  was  concentrated  using  vivaspin  centrifugal 
concentrators (GE Healthcare) with a 10 kDa filter and added to 4x lithium dodecyl sulphate sample 
buffer (Invitrogen, Carlsbad, California, USA), and 0.5 M DTT in a 65:25:10 volume ratio, respectively.   
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Samples were heated at 95°C for 10 mins and loaded onto NuPAGE 4-12% Bis-Tris polyacrylamide 
gels (Invitrogen).  Novex pre-stained molecular weight markers (Invitrogen) were loaded on each gel.  
Electrophoresis was performed between 125 V to 200 V using 50 mM MOPS, 50 mM Tris base, 3.5 mM 
SDS, 1mM EDTA, pH 7.7 as running buffer in XCell SureLock™ 1D gel tanks (Invitrogen, Carlsbad, 
California, USA).  The resulting gels transferred to a nitrocellulose membrane using the wet transfer 
blotting system (Invitrogen) for 2 hours according to manufacturers‟ instructions.  After transfer, the 
membrane was blocked in Tris-Buffered Saline Tween-20 (TBST) solution (10 mM Tris-HCl, pH 7.5, 150 
mM  NaCl,  0.05%  Tween-20)  containing  0.5% bovine  serum  albumin  (BSA)  overnight  at  4°C  with 
agitation.  The blots were then probed with either 4G10 Ab (1 µg/mL) in TBST containing 3% skim milk 
powder (3% MLK-TBST), phopsho-IR /IGF-1R [Y1158/1162/1163] in TBST containing 3% BSA (Biosource 
International, Camarillo, CA), CT-1 anti-IR (a gift from Professor K. Siddle, Cambridge, UK) in TBST or 
the PathScan® Multiplex Western Cocktail 1 (Cell Signalling) Ab for 2 hours at room temperature with 
agitation. 
 
After washing 5x with TBST for 5 mins each, the blots were probed with the relevant secondary Abs 
using donkey anti-mouse horseradish peroxidise (Rockland Immunochemicals, Gilbertsville, USA) at 
1/5000 dilution in 3% MLK-TBST for 1 hour at room temperature with agitation.  Following three washes 
with TBST for 10 mins each, the blot was developed using Chemiluminescent Western Blotting Kit 
(Sigma-Aldrich) for 5 mins.   
 
4.2.4 Flow Cytometry - Fluorescence activated cell sorting (FACS) 
Cultured cells were serum starved for 4 hours in serum-free medium before being disrupted using cell 
disruption buffer (40 mM Tris-HCl, pH 7.5, 10 mM EDTA, 150 mM NaCl, filter sterilised).  Cell counts 
were performed using trypan blue staining and cells re-suspended at 4 x 106 cells/mL in 1 x phosphate 
buffered saline (PBS)/1% BSA/0.01% sodium azide.  Fc receptors were blocked using murine gamma 
globulin for 20 mins on ice and the cells were subsequently treated with IgG1 for negative control or the 
monoclonal anti-IR antibody 83-7 (a gift from Professor K. Siddle, Cambridge, UK) for 1 hr on ice in the 
dark.  After washing twice with  1 x PBS/1% BSA/0.01% sodium azide, Fluorescein isothiocyanate 
(FITC) conjugated secondary Ab (anti-IgG) was added to the cells and incubated for 30 mins on ice in 
the dark.  Cells were washed three times using 1 x PBS/1% BSA/0.01% sodium azide, and fixed in 1/10 
dilution of 37% Formaldehyde (3.7%) in PBS for 20 mins on ice in the dark prior to storing cells in PBS 
with 1% formaldehyde in the dark.  IR expression was determined by FACS analysis using the BD 
FACSCanto  Flow  Cytometer  (BD  Biosciences,  San Jose,  CA)  controlled using  FACSdiva  software 
(Version 5.0.3, firmware version 1.14).  
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4.2.5 ICPL™ protein labelling 
Precipitated protein was re-dissolved in ICPL lysis buffer (6M Guanidine-HCl/0.1M HEPES, pH 8.5) and 
protein concentration was determined as described in section 3.2.3.  Protein lysates were labelled using 
the ICPL™ reagent kit (Serva Electrophoresis, Heidelberg, Germany) according to the manufacturers‟ 
instructions.  A more detailed description of the protocol is described elsewhere [13, 210, 211].  After 
labelling and precipitation with acetone (according to the ICPL protocol), lysates were prepared for in-
solution digests using trypsin. 
 
4.2.6 In-solution digestion with trypsin 
Following reduction and alkylation according to the ICPL protocol (for both protein and peptide labelling 
- [13, 210, 211]), trypsin in 50 mM acetic acid was added to a final ratio of substrate: enzyme of 50:1.  
The sample was incubated overnight at 37°C; the reaction was stopped using 5 μL 10% TFA  or 
prepared for ICPL peptide labelling.  For protein labelling experiments, 50 mM ammonium bicarbonate 
(NH4HCO3) was used as the digestion buffer. 
 
4.2.7 ICPL™ peptide labelling 
ICPL peptide labelling was carried out as per manufacturers‟ instructions with modifications to improve 
protein recovery.  For control labelling experiments, lysate from R-veIR-A cells was dissolved in ICPL 
lysis buffer.  Proteins were reduced and alkylated as described by the ICPL protocol [13, 210, 211].  
Subsequently  the  labelled  protein  was  diluted  with  six  volumes  of  deionised  water  to  bring  the 
concentration of guanidine-HCl to 1M.  Labelled proteins were digested in-solution as described above.  
Following digestion, the pH of the peptide mixture was adjusted to 8.5 using 2N NaOH and HCl for ICPL 
labelling.    After  labelling,  the  peptide  mixture  was  either  analysed  by  LC-MALDI-TOF/TOF  MS  or 
desalted  using  columns  (Alltech)  packed  in-house  using  zorbax-C18  packing  material  (Agilent 
Technologies).  After desalting, samples were concentrated by lyophilisation for HILIC analysis. 
 
4.2.8 HILIC 
An Agilent 1100 series binary LC system was used for LC-MALDI-TOF/TOF MS applications.  The 
system was operated using binary gradients of solvent A (98% water with 0.1% TFA) and solvent B 
(98% ACN with 0.1% TFA) was utilised. A 4.6 x 250mm TSK-gel Amide-80 HILIC column packed with 5 
μm, particle column (TOSOH Biosciences) was used for separation. Additional LC components included  
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a degasser system (G1379A) coupled to a quaternary pump (G1311A), multi-wave detector (G1365B), 
fraction collector (G1364C) and automated sampler (G1329A). The TSK-gel Amide-80 column used a 
flow rate of 0.5 mL per minute and 10 µL of peptide sample was loaded in 90% solvent B.  Loaded 
samples were eluted using an inverse gradient of 90% B to 85% B in 5 minutes, followed by 85% B to 
70% B in 40 minutes and finally a steep gradient to 0% B in 5 minutes.  Twenty-three 1 mL fractions 
were collected throughout the gradient.  HILIC fractions were pooled according to their retention times 
such that two fractions; hydrophobic and hydrophilic fractions remained.  After lyophilisation, samples 
were re-dissovled in 30% ACN in ultrapure water followed by 10 mM NH4HCO3 and pH was adjusted to 
8.5 using 2N NaOH for pTyr peptide enrichment. 
 
4.2.9 4G10 column generation 
Protein  A  sepharose™  beads  (GE  healthcare)  were loaded  into  Micro  Bio-Spin™  chromatography 
columns (Bio-Rad, California, USA) and the column was equibrilated with 10x bed volumes of 50 mM 
Tris-HCl, pH 8.0. 4G10 Ab in 50 mM Tris-HCl was loaded at a ratio of 1:1 (1 µg beads: 1 µg 4G10) and 
incubated for 1 hour at room temperature with mixing.  After incubation, the column was washed with 
10x bed volumes of 50 mM Tris-HCl and subsequently stored in 50 mM Tris-HCl, pH 8.0/0.01% sodium 
azide.  Flow-through and wash fractions were collected at binding efficieny was determined using 
absorbance at 280 nm using the SmartSpec™ 3000 (Bio-Rad, California, USA). 
 
4.2.10 Tyrosine phosphopeptide enrichment 
4G10 Ab columns were equibrilated using 10x bed volumes of 10 mM NH4HCO3.  Peptide samples (in 
10 mM NH4HCO3) were loaded and column was  incubated for 3 hours at 4°C with mixing.  After 
incubation, flow-through fractions were collected (for unbound non-phosphorylated peptides as well as 
serine and threonine phosphopeptides) and the column was washed with 10x bed volumes 10 mM 
NH4HCO3.  Bound peptides were eluted with 10 mM NH4HCO3/150 mM phenylphosphate.  All flow-
though and eluted fractions were dried down and prepared for LC-MALDI-TOF/TOF MS analysis. 
4.2.11 Capillary HPLC for MALDI-TOF/TOF MS 
An Agilent 1100 capillary HPLC (LC) system was used for LC-MALDI applications. The system was 
operated using binary gradients of solvent A (0.1% TFA in 5% ACN) in ultrapure water and solvent B 
(0.1% TFA in 95% ACN) was utilised. A 0.18 x 150mm Acclaim Pepmap100™ reverse-phase (RP) 
column packed with 3 μm, porous (100 Å) C-18-coated silica beads (LC Packings Dionex) was used for 
separation. Additional LC components included a degasser system (G1379A) coupled to a capillary  
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pump (G1376A) and micro-Well-plate-sampler (µ-WPS) automated sampler (G1377A). The Acclaim 
Pepmap100 column used a flow rate of 1 μL per minute and 5 µL of peptide sample was loaded in 0% 
solvent B.  After loading for 5 minutes, peptides were eluted with a gradient of 0% B to 12% B in five 
minutes followed by 12% B to 48% B in 36 minutes, then 48% B to 60% B for five minutes and finally a 
steep gradient to 80% B for 4.5 minutes before returning to initial conditions (0% B).  Fractions were 
spotted from 7 minutes onwards to ensure collection of any peptides that did not bind to the column. 
 
4.2.12 LC Fraction Collecting 
Eluted  peptides  were collected  directly  from  the  post-column  capillary  using  a  Proteineer  Fraction 
Collector™ (Bruker Daltonics). The fraction collector (Fc) was used to deposit chromatographic fractions 
directly onto a MTP 384 MALDI 600 µm AnchorChip™ target (Bruker Daltonics) every 15 seconds (192 
fractions)  over  the  course  of  the  gradient.  With  each  fraction,  a  sheath  solution  (0.5  µL) of  50% 
ACN/0.05%  PA/0.05%  TFA  in  water  was  deposited  using  the  matrix  deposition  function  of  the 
Proteineer Fc. A 1:100 dilution of Bruker standard peptide calibrant (Bruker Daltonics) dissolved in 0.1% 
TFA in water was deposited manually in 1 μL amounts onto each calibration spot.  
 
4.2.13 Matrix deposition strategies 
Following fraction collection, target sample spots were allowed to dry completely at room temperature. 
Two matrix deposition strategies were utilised; CHCA SMW application, as described previously [152], 
was used for ICPL labelling optimisation experiments and analysis of non-phosphorylated samples.  For 
all other LC-MALDI-TOF/TOF MS experiments, EZYprep matrix deposition with DHB matrix was utilised 
as described previously [306], in which a total of 80 layers were applied to effectively cover all raster 
positions on the MALDI target. 
 
4.2.14 MALDI-TOF MS 
MALDI  TOF  mass  spectra  were  acquired  using  a  Bruker  ultraflex  III  MALDI-TOF/TOF  mass 
spectrometer  (Bruker  Daltonics,  Bremen,  Germany)  operating  in  reflectron  positive  ion  mode.  
FlexControl  (version  3.1,  Bruker  Daltonics,  Bremen,  Germany)  software  was  used  to  control  the 
analysis.    Auto-execute  acquisition  (high-throughput  automatic  collection)  of  mass  spectra  of  LC-
fractions was controlled using WARP-LC software (version 3.2, Bruker Daltonics, Bremen, Germany) in 
SILE mode interfaced with FlexControl.  MALDI laser intensity was selected by the operator to provide 
optimal intensity and resolution of acquired mass spectra.  External calibration was performed using  
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peptide  standards  (Bruker  Daltonics,  Bremen,  Germany)  which  were  analysed  under  identical 
conditions. Peak masses and intensities of TOF and MS/MS spectra were detected with FlexAnalysis 
(Version 3.1, Bruker Daltonics, Bremen, Germany) using the SNAP algorithm.  
 
4.2.15 MALDI-TOF/TOF MS/MS analysis and database search 
Following completion of auto-execute MS collection, a WARP-LC method was used for calculation of a 
list of labelled peptide pairs for MS/MS analysis, based upon a pre-set LC-MALDI SILE experimental set 
up, known as a WARP-LC method.  The criteria for this automatic method were the following: MS 
tolerance set to 100 ppm, compounds separated by less than 5 HPLC fractions were combined and 
peaks appearing in more than 50% of spectra were defined as background.  Signal to noise (S/N) 
thresholds for MS/MS acquisitions were between 15 and 30 depending on the calculated compound list.  
Auto  execute  data  files  from  WARP-LC  containing  combined  peptide  MS  and  MS/MS  data  were 
exported to BioTools (Version 3.1, Bruker Daltonics, Bremen, Germany) and submitted to the in-house 
Mascot database search engine (Matrix Science).  The specifications were the following: (i) enzyme: 
Trypsin,  (ii)  fixed  modifications:  Carbamidomethyl  (C*),  (iii)  variable  modifications:  Oxidation  (M), 
Phosphorylation (ST) and (Y), (iv) mass tolerance MS: 100 ppm, (v) MS/MS tolerance: 0.8 Da, (vi) 
missed cleavages: 2, (vii) Taxonomy: Mus.  The MOWSE and probability scores were used as the 
criterion for ion annotation in the spectra.  Alternatively, MS/MS spectra matching to precursor ions of 
potential phosphotyrosine peptides were automatically annotated using Biotools and/or manually using 
FlexAnalysis and different positions of phosphorylation were compared.  For replicate analyses of the 
insulin stimulated R-veIR-A and R-veIR-B lysates, the individual search results were combined into protein 
compilations  using  the  ProteinExtractor  functionality  of  Proteinscape  2.1.0  573  (Bruker  Daltonics, 
Bremen, Germany), which conserved the individual peptides and their scores, while combining them to 
identify proteins with much higher significance than achievable using individual searches.  In order to 
exclude false positive identifications, peptides with Mascot scores below 25 (which was chosen on the 
basis  of  manual  evaluation  of  the  MS/MS  data  of  peptides  with  scores  below  this  number)  were 
rejected, unless part of a peptide pair in which one peptide pair had a score above 25.  In addition, any 
protein with a score of 30 or less was instantly rejected. 
 
4.2.16 Ingenuity Pathways Analysis (IPA) 
Identified proteins from the insulin stimulated ICPL labelled  R-veIR-A/R-veIR-B lysate with regulation 
values deemed significant were searched in the Ingenuity Pathways Analysis® (IPA) software (Ingenuity 
System Inc, USA).  The “Core Analysis” function of IPA was used to identify the biological functions and  
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diseases that most significantly correlated with the proteomic data set submitted.  Fischer‟s exact test 
was utilised for p-value calculation to determine the probability that each biological function and/or 
disease assigned to the regulated proteins were by chance alone. Networks of the regulated proteins 
were algorithmically generated based on their connectivity and assigned  a score, which takes into 
account the number of proteins in the network and size of the network to determine the relevance to the 
selected regulated proteins.  
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4.3 Results 
The  study  presented  here  aims  to  quantify  phosphorylation  (with  a  particular  focus  on  tyrosine 
phosphorylation) of both the IR isoforms upon insulin stimulation as well as tyrosine phosphorylation of 
proteins  involved  in  activated  downstream  signalling  pathways.  In  order  to  achieve  this,  the 
implementation of an optimised sample preparation method, which was compatible with MS analysis 
and minimised phosphorylation loss, was utilised.  The low abundance of phosphoproteins compared 
with non-phosphoproteins in the proteome emphasises the requirement for enrichment prior to MS 
analysis.  The use of ICPL for quantitation coupled directly with HILIC and pTyr enrichment prior to MS 
sought to provide effective fractionation of the sample such that pTyr enriched fractions, pSer/pThr 
enriched  fractions  and  non-phosphorylated  fractions  could  be  analysed  independently  using  an 
optimised LC-MALDI-TOF/TOF MS analysis. 
4.3.1 ICPL labelling optimisation for peptide quantitation 
The use of stable isotope labelling in conjunction with MS shows promise to effectively quantify and 
characterise the phosphoproteome of complex protein samples.  In particular, ICPL, with its ability to 
improve peptide ionisation and quantify peptide abundance at the MS level minimises data acquisition 
at the MS/MS level, thereby minimising redundancy and subsequently improving characterisation of only 
differentially-expressed proteins.   
In  order  to  utilise  ICPL  labelling  for  quantitation  of  protein  phosphorylation,  the  ICPL  labelling 
methodology required alteration such that all peptides generated from protease digestion of complex 
samples were labelled.  This was achieved by labelling samples after protease digestion (using trypsin), 
which results in at least one free amino group (labelling site) per peptide.  The efficiency of ICPL peptide 
labelling was determined using lysate collected from R-veIR-A cells, which was split at a 1:1:1:1 ratio in 
four vials. Two lysate samples were directly labelled according to the conventional ICPL approach (for 
protein labelling [13]), whilst the other two lysate samples were labelled using a modified ICPL peptide 
approach, involving digestion of protein samples with trypsin prior to labelling (Figure 4.1).  Upon 
labelling, light and heavy samples from the protein and peptide samples were combined and 2µg lysate 
was analysed using LC-MALDI-TOF/TOF MS. 
  
- 103 - 
 
 
Figure 4.1: ICPL protein versus peptide labelling 
Diagram of the experimental workflow used for the comparative analysis of ICPL protein 
versus peptide labelling.  R-veIR-A lysate is collected and split evenly across four tubes 
(1:1:1:1).  Protein is labelled according to the standard ICPL protocol; the samples are 
precipitated and subsequently digested with trypsin for LC-MALDI-TOF/TOF MS analysis.  
Alternatively,  protein  is  digested  prior  to  labelling  with  ICPL.    Once  labelled,  peptide 
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A summary of proteins identified following LC-MALDI-TOF/TOF MS analysis of R-veIR-A lysate labelled 
on either a protein or peptide level is shown in Table 4.1.  LC-MALDI-TOF/TOF MS analysis of 2µg R-
veIR-A lysate labelled with ICPL on the protein level identified eighteen proteins, providing quantitative 
information for ten proteins.  Using ICPL protein labelling strategy, 4 proteins were quantified by one 
labelled peptide pair, 4 proteins quantified by 2 labelled peptide pairs, 1 protein quantified by three 
labelled peptide pairs and only 1 protein quantified by 4 labelled peptide pairs.  In contrast, twenty-five 
proteins were identified following LC-MALDI-TOF/TOF MS analysis of lysate labelled with ICPL at the 
peptide level (Table 4.1).  Significantly, quantitative information was obtained for all twenty-five proteins.  
Using ICPL peptide labelling, 6 proteins were quantified by one labelled peptide pair, 7 proteins by two 
labelled peptide pairs and the remaining (12) proteins quantified by more than two labelled peptide 
pairs.  In the whole analysis of the ICPL peptide labelled sample, only one un-labelled peptide could be 
identified.  Nine proteins were identified and quantified solely using ICPL peptide labelling. This is in 
contrast to only two proteins being identified solely with ICPL protein labelling; protein S100-A4 and 
ubiquitin.   
 
The sequence coverage of all observable peptides, such as proteins such as Pyruvate kinase isozymes 
M1/M2 (total MS/MS ICPL peptide labelling – 19%; total MS/MS ICPL protein labelling – 17.3%) and 
Tubulin beta-5 chain (total MS/MS ICPL peptide labelling – 13.7%; total MS/MS ICPL protein labelling – 
15.7%) was comparable between the two strategies (ICPL protein labelling and ICPL peptide labellling, 
Table 4.1).  However, the sequence coverage of only ICPL labelled peptides was, not surprisingly, 
higher in the ICPL peptide labelling approach, such as with Actin cytoplasmic 1 protein (ICPL peptide 
labelling strategy = 32.3% MS/MS coverage, ICPL protein labelling strategy = 19.2% MS/MS coverage) 
and Tubulin beta-5 chain (ICPL peptide labelling strategy = 13.7% MS/MS coverage, ICPL protein 
labelling strategy = 3.6% MS/MS coverage).  The results from Table 4.1 suggest an improvement in 
quantitative data acquisition using the optimised ICPL peptide labelling, which was achieved because all 
observable peptides were labelled. 
 
In  an  ICPL  label  experiment,  one  should  consider  determining  the  regulation  window  of  the 
experimental variation by combining identical amounts of differentially labelled samples (i.e. labelled 
lysate combined at a 1:1 ratio) and quantify the peptide pairs.   In a situation without experimental 
variability, all ratios obtained would be 1.  Previous analyses on ICPL-labelled lysate samples combined 
at a 1:1 ratio (using the conventional ICPL protein labelling strategy) have determined that ICPL H/L 
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(utilising alternative SILE labelling such as SILAC) have adopted a regulation window of 0.66 to 1.5 
[197] or the use of a normalised expression difference of 1 standard deviation (1SD) as exclusion 
criteria [211].  In order to determine an appropriate regulation window for proteins at a 1:1 ratio, a 
preliminary assessment of variance was performed using 50 randomly selected peptide pairs from a R-
veIR-A ICPL peptide labelling experiment.  The intensity ratio of heavy to light peptides in each pair was 
log transformed, mean and standard deviation were calculated and these values were converted back 
to ratios using an exponential function (data not shown).  A regulation ratio of 1.2 was calculated for one 
standard deviation [1.45 for two standard deviations]. Thus, 95% of all control regulated peptides should 
fall within the range 0.689 and 1.452. 
 
Of the twenty-five proteins identified using the optimised ICPL peptide labelling strategy, only three 
proteins (Annexin A3, A5 and Elongation Factor 1-alpha) produced ratios outside the regulation window 
(0.64 ± 0.02, 1.67 ± 0.17 and 1.73 ± 0.19, respectively).  The reasons why these ratios were obtained 
were unclear; however one possible explanation is that ICPL-labelled peptides may co-elute with other 
peptides with almost identical m/z, thereby increasing the MS intensity obtained.  Despite the presence 
of proteins with H/L ratios outside the regulation window, the majority (22 out of 25) of ratios obtained 
were close to 1 (Table 4.1). 
 
In contrast, only two (tubulin beta-5 chain and Galectin-1) of the ten proteins from the conventional ICPL 
protein labelling strategy that yielded quantitative information were within the regulation window of 0.689 
to 1.452 (Table 4.1).  Our laboratory has previously determined a regulation window (using a different 
lysate) for ICPL protein labelling to be between 0.67 and 1.5 (Gustafsson et. al. unpublished).  This 
regulation window is almost identical to the window obtained with the optimised ICPL peptide labelling 
approach.  Using the previously reported regulation window, the number of ratios obtained from the 
conventional ICPL protein labelling strategy of R-veIR-A lysate increases to four (tubulin beta-5 chain, 
Galectin-1, Pyruvate kinase isozymes M1/M2 and Ubiquitin, Table 4.1).  All L/H ratios obtained from 
ICPL protein labelling were between 1.32 and 1.88, suggesting a systematic error with the heavy label 
used in ICPL protein labelling experiments. 
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4.3.2  Quantitative  analysis  of  the  tyrosine  phosphoproteome  after  IR 
stimulation with insulin 
The results from 4.3.1 presented here clearly showed that labelling of complex samples using the 
optimised ICPL peptide labelling strategy increased the number of proteins identified compared with the 
conventional  ICPL  labelling  strategy.    Furthermore,  the  ICPL  peptide  labelling  provided  more 
quantitative information of these proteins identified as it ensured the observed peptides contained at 
least one label for ratio determination.  The labelling of every observable peptide with at least one ICPL 
label is important for bottom-up PTM analysis, such as phosphorylation, as phosphopeptides produced 
after trypsin digestion of protein samples may not contain an ICPL labelling site (lysine residue or an N-
terminal fragment).  As such, in order to quantify changes in tyrosine phosphorylation after insulin 
stimulation of lysate IR-A and IR-B isoforms and downstream signalling proteins, the ICPL optimised 
peptide labelling strategy was combined with HILIC and pTyr enrichment (by affinity chromatography) 
for analysis using EZYprep LC-MALDI-TOF/TOF MS analysis. 
 
Figure 4.2 outlines the proteomic-based approach taken for global tyrosine phosphorylation analysis.  
The protocol utilises multiple techniques in order to provide information on changes in pTyr depending 
on which IR isoform was activated.  For insulin stimulation, a concentration of 100 nM was chosen.  
Although this concentration is higher than the typical insulin concentration of ≥ 10 nM used in many 
insulin signalling studies [412-418], it has been consistently used to stimulate phosphorylation of insulin-
activated pathways [412].  Interestingly, insulin stimulation at physiological concentrations (between 
100-500 pM) has been shown to stimulate phosphorylation of IR-B whereas higher physiological and 
pharmacological concentrations do not increase IR-B phosphorylation signal intensity [412].  However, 
the  100  nM  concentration  strongly  stimulates  phosphorylation  of  downstream  signalling  proteins, 
including Akt and eNOS [412].  As such, higher insulin concentrations have been used, particularly in 
proteomic-based strategies analysing the phosphoproteome of insulin signalling [203, 283]. 
 
Lysate was collected from unstimulated and stimulated cells for downstream western blot analyses or 
ICPL labelling followed by pTyr enrichment (utilising HILIC followed by a pTyr-specific 4G10 Ab column) 
and analysis using LC-MALDI-TOF/TOF MS (Figure 4.1).  In addition, FACS analysis was employed to 
determine IR receptor expression of both R-veIR-A cells and R-veIR-B cells.  Here, unstimulated R-veIR-A 
and R-veIR-B cells were collected and probed using the 83-7 Ab (specific for the IR) or an IgG negative 
control.  Using flow cytometry, cell populations for both the negative control and IR+ cells were defined  
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based on the negative control for both R-veIR-A and R-veIR-B cells.  Figure 4.3 shows the overlayed 
FACS graphs of R-veIR-A and R-veIR-B cells.  As shown in the graph, the IR+ populations from both R-
veIR-A and R-veIR-B cells are similar; meaning that the cells are expressing similar levels of receptor 
(slightly higher levels on the R-veIR-A cells) and a direct comparison of these cell types can be achieved 
with confidence.  
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Figure 4.2: Proposed global pTyr phosphoproteome approach 
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Diagram of the experimental workflow used for the quantitative and qualitative analysis 
of pTyr of a complex protein sample (cell lysate). (A):  R-veIR-A and R-veIR-B cells are 
placed  in  serum  starved  media  for  four  hours  (4  x  technical  replicates).    Cells  are 
stimulated  with  100  nM  insulin  for  10  minutes  prior  to  cell  lysis  using  RIPA  buffer.  
Unstimulated cells are also lysed as a control for western blot analysis or collected for 
FACS  analysis.    Lysate  is  split  equally  and  one  lot  is  used  for  western  blot  analysis 
(along  with  lysate  from  the  unstimulated  control),  whilst  protein  from  the  other  lot  is 
precipitated  and  re-dissolved  in  ICPL  lysis  buffer.    After  protein  concentration 
determination,  identical  sample  amounts  (40.3  µg)  from  R-veIR-A  and  R-veIR-B  lysates 
are  digested  with  trypsin  prior  to  labelling  with  the  light  and  heavy  ICPL  label, 
repectively.    (B)  After  labelling,  samples  are  combined  and  desalted  prior  to  HILIC 
fractionation to separate hydrophobic and hydrophilic peptides.  The pTyr component of 
the two (4) resulting HILIC fractions (Hydrophobic and Hydrophilic) are enriched using 
4G10  Ab  Protein  A  column  to  produce  four  (4)  fractions;  Hydrophobic  Flow  Though 
(HFT),  Hydrophobic  Eluate  (HE),  Hydrophilic  Flow  Through  (HIFT)  and  Hydrophilic 
Eluate (HIE).  The fractions were then analysed using LC-MALDI-TOF/TOF MS analysis 
with CHCA SMW for HFT and EZYprep DHB matrix deposition for HE, HIE and HIFT. 
 
Figure 4.3: FACS analysis of R
-IR-A and R
-IR-B cells 
To determine whether the IR expression of R-veIR-A and R-veIR-B cells were similar, R-
veIR-A  and  R-veIR-B  cells  were  harvested  and  probed  with  the  IR  specific  Ab  83-7 
according  to  the  material  and  methods  and  analysed  by  flow  cytometry.    Graphical 
representation of the data produced from the analysis of both R-veIR-A and R-veIR-B cells 
show  a  similar  level  of  IR  expressed  in  each  cell  type.    This  ensures  that  direct 
comparison  of  IR  phosphorylation  in  both  cell  types  can  be  achieved  with  a  high 
confidence as similar IR numbers will be stimulated.  
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To confirm this observation as well as determine similar downstream activation upon insulin stimulation 
of the IR of both cell types, western blot analyses were performed (as described in the material and 
methods 1.2.3 LDS-PAGE and Western Blotting).  Lysate collected from unstimulated and stimulated R-
veIR-A and R-veIR-B cells were assayed using four western blots; utilising CT-1 (IR specific Ab), 4G10 
(pTyr specific Ab), phopsho-IR /IGF-1R [Y1158/1162/1163] Ab and the the PathScan® Multiplex Western 
Cocktail 1 (which assays activation of multiple pathways by detection of phosphor-p90RSK, phosphor-
Akt, phosphor-p44/42, MAPK (Erk 1/2), phosphor-S6 Ribosomal protein as well as eIF4E detection for a 
loading control).  Shown in Figure 4.4 are the western blot analyses obtained from unstimulated and 
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Figure  4.4:  Western  blot  analysis  of  R-veIR-A  and  R-veIR-B  stimulated  and 
unstimulated lysate 
To confirm IR activation and subsequent activation of downstream signalling cascades, 
lysates  collected  from  unstimulated  and  stimulated  R-veIR-A  and  R-veIR-B  cells  were 
fractionated using LDS-PAGE and subjected to western blot analysis as described in the 
materials and methods. A. Western analysis probing with the PathScan® Multiplex assay, 
containing Abs detecting downstream activation of known signalling pathways, including 
phospho-p90RSK,  phospho-Akt,  phospho-p44/p42,  MAP  Kinase  (MAPK),  and  phospho-
S6  ribosomal  protein.    A  loading  control  eIF4E  is  also  included.    An  increase  in  the 
expression  of  both  phospho-Akt  and  phospho-S6  ribosomal  protein  is  seen  in  the 
stimulated lanes. B. Western analysis probing with the pTyr specific Ab 4G10.  Although 
multiple bands across all lanes can be seen (which may be due to non-specific binding of 
the  Ab),  definitive  differences  between  stimulated  and  non-stimulated  bands  are 
apparent, such as a band ~160 kDa (highlighted).  C. After probing with the CT-1 Ab, a 
band  at  ~95  kDa,  representing  the  β-region  of  the  IR  can  be  seen  across  all  lanes, 
however  the  band  in  the  stimulated  R-veIR-A  lysate  (highlighted)  lane  is  less  intense 
compared with the band from the stimulated  R-veIR-B lysate lane.  The re-probing with 
tubulin  (as  a  loading  control)  verifies  a  lower  concentration  being  loaded  in  the 
stimulated R-veIR-A lysate lane compared with the stimulated R-veIR-B lane. D. Western 
blot  analysis  probing  with  the  Ab  specific  for  the  3-Y  residues  known  to  be 
phosphorylated in IR and IGF-1R shows an intense band only in the lane corresponding 
to the stimulated  R-veIR-B lysate (highlighted).  Analysis of the tubulin loading control 
shows  no  differences  in  loading  material,  suggesting  the  presence  of  the  triply 
phosphorylated region in the stimulated R-veIR-B only. 
 
The analysis of the western blot showed clear differences between unstimulated and stimulated lysates 
when probed with 4G10, which is indicative of different phosphotyrosine abundances (Figure 4.4B).  
Further western blot analysis on unstimulated and stimulated R-veIR-A and R-veIR-B lysates showed that 
although similar activation with respect to known downstream proteins (including phosphor-Akt and 
phosphor-S6 ribosomal protein from the PathScan® Multiplex assay) occurred, a clear difference in the 
expression of the phosphorylated 3Y region of the IR receptor can be seen between insulin stimulated 
R-veIR-A and R-veIR-B cells (Figure 4.4D).  This observation correlates with previous reports showing 
that  insulin  binding  to  the  IR-B subtype  results  in greater  auto-phosphorylation  (and  has  a  higher 
tyrosine kinase activity) than IR-A, despite IR-A having a greater binding affinity than IR-B [403, 419].  
The inability to detect this phosphorylated 3Y region may be due to the levels being lower than the 
detection threshold of the western blot analysis. Interestingly, this difference in auto-phosphorylation 
between IR-A and IR-B did not affect qualitatively the activation of downstream signalling proteins, such 
as Akt (as shown in Figure 4.4A) at this time-point, yet this is based on visual inspection only.  As such, 
there may be quantitative differences in downstream phosphorylation, which would indicate that the 
difference in auto-phosphorylation seen between the receptors did affect the activation of signalling 
pathways.  Any differences in phosphorylation of these downstream proteins would be identified and 
characterised using the proposed quantitative proteomic strategy.  
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The FACS analysis indicated similar IR expression levels in both R-veIR-A and R-veIR-B cells, while the 
western blot analyses showed phosphorylation (particularly tyrosine and serine) of proteins following 
insulin stimulation of both the IR-A and IR-B receptors.  As such, the remaining lysates collected from 
insulin stimulated R-veIR-A and R-veIR-B cells were ICPL-labelled using the optimised ICPL peptide 
labelling strategy (R-veIR-A with the light isotope and R-veIR-B with the heavy isotope), combined and 
fractionated using HILIC to produce a Hydrophobic and Hydrophilic fraction.  These fractions were then 
subjected to pTyr peptide enrichment using 4G10 (as outlined in Figure 4.2).  Following HILIC and pTyr 
enrichment,  four  fractions,  Hydrophobic  Flow-Through  (HFT),  Hydrophobic  eluate (HE),  Hydrophilic 
eluate (HIE) and Hydrophilic Flow-Through (HIFT) were subjected to LC-MALDI-TOF/TOF MS analysis.  
The EZYprep method was utilised as the matrix preparation for LC-MALDI-TOF/TOF MS analysis of the 
HE,  HIE  and  HFT  fractions  as  phosphopeptides  were  anticipated  to  be  localised  in  these  after 
phosphopeptide enrichment. 
 
Table 4.2 outlines the proteins identified from each fraction, the % sequence coverage (MS/MS data) 
obtained for each hit, the number and sites of any phosphorylation on the identified proteins, the 
average regulation (H/L) obtained from each proteins and the number of ICPL-labelled peptide pairs 
used to identify the proteins.  In order to minimise false positives, only proteins with at least one peptide 
above a mascot score >25 were considered as being present. 
 





















HS90B_MOUSE  7.3  -  -  1.04  5 
Annexin A2  ANXA2_MOUSE  14.5  -  -  1.23  4 
Heat shock 
cognate 71 
HSP7C_MOUSE  9.9  -  -  0.97  3  
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kDa protein 
Annexin A1  ANXA1_MOUSE  12.7  -  -  1.36  2 
Alpha-




TBA1C_MOUSE  6.7  -  -  1.18  2 
Serum 
albumin  ALBU_MOUSE  4.3  -  -  1.16  1 
Annexin A5  ANXA5_MOUSE  10.3  -  -  1.20  2 
Tubulin beta-








RL6_MOUSE  8.4  -  -  0.98  2 
Tropomyosin 





KPYM_MOUSE  5.6  -  -  1.00  2 












RS8_MOUSE  7.2  -  -  1.03  1 
Galectin-1  LEG1_MOUSE  8.9  -  -  1.24  1 
Serpin B6  SPB6_MOUSE  5.0  -  -  1.73  1 
Filamin-A  FLNA_MOUSE  0.9  -  -  1.53  2  
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Alpha-








RBM3_MOUSE  9.2  -  -  1.21  1 
Serpin H1  SERPH_MOUSE  3.6  -  -  1.56  1 
HE 
Serum 
albumin  ALBU_MOUSE  2.1  -  -  1.25  1 
HIE 
Actin, 
cytoplasmic 1  ACTB_MOUSE  7.7  -  -  1.00  2 
HIFT 
Actin, 









MARCS_MOUSE  10.7  -  -  1.05  1 
Galectin-1  LEG1_MOUSE  27.4  -  -  1.24  3 
Filamin-A  FLNA_MOUSE  1.5  -  -  1.77  2 
Reticulon-4  RTN4_MOUSE  3.8  -  -  1.04  2 





ROA2_MOUSE  4.2  -  -  0.99  1 
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Table 4.2 shows that the majority of proteins identified (25) were in the HFT fraction, with only one 
protein  positively  identified  in  the  HE  (serum  albumin)  and  HIE  (Actin,  cytoplasmic  1)  fractions.  
Additionally, the HIFT fraction identified 8 proteins, all with H/L ratios within the regulation window set in 
control ICPL experiments.  Of the 25 proteins positively identified in the HFT fraction, 5 proteins were 
shown to be significantly regulated (i.e. outside the determined 0.689  – 1.452 regulation window), 
including tubulin-beta-5 chain (1.55), Rho GDP-dissociation Inhibitor (1.72), Serpin B6 (1.73), Filamin-A 
(1.53) and Serpin H1 (1.56).  These proteins were entered into the IPA database to determine their 
function/s, their connectivity in characterised biological networks, and whether these proteins in the 
networks have been previously characterised in biological disorders.  Filamin-A, Serpin-H1 and tubulin-
beta-5  chain  were  categorised  as  being  involved  in  filament  organisation  (p-value  6.82  e-6)  and 
individual searches of the proteins identified their primary functions to be increasing actin filament 
organisation,  organisation  of  collagen  fibrils  and  decreasing  microtubule  organisation,  respectively.  
Similarly, Rho GDP-dissociation inhibitor was identified as being involved in actin reorganization.  Serpin 
B6 has numerous functions, such as serine-type endopeptidase inhibitor activity, protein binding and 
peptidase inhibitor activity.  As anticipated, no phosphorylation sites were identified in  this fraction, 
which can be attributed to it being obtained from the hydrophobic fraction (after HILIC enrichment) and 
also run through the 4G10 column (to enrich remaining pTyr peptides).  In addition, the majority of the 
digested  lysate  would  be  contained  in  this  fraction  (after  HILIC  and  pTyr).    As  such,  LC-MALDI 
fractionation over a half-target will be limited in its capacity to effectively fractionate a sample of this 
complexity, which is evident by the low number of proteins identified.  The complexity of the HFT 
fraction also minimises the possibility of identification of any remaining hydrophobic pSer and pThr 
peptides,  primarily  due  to  low  abundance  of  phosphopeptides  compared  with  non-phosphorylated 
peptides as well as ion suppression effects. 
 
Table  4.2  shows  that  despite  HILIC  fractionation  coupled  with  4G10  pTyr  enrichment,  no 
phosphopeptides were successfully identified and characterised in any of the eluted fractions (i.e. HE 
and HIE) after EZYprep LC-MALDI-TOF/TOF MS analysis.  Only a small number of peptides were 
matched  to  proteins  present  in  the  sample,  namely  serum  albumin  in  the  HE  fraction  and  actin 
cytoplasmic, 1 in the HIE fraction.  The identification of these proteins reflects non-specific binding of 
high abundance peptides/proteins remaining despite multiple phosphopeptide enrichment strategies.  
EZYprep LC-MALDI-TOF/TOF MS analysis of the HIFT fraction identified 8 proteins, with Filamin-A 
once again having a regulation (1.77) outside the pre-defined window.  As with the other fractions, no 
phosphopeptides were identified and characterised, suggesting that phosphorylation in the samples was  
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at a level below the sensitivity threshold of the proposed HILIC/pTyr specific Ab EZYprep LC-MALDI-
TOF/TOF MS analysis. - 118 - 
 
5 Discussion 
5.1 Discussion for Chapter 2: 
The studies presented in this chapter sought to develop a sensitive approach for pTyr characterisation 
on targeted proteins of interest by exploiting the availability of pTyr-specific Abs and MALDI TOF/TOF 
MS.  Utilising pTyr-specific Abs for pTyr protein identification is not a new concept, as these Abs have 
been used for IP and western blot analysis and, more recently, these Abs have been used prior to MS 
analysis to improve pTyr protein identification, particularly for global pTyr analysis [191, 229, 231, 283, 
294-297, 301, 323].  However, research on individual proteins will commonly utilise more traditional 
biochemistry techniques (IP and/or western blot), mainly as these methods are straight-forward, cost 
effective and of high sensitivity.  Despite their ability to provide phosphoprotein identification and to a 
lesser extent, quantitation, these methods will not provide phosphosite information without the use of 
site-directed mutagenesis experiments or MS [229, 252].  Furthermore, because of the low abundance 
of phosphoproteins and peptides compared with non-phosphorylated proteins or peptides, the success 
of MS is limited.  For the analysis of proteins of interest where tyrosine phosphorylation is known to 
occur  but  the  site  has  not  been  elucidated,  there  is  a  need  for  methods  that  enrich  and  isolate 
phosphopeptides to improve subsequent MS identification and characterisation. 
 
The Pro-GP/Cov-P approach exploits the availability of super para-magnetic beads that are compatible 
with MS.  These beads can be removed from enriched samples using a magnet so they do not interfere 
with MS analysis.  Proteins can be isolated or separated from complex samples by a number of different 
methods such as IP or SDS-PAGE.  Alternatively, recombinant proteins, generated for protein structure 
and function analyses, can be phosphorylated in vitro using known interacting phosphotyrosine kinases.  
Following in-gel or in-solution digestion with proteases such as trypsin, phosphopeptides generated 
from  the  protein  of  interest can be subjected  to  MS  analysis  or  enriched  using various  strategies 
targeting the phosphoproteome, including IMAC, TiO2, Pro-GP/Cov-P, HILIC, SCX or a combination of 
these strategies.  Magnetic beads compatible with MS are of particular importance as multiple surface 
chemistries can be exploited to enrich for proteins, peptides and PTMs of interest. 
 
The Pro-GP/Cov-P approach described here combines pTyr-specific Ab enrichment with these magnetic 
beads  to  enrich  pTyr  peptides  for  direct  analysis  by  MALDI-TOF/TOF  MS  analysis.    Specifically 
targeting pTyr phosphopeptides improves pTyr enrichment in comparison to methods targeting the  
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entire  phosphoproteome.    Many  strategies  targeting  the  tyrosine  phosphoproteome  will  utilise  a 
combination  of  pTyr-specific  Ab  enrichment  in  combination  with  a  more  global  phosphopeptide 
enrichment strategy such as IMAC or TiO2 [191, 264, 295, 301, 420].  Previous strategies solely utilising 
pTyr  Ab-conjugated  beads  for  phosphopeptide  enrichment  have  been  focused  on  global 
phosphoproteome mapping of signalling networks [191, 229, 301].  Although it is possible to utilise 
these methods for less complex sample analyses, an optimised strategy developed for pTyr analysis is 
required as a straight-forward, cost-effective and reproducible alternative to conventional biochemistry 
techniques.  The Pro-GP/Cov-P protocol was developed primarily for low complexity samples.  The 
ability to directly analyse eluates without the requirement for additional sample preparations (e.g. de-
salting) minimises sample loss (including pTyr-peptides), which is important for analysis of extremely 
low abundant phosphopeptides.  The direct analysis coupled with the use of optimised DHB matrix 
deposition strategies further enhances MALDI-TOF/TOF MS sensitivity. 
 
Often, tyrosine phosphopeptides generated from proteins will be at a significantly lower abundance than 
non-phosphorylated peptides from the same protein.  This is because only a small percentage of a 
protein may be tyrosine phosphorylated after a specific stimulation time.  Hence, if only 1% of the 
protein of interest is tyrosine phosphorylated, then only 1% of the peptides generated from this protein 
will  be  phosphorylated  on  tyrosine.    This,  in  conjunction  with  ion-suppression  effects  of  non-
phosphorylated  peptides,  makes  it  extremely  difficult  to  detect  those  phosphopeptides  and  it  is 
imperative  to  be  able  to  visualise  low  abundant  peptides  in  order  to  ensure  adequate  sequence 
coverage, particularly on areas of proteins known or thought to be phosphorylated.  As shown in 
Chapter  2  (Figures  2.3  and  2.4),  the  Pro-GP/Cov-P  approach  is  able  to  successfully  enrich 
phosphopeptides that are at a 200:1 ratio compared with non-phosphorylated peptides present in a 
sample.   
 
An important factor of the Pro-GP/Cov-P approach is that it targets solely the pTyr phosphoproteome.  
Although other strategies, such as IMAC and TiO2, are commonly promoted phosphopeptide enrichment 
strategies,  they  are  only  utilised  for  pTyr  research  in  combination  with  pTyr  protein  or  peptide 
enrichment with pTyr Abs [191, 264, 295, 301, 420].  As shown in Chapter 2 (Figure 2.2), the Pro-
GP/Cov-P approach was necessary to identify three pTyr peptides added to a BSA tryptic digest at 1:10 
ratio.  Enrichment using these strategies ensured the phosphopeptides were amongst the top five most 
intense  peptide  ions,  and  these could  subsequently be  selected  for  MS/MS  characterisation  if  the 
sample was unknown.  In contrast, although the IMAC enrichment approach was able to detect two of  
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the three phosphopeptides, neither of these constituted the top five most intense peptide ions.  As such, 
these peptides would not be selected for MS/MS analysis unless prior sequence information of the 
protein/s of interest was known.  These results show the need to couple IMAC with pTyr protein or 
peptide enrichment to ensure detection of low abundant pTyr peptides. 
 
The ability to use the Pro-GP/Cov-P strategy as a sole method for phosphotyrosine characterisation is 
particularly  useful  for  laboratories  that  are  unable  to  access  sensitive  LC-MS/MS  equipment  for 
proteomic analyses.  The high set-up costs associated with LC systems means many laboratories are 
limited to more traditional biochemical techniques, such as western blot analysis.  The Pro-GP/Cov-P 
approach allows for researchers to undertake pTyr characterisation without the need for more expensive 
LC-MS systems using MALDI-TOF/TOF MS instruments. 
 
The Pro-GP/Cov-P strategy can also be utilised for the analysis of more complex samples.  This is 
because the super para-magnetic beads utilised form part of the ClinProtTM magnetic bead system 
developed by Bruker for large-scale automation of magnetic bead enrichment strategies.  Multiple Pro-
GP/Cov-P  beads  can  be  loaded  into  wells  for  a  serial  enrichment  of  complex  samples.    Serial 
enrichment is necessary due to the capacity limitations of the beads.  The manufacturers‟ instructions 
suggest a loading concentration of 100 pmol or less.  Large sample analysis would therefore require a 
serial  enrichment  strategy  where  non-bound  peptides  (sample  flow  through  fraction)  would  be  re-
enriched over the following Pro-GP/Cov-P beads.  This process is automated using the robotic system 
supplied by Bruker Daltonics. 
 
Additionally, the Pro-GP/Cov-P beads can be combined with more conventional SDS-PAGE for sample 
analysis.    In  chapter  2,  1D  SDS-PAGE  and  Pro-GP/Cov-P  was  used  to  characterise  pTyr 
phosphorylation on the βic recombinant protein after in vitro phosphorylation (Figure 5 and 6).  For more 
complex analysis, 2-DE could be used for more effective separation of proteins.  Replicate gels can be 
used for western blot analysis of the 2-DE using 4G10 to identify the location of tyrosine phosphorylated 
proteins.  These spots can be excised from replicate coomassie stained gels and proteins digested in-
gel for subsequent Pro-GP/Cov-P enrichment.  Alternatively, proteins can be extracted off the western 
blot  membrane  itself  to  ensure  accurate  excision  of  protein  spots  identified.    After  extraction  and 
digestion, Pro-GP/Cov-P enrichment of pTyr peptides can be conducted.  
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An appealing component of the current Pro-GP/Cov-P protocol is that any pTyr Ab can be used.  It is 
known that pTyr specific Abs have varying affinities to different ligands [225, 244, 421], which is due to 
the fact that particular Abs are generated to target specific antigens  [294].  In order to account for 
varying affinities of pTyr specific Abs to ligands, alteration of the protocol to conjugate a combination of 
pTyr specific Abs will improve coverage of the tyr phosphoproteome (overall tyrosine phosphopeptide 
recovery).  Abs raised against specific pSer and pThr epitopes can also be conjugated to Pro-G/Cov-P 
magnetic beads to enrich the relevant phosphopeptides and confirm the site of phosphorylation by MS.  
These Abs specific to pSer/pThr recognise multiple consensus sequences (up to ten residues either 
side of the phosphorylation site to form epitopes), which improve pSer/pThr enrichment and subsequent 
identification by MS. 
 
5.2 Discussion for chapter 3: 
 
5.2.1 Matrix deposition for phosphopeptide analysis 
Improvement of phosphopeptide detection is critical in order to increase  the ability to characterise 
phosphorylation  in  both  targeted  and  global  approaches.    Research  on  phosphoproteome  method 
development  focuses  on  optimisation  of  both  the  enrichment  strategies  as  well  as  MS  sample 
preparations.  Optimisation of phosphoproteomic strategies, such as methylation prior to IMAC [50] or 
the  implementation  of  a  DHB  conditioning  step  with  TiO2  enrichment  [261]  have  both  improved 
phosphopeptide recovery.  Similarly, the results from Chapter 2 showed that alteration of the protocols 
developed  for  MB-IAC  Prot  G  and  MB-CovAC-Select  beads  to  develop  Pro-GP/Cov-P  enrichment 
(namely the use of a matrix solution for phosphopeptide elution) increased detection sensitivity. 
 
Despite  improvements  in  proteomic  enrichment  methods,  the  low  stoichiometry  of  phosphorylation 
coupled with the ionisation suppression effects of phosphorylation [256, 422] still pose a challenge for 
phosphosite characterisation.  To aid phosphopeptide enrichment strategies and subsequent detection 
using MS, a number of optimised sample preparation methods have been developed.  In terms of 
MALDI-TOF-MS  analysis  of  phosphopeptides,  several  methods  have  been  employed,  including 
alternating polarity (from positive-ion mode to negative-ion mode) to aide in phosphopeptide selection 
for MS/MS [333, 423-427].  Analysing in negative-ion mode favours negatively charged ions and as the  
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phosphate  group  carries  a  negative  charge,  analysis  in  this  mode  has  been  shown  to  improve 
phosphopeptide ionisation [333, 423-427].  Other methods have employed the use of ammonium salts 
as an additive to matrices such as diammonium hydrogen citrate (DAHC) [428-431], ammonium acetate 
[428] and monoammonium dihydrogenphosphate [426].  These salts improve ionisation efficiency of 
phosphopeptides crystallised with matrices in an ionic form.  As each phosphate group can carry up to 
two charges, if a multiply charged analyte is co-crystallised in matrix in ionic form, insufficient energy is 
available for analyte desorption.  The higher the number of phosphate groups attached, the higher the 
negative charge state of the peptide.  As predominately singly-charged ions are favoured in MALDI 
[116], a low energy chemical pathway to allow a lowering of charge state is required [428].  The addition 
of ammonium cations (NH4+) forms complexes with negatively-charged groups, including phosphate 
groups.  During the desorption/ionisation process, NH3 is lost, leaving the charged group in a neutral 
form with a proton attached [428, 432].   
 
More recent strategies have combined the use of matrix additives with particular matrix types to improve 
phosphopeptide ionisation and characterisation.  In particular, the advantages of the combination of 
DHB with phosphoric acid have been well documented and utilised in a number of phosphoproteomic 
analyses [51, 125, 200, 320].  The benefits of DHB/PA for phosphopeptide ionisation and detection are 
attributable to a number of observations.  The DHB matrix is considered a „cold‟ matrix as it leads to the 
formation of ions with a low internal energy [125, 433].  As such, these ions remain intact during the 
mass  analysis.    The  use  of  this  matrix  for  phosphopeptide  analysis  improves  peptide  stability, 
minimising loss of the phosphate group during ionisation.  In contrast, the use of CHCA (considered a 
„hot‟ matrix) leads to significant decomposition of the phosphopeptides, resulting in the loss of the 
phosphate group or phosphoric acid (80 and 98 Da, respectively) [125].  The addition of between 0.1 – 
1%  PA  to  the  matrix  has  shown  to  further  improve  ionisation  of  co-crystallised  phosphopeptides.  
Previous analyses have shown that the rate of matrix/analyte crystallisation affects the incorporation 
ratio  of  hydrophilic  peptides  [434].    It  has  been  speculated  that  the  slow  evaporation  helps  drive 
phosphopeptides  and  phosphoric  acid  into  the  matrix  crystals,  improving  recovery  [51,  125].  
Additionally, PA is thought to incorporate phosphopeptides with higher charge states, due to previous 
analyses that have observed the presence of both doubly-charged ions and molecular cluster ions of 
phosphopeptides but not of non-phosphorylated peptides in the crystalline analyte/matrix deposit.  As 
such, it has been hypothesised that PA creates a “salting out” of phosphopeptides, leading to more 
efficient incorporation into the matrix crystals [51, 125].  Finally, PA has been observed to reduce the 
number of sodium adducted peptide ions in mass spectra, which may be due to it acting as a “sodium 
sink” to capture sodium ions, minimising sample complexity [125].  
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In our hands, comparative analysis of a tryptic digest of β-casein using either CHCA or DHB/PA clearly 
shows and increase in phosphopeptide ionisation, particularly for multiply-phosphorylated peptides (as 
shown in Figure 5.1). 
 
 
Figure  5.1:  The  analysis  of  two  phosphopeptides  generated  from  a  tryptic 
digest of β-casein using MALDI-TOF MS analysis with either DHB/PA matrix or 
CHCA matrix. 
A 10 pmol β-casein digest mixture was spotted with either 5 mg/mL DHB/1% PA or with 
CHCA  Thin-layer  (CHCA  TL)  method.    As  shown,  the  intensity  of  two  common 
phosphopeptides produced are more intense in spectra obtained when DHB/PA was used 
compared  with  CHCA.    This  is  particularly  apparent  with  the  multiply  phosphorylated 
peptide, which was not detectable with CHCA matrix. 
 
In addition to the advantageous observations from previous analyses focusing on DHB/PA, we have 
observed that DHB/PA displays a higher tolerance to sample contaminants compared with CHCA, as 
outlined  in  Chapter  2.    Another  property  of  DHB/PA  matrix  that  has  increased  its  use  for 
phosphopeptide  analysis  is  its compatibility  with  phosphopeptide  enrichment  strategies,  particularly 
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IMAC.  It can be used as an elution solution, minimising sample handling prior to MS.  The use of 
DHB/PA to elute phosphopeptides bound to IMAC resin was shown to improve recovery of both singly- 
and multiply-phosphorylated residues [51].  Interestingly, the use of CHCA/PA as an elution solution 
resulted in poor peptide recovery from IMAC, indicating that PA alone is not enough to elute bound 
phosphopeptides.  A similar result was also noticed during optimisation of the Pro-GP protocol, where 
no phosphopeptides were obtained when CHCA was used as the elution solution, but were obtained 
when DHB/PA was used (data not shown).  Although the CHCA did not contain PA, it did contain TFA 
(0.1%), which should be sufficient to denature the 4G10 Ab as the pH is low (2.0).  The results obtained 
from these Pro-GP optimisation experiments are more likely due to the DHB/PA matrix being more 
tolerant to residual immobilisation and wash buffers remaining in the sample after elution. 
 
Although the advantages of DHB/PA matrix for phosphopeptide ionisation have been well documented, 
the heterogeneity of the DHB crystals have hampered it widespread use.  The generation of non-
homogeneous sample preparations often results in hot-spot formation, making it difficult to utilise this 
matrix for more complex sample analysis, which typically utilises automated data collection, including 
LC-MALDI-TOF/TOF MS analysis [430, 433].  In order to overcome DHB crystal heterogeneity, the 
ImagePrep™ station (Bruker Daltonics), a device developed to apply homogenous matrix layers over 
tissue sections for MALDI imaging, was utilised to generate a DHB matrix „mist‟ for matrix application 
onto MALDI targets for subsequent MALDI-TOF/TOF MS analysis.  The use of this instrument as a DHB 
deposition strategy was based on the improved homogeneity of DHB crystals formed on tissue sections, 
as shown in Figure 5.2. 
  
- 125 - 
 
 
Figure 5.2: (A) DHB crystallisation after ImagePrep station deposition onto a 
tissue  section  slide.  (B)  MALDI  CCTV  shots  of  raster  positions  highlighting 
crystal  formation  using  DHB  DD  deposition  or  EZYprep  (using  ImagePrep 
Station) DHB post sample matrix deposition. 
 
As  shown  in  Figure  5.2B  (and  Table  3.2  from  Chapter  3),  crystals  generated  using  the  EZYprep 
approach (using the ImagePrep station) have a higher degree of homogeneity than crystals generated 
from conventional DHB DD matrix deposition.  In addition, the results from Chapter 3 clearly show that 
the EZYprep approach substantially improved LC-MALDI-TOF/TOF MS analysis results for  peptide 
digest mixture PM1 compared with results obtained using the DHB DD approach.  This highlights the 
improvement of automated acquisition (by EZYprep approach) on homogenous analyte/matrix crystal 
preparation,  which  ensures  that  spectra  can  be  obtained  at  more  positions  on  the  raster.    Also, 
improved crystal homogeneity minimises spatial distribution of analyte on the raster position.  This is 
important as large differences in spatial distribution of analytes results in variations in initial kinetic 
DHB (20 mg/mL in 50% methanol with 0.2% TFA) sprayed onto ITO glass slide 
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energies after desorption/ionisation, which can decrease mass accuracy  [88].  In contrast, although 
DHB DD preparation has similar advantages in terms of phosphopeptide ionisation, the numbers of 
proteins identified as well as phosphopeptides detected for PM1 were lower compared with EZYprep 
DHB  deposition.    The  crystal  heterogeneity  of  the DHB  DD  method can cause slight  mass  shifts 
between individual spectra across the raster position, which decreases the mass accuracy of peptides 
obtained.  Furthermore, the large crystals formed in DHB DD deposition could be missed when utilising 
automated acquisition, which is required for LC-MALDI-TOF/TOF MS analysis, and this decreases 
spectra quality and intensity. 
 
As  shown  in  Chapter  3,  the  protein  identification  and  phosphopeptide  detection  results  between 
EZYprep DHB and CHCA SMW were comparable.  This can be attributed to the improvement of 
analyte/DHB  crystallisation  using  EZYprep.    Consistent  with  previous  analyses  comparing 
phosphopeptide  intensity  obtained  with  DHB/PA  with  other  matrix  types,  a  statistically  significant 
increase  in  phosphopeptide  intensity  was  observed  when  using  EZYprep  DHB  instead  of  CHCA 
(Chapter 2).  Although this was not beneficial for the analysis of phosphopeptides in PM1, this increase 
in phosphopeptide intensity will aid in the detection of phosphopeptides from more complex sample 
analyses.    This  is  because  a  higher  number  of  non-phosphorylated  peptides  will  co-elute  with 
phosphopeptides, despite LC fractionation.  The increase in non-phosphorylated peptides will increase 
ion suppression effects on phosphopeptides in the same fraction.  As such, phosphopeptides with a low 
intensity may no longer be detectable.  Improving phosphopeptide intensity using EZYprep DHB will 
decrease instances where phosphopeptides succumb to ion suppression effects. 
 
5.2.3 LC-MALDI-TOF/TOF MS versus LC-ESI-IT-MS/MS 
The EZYprep DHB approach is suitable for the analysis of the phosphoproteome of complex samples as 
it  is  coupled  to  LC  sample  fractionation  prior  to  MALDI-TOF/TOF  MS  analysis.    The  use  of  this 
separation strategy has particular advantages over LC-ESI-IT-MS/MS, which has been the method of 
choice to date for phosphoproteome analysis [200].  Samples fractionated onto MALDI targets become 
stable, essentially „frozen in time,‟ and repeated analysis can be conducted should more information 
from  the  sample  be  required.    In  addition,  MS/MS  data  acquisition  is  not  restricted  to  any  time 
constraints (like with LC-ESI-IT-MS/MS), meaning more time can be spent on MS/MS data collection on 
peptides of interest that may not constitute the most intense ions in the spectra.  This allows manual 
intervention at any stage of the acquisition and ultimately reduces the number of acquired MS/MS  
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spectra as it minimises the collection of redundant MS/MS spectra.  Moreover, LC-MALDI-TOF/TOF MS 
is more tolerant to sample contaminants and/or additives compared with LC-ESI-IT-MS/MS.  The main 
disadvantage of LC-MALDI-TOF/TOF MS is the longer time required to analyse samples, making it less 
suited for high through-put analyses.  As such, LC-ESI-IT-MS/MS is ideal for routine sample analysis 
where MS data alone is insufficient, whilst LC-MALDI-TOF/TOF MS can be utilised for the analysis of 
more precious samples.  Previous analyses comparing LC-MALDI-TOF/TOF-MS and LC-ESI-MS/MS 
have found that although a degree of overlap occurs in regards to results, the two approaches can be 
complementary [321, 435-437]. 
 
In order to gauge the sensitivity of the proposed EZYprep LC-MALDI-TOF/TOF MS approach and 
evaluate the complementarity of LC-MALDI-TOF/TOF MS with LC-ESI-IT-MS/MS, both methods were 
utilised to characterise EGF-stimulated EGFR phosphorylation over 5 minutes.  In addition, the Pro-GP 
protocol was  also  evaluated  using  this sample  to  highlight  the  capacity  of  this  approach  for  pTyr 
characterisation.  Analysis of EGFR phosphorylation using the three approaches successfully identified 
16 unique phosphopeptides over the time-course analysed, as outlined in Chapter 3 (Figure 3.2, Table 
3.4) and in Table 5.1. 
 
 
Table  5.1: Overview  of the  phosphopeptides  identified from  chapter 2  using 
Pro-GP, EZYprep LC-MALDI-TOF/TOF MS and LC-ESI-IT-MS/MS. 
 
At each time point, EZYprep LC-MALDI-TOF/TOF MS analysis detected the most phosphopeptides, 
which highlights the improved sensitivity of the approach.  After automated MS acquisition for each time 
point using Pro-GP bead enrichment or EZYprep LC-MALDI-TOF/TOF MS, the spectra were evaluated 
manually and ions whose m/z corresponded to potentially phosphorylated peptides (generated from an 
Process Number of phosphopeptidesfrom EGFR identified and characterized
Time 0 min Time 1 min Time 3 min Time 5 min
Pro-GP (pTyr Only) 0 6 7 5
EZYprep LC-MALDI 5 9 13 13
LC-ESI-IT-CID/ETD 2 4 4 6
Unique EGFR 
phosphopeptides 5 10 14 15 
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in silico digest of the EGFR) were selected for MS/MS analysis.  In contrast, an inclusion list (also 
generated from an in silico digest of the EGFR) was analysed using the software controlling automated 
LC-ESI-IT-MS/MS acquisition.  Although the same inclusion list was used for all approaches, only in LC-
MALDI-TOF/TOF MS was the collection of MS/MS data controlled such that potential phosphopeptides 
were the primary choice for MS/MS acquisition.  With LC-ESI-IT-MS/MS, potential phosphopeptides 
were selected (even if they did not constitute the top 3 ions).  However, the time constraints on MS/MS 
acquisition may have hampered adequate MS/MS data.  In addition, ion-suppression effects (due to the 
high abundance of co-eluting non-phosphorylated peptides) may have hampered detection.  Although 
ion suppression effects also hamper phosphopeptide detection using LC-MALDI-TOF/TOF MS analysis, 
the ability to load fractionated samples across multiple raster positions on a MALDI target improved the 
chances of phosphopeptide detection.  It is important to mention that less starting material (1 µL) was 
used for LC-ESI-IT-MS/MS compared with LC-MALDI-TOF/TOF MS (3.5 µL).  This was due to capacity 
limitations of the  trapping column used for LC-ESI-IT-MS/MS.  Despite this, the approach allowed 
identification and characterisation of many of the phosphopeptides at each time point, highlighting the 
superior sensitivity over LC-MALDI-TOF/TOF MS.  However, the venn diagrams generated show that 
whilst some phosphopeptides were detected using both approaches, many were detected solely by LC-
MALDI-TOF/TOF MS.  This may be attributable to different ionisation efficiencies of peptides with 
MALDI and not just because a larger sample amount was used.  
 
One highlight was the ability of the Pro-GP approach to identify and characterise phosphopeptides 
without the need for LC separation.  As shown in the venn diagrams in chapter 3 (Figure 3.2), the Pro-
GP  approach  identified  many  of  the  phosphopeptides  identified  using  EZYprep  DHB  LC-MALDI-
TOF/TOF MS at each time point, with the exception at time 0 min.  The Pro-GP failed to detect any of 
the phosphopeptides detected at time 0, even at later time points (Chapter 3, Table 3.4).  This is due to 
the fact that all but one phosphopeptide was found to be a phosphorylated at either serine or threonine, 
which would not be enriched using the Pro-GP approach utilising 4G10 pTyr specific Ab.  Moreover, the 
inability for the Pro-GP approach to detect the pTyr peptide at time 0 may be due to the varying affinity 
of the 4G10 Ab to pTyr, as previously reported in Chapter 2 and elsewhere [225, 244].  Despite the 
inability of the Pro-GP to detect phosphopeptides at time 0, these results show the effectiveness of the 
magnetic bead strategy as an alternative to LC-based strategies, successfully providing phosphopeptide 
information,  albeit  providing  less  sites  than  the  more  sensitive  alternatives.    Moreover,  Pro-GP 
enrichment identified and characterised one phosphopeptide [M+H]+ 1644.688, that was not detected 
using the other approaches.  
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Despite  the  EZYprep  DHB  LC-MALDI-TOF/TOF  MS  approach  identifying  the  majority  of 
phosphopeptides,  none  of  the  approaches  analysed  was  able  to  provide  total  phosphosite 
characterisation of EGFR phosphorylation, emphasizing the potential importance of using  both LC-
MALDI and LC-ESI-MS/MS approaches to obtain a more complete overview of the phosphoproteome.  
However,  further  improvement  of  either  strategy  could  increase  phosphopeptide  identification  and 
characterisation.  Particular emphasis on LC separation of phosphopeptides using alternative or varying 
combinations of ion-paring reagents has the potential to improve phosphopeptide binding to the RP 
column.  For example, the addition of PA in the analyte solution has been shown to enhance detection 
of multiply-phosphorylated peptides in LC-ESI-MS/MS [438].  Alternatively, PA can be added to the 
mobile phase, which can improve peptide separation as  it increases the hydrophilicity of peptides, 
meaning an earlier elution in the gradient [74] which means elution occurs over a longer period of time.  
Interestingly, preliminary LC-MALDI-TOF/TOF MS analyses of PM1 were conducted using 0.05% PA in 
the mobile phase instead of TFA.  On analysis of chromatographic peak shape and retention time of 
both phosphorylated and non-phosphorylated peptides present in both tests, no discernable differences 
were noted.  Chromatographic peak width did vary randomly between tests.  However, retention times 
of the peptides analysed were identical (data not shown).  Furthermore, as PA can be destructive not 
only on surfaces in the LC system but on the AnchorChip™ target, the buffer system with 0.1% TFA 
was used for all future analyses. 
 
Without the introduction of phosphopeptide enrichment (e.g. online coupling of TiO2 with RP-HPLC), 
modifying phosphopeptide separation (by utilising lower flow rates and/or a more gentle gradient) may 
improve  phosphopeptide  detection  using  EZYprep  LC-MALDI-TOF/TOF  MS.    A  higher  number  of 
fractions  would  consequently  be  collected,  which  would  improve  separation.    However,  a  more 
extensive fractionation would increase the chromatographic peak width of peptides, resulting in peptide 
dilution across fractions, which is not ideal for the analysis of low abundance phosphopeptides.  In 
addition, because of the design of the ImagePrep™ station, the AnchorChip™ target does not sit flat in 
the chamber.  As such, it is difficult and time consuming to apply matrix using EZYprep, particularly over 
the entire target surface.  As a more extensive LC separation would utilise more fractions on the 
AnchorChip™ target, a modified ImagePrep with a chamber suitable for the target would be useful.  
Alternatively,  the  use  of  an  AnchorChip™  target  with  a  higher  number  of  raster  positions  (e.g. 
AnchorChip™  with  1536  raster  positions)  would  be  better  suited  for  EZYprep  matrix  deposition.   
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However, it is important to consider that no one method can provide a complete „snapshot‟ of the 
phosphoproteome and as a result, the use of multiple approaches will be necessary. 
 
5.3 Discussion for Chapter 4: 
 
5.3.1 ICPL Labelling Optimisation for Phosphopeptide analysis 
Isotopic labelling of samples prior to MS analysis has proved to be a versatile strategy to identify, 
quantify and characterise complex proteomic samples.  Of the various labelling strategies available, the 
non-isobaric strategy ICPL has great potential, particularly in regards to the analysis of post-translational 
modifications.    This  is  because  of  the  specific  advantages  this  strategy  has  over  other  labelling 
strategies, namely ICAT (low label site number), iTRAQ (quantitation only on the MS/MS level and poor 
detectability of the reporter ions in several types of mass spectrometers) and SILAC (developed solely 
for in vivo labelling and applicable to certain cell types only) [163].  Additionally, the ICPL reaction 
labelling technique has been found to be very specific and efficient, with no apparent by-products or 
undesired side reactions [13, 163]. 
 
ICPL is a protein labelling strategy, designed to label free amino groups both on lysine residue side-
chains and protein N-termini.  Once samples (e.g. Control and Test samples) are labelled, they are 
combined for subsequent fractionation (most commonly 1 or 2-DE), digested in-gel and finally analysed 
using LC-MALDI-TOF/TOF MS analysis.  After MS analysis, intensity ratios between labelled peptide 
pairs are used to quantify expression levels of the associated proteins and these pairs are subsequently 
selected for MS/MS analysis to identify the differentially-expressed proteins.  The selection of only the 
differentially-regulated pairs for MS/MS data minimises redundancy and ultimately can improve the 
quality  of  the  data.    The  use  of  ICPL  as  a  labelling  strategy  in  proteomics  is  beginning  to  gain 
momentum, with more laboratories utilising it as the preferred approach [163, 168, 214, 439, 440]. 
 
The advantages of ICPL (namely the improvement of peptide ionisation as well as the ability to quantify 
on the MS level) made it the labelling strategy of choice to be combined with pTyr enrichment and 
EZYprep  LC-MALDI-TOF/TOF  MS  analysis  for  phosphopeptide  identification,  quantitation,  and 
characterisation.  However, in order to successfully quantify post-translational modifications in proteins  
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using ICPL, it must be considered that ICPL will not label all peptides when used according to the 
original methodology.  This is because ICPL has been developed for labelling at the protein level of 
samples from cell or tissue lysates.  As such, labelling occurs only on free amino groups.  The free 
amino groups on lysine residues and protein N-termini ensure that the majority of proteins will be 
labelled, however, upon digestion, only peptides with lysine (or the N-terminal peptide) will be able to be 
used for quantitation.  As a result, comparative analysis of phosphopeptides that do not contain labelled 
residues is not possible.  Optimisation of the protocol to increase the number of labelled peptides per 
protein is imperative, particularly for PTM analysis [163].  This is achieved by alteration of the ICPL 
protocol such that labelling occurs at the peptide level, ensuring a label on either lysine (if present) or 
the free N-terminus of a peptide. 
 
In the present study, R-veIR-A lysate was divided into four fractions equally (1:1:1:1) and labelled at 
either a protein or peptide level using the four isotopes available in the ICPL 4-plex kit (i.e. the 1-
(12C61H4)-Nicotinoyloxy-succinamide  12C-Nic-Reagent  [Mr  =  105.0215  Da]  and  1-(13C61H4)-
Nicotinoyloxy-succinamide  13C-Nic-Reagent  [Mr  =  111.0419  Da]  for  peptide  labelling,  1-(12C62D4)-
Nicotinoyloxy-succinamide  2D-Nic-Reagent  [Mr  =  109.0715  Da]  and  1-(13C62D4)-Nicotinoyloxy-
succinamide 13C2D-Nic-Reagent [Mr = 115.0919 Da] for protein labelling).  Upon labelling, differentially 
labelled samples were combined and either analysed directly using LC-MALDI-TOF/TOF MS analysis 
(i.e. ICPL peptide labelled samples) or subjected to clean-up steps (i.e. the protein precipitation step for 
ICPL protein labelling) followed by LC-MALDI-TOF/TOF MS analysis. Eluted peptides were fractionated 
over half a target (192 fractions), which was chosen on the basis that this LC-MALDI-TOF/TOF MS 
approach would be subsequently used for the analysis of pTyr-purified lysate. Triplicate analyses over 
half-target (192 fractions) of both ICPL protein- and peptide-labelled lysate identified eighteen and 
twenty-five proteins, respectively.  The number of positively identified proteins from this analysis is low 
when considering the complexity of cellular lysate, which is attributable to utilising a gradient optimised 
for samples that have been pre-fractionated.  The SurveyViewer (Bruker Daltonics) shows simulated 2-
D maps (Figure 5.3), outlining the peptide chromatographic separation of representative ICPL protein 
and peptide runs.  The sample fractionation has allowed the detection of peptides that would otherwise 
be suppressed by the ionisation of the more abundant/better ionisable peptides.  Yet, many fractions 
(matrix spots) contain multiple peptides, meaning a greater fractionation (e.g. over an entire target) 
would further improve peptide identification.  Although this was anticipated, the fractionation over a half-
target (192 fractions) was utilised as this level of fractionation was deemed adequate for the analysis of 
pTyr purified fractions, as the phosphotyrosine component of the phosphoproteome is considered to be 
less than 1%.  These control ICPL labelling experiments served to determine both the most efficient  
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Figure  5.3:  The  SurveyViewer  (version  1.1,  Bruker  Daltonics)  generated  2-D 
maps outlining the peptide chromatographic separation for each ICPL labelled 
(peptide or protein) sample after LC-MALDI-TOF/TOF MS analysis. 
 
The results from Table 4.1 showed that modifying the ICPL protocol such that all peptides are labelled 
not only increases the number of proteins identified, but also provided more information regarding 
protein expression levels between two samples, which improved the quality of the quantitation data 
obtained.  A recent publication utilising an ICPL post-digest approach also showed an improvement in 
the quantitation and number of proteins identified in both standard protein samples as well as complex 
bacterial  samples  [440].    This  is  because  the  addition  of  the  label  to  each  peptide  improves  MS 
ionisation due to the addition of nicotinic acid (up to 100-fold) as described previously [13, 441].  Also, 
the increase in peptide pairs identified provides more information about the level of protein expression, 
and this is clearly shown in Table 4.1, where the known 1:1 ratio of R-veIR-A lysate was deduced with a 
higher degree of accuracy with ICPL peptide labelling (88% of proteins [22 out of 25] obtained a 
ICPL Protein Labelled Sample
ICPL Peptide Labelled Sample 
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regulation within the pre-determined window of 0.689 to 1.452).  Three proteins (Annexin A3, A5 and 
Elongation Factor 1-alpha) produced ratios outside the regulation window (0.64 ± 0.02, 1.67 ± 0.17 and 
1.73 ± 0.19, respectively).  This may have been due to the co-elution of ICPL-labelled peptides with 
other peptides with an almost identical m/z, increasing the MS intensity obtained.  Although this has 
been reported previously [163], it may not explain the observations here as multiple peptide pairs for 
two proteins (4 peptide pairs for Annexin-A5 and 2 peptide pairs for Elongation Factor 1-alpha) were 
used to obtain the average ratio.  A combination of factors may be responsible, such as co-elution 
issues coupled with the relative abundance of the proteins.  Previous analyses determining the labelling 
efficiency of the ICPL technique have reported effective labelling at protein concentrations of 5 fmol [13].  
However,  this  was  analysed  solely  with  ICPL  protein  labelling.    As  such,  the  increase  in  sample 
complexity by trypsin digestion of lysates may produce peptides at varying abundances (depending on 
the digest conditions of the samples to be labelled) and this may account for variances. 
 
Utilising the conventional ICPL protein labelling strategy resulted in only two of the ten (20%) proteins 
having  expression  ratios  within  the  regulation  window.    It  should  be  noted  that  the  regulation 
discrepancy seen with the ICPL protein labelling strategy was consistent, with the heavy labelled lysate 
being lower.  The labelling efficiencies for all four available isotopes should be identical; however this 
systematic error in protein expression seen with the 1-(13C62D4)-Nicotinoyloxy-succinamide 13C2D-Nic-
Reagent [Mr = 115.0919 Da] may be indicative of incomplete labelling by the heaviest tag in the ICPL 
protein labelled samples.  Recent analysis of the ICPL reagents for the development of novel ICPL-
based software has identified that a few percent of the ICPL reagents do not exhibit the complete 
isotopic labelling, particularly with the  13C containing labels [214].  Around 20% of the 1-(13C62D4)-
Nicotinoyloxy-succinamide  13C2D-Nic-Reagent  [Mr  =  115.0919  Da]  has  been  shown  to  display  this 
impurity, which would not have been accounted for in the WARP-LC software used to determine the 
ratios.  If a 20% variance is considered, seven (7) of the ten ratios obtained can be considered to be 
within  the  regulation  window  obtained  for  this  study  (0.689  to  1.452).    Of  the  peptides  used  for 
identification  and  quantitation,  only  one  unlabelled  peptide  was  characterised  using  ICPL  peptide 
labelling (1 peptide from serum albumin).  In contrast, unlabelled peptides were identified consistently in 
seventeen of the eighteen proteins identified with ICPL protein labelling, with labelled peptides being 
identified in ten. 
 
The results here clearly highlight the advantage of labelling with ICPL on a peptide level with respect to 
quantitation (as more labelled proteins are identified), however it is important to consider that the  
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preferred ICPL workflow originally described in [13] describes a fractionation step after protein labelling, 
such as 1- or 2-DE or LC.  In contrast to this recommendation, lysate ICPL labelled on the protein level 
was  combined  and  digested  in-solution,  without  any  pre-fractionation.    Although  this  protocol  is 
complementary with the described protocol, the complexity of the labelled lysate will result in a decrease 
in the number of identified proteins compared with multiple digests of pre-fractionated protein bands.  
The  ability  to  pre-fractionate  ICPL  protein-labelled samples  to  improve subsequent  identification  in 
complex samples is advantageous over ICPL peptide labelling, as pre-fractionation prior to labelling will 
introduce  new  sources  of  error.    These  observations  show  that  an  ideal  strategy  to  provide  both 
increased identification of proteins as well as quantitative data for not only proteins but also post-
translational modifications may be to undertake a comparative analysis of a complex sample split for 
both  ICPL  peptide  and  protein  labelling.    This  combined  approach  will  allow  protein  fractionation 
(utilising 1D or 2D PAGE with ICPL protein labelled samples) to increase the number of proteins 
identified  by  undertaking  a  more  exhaustive  analysis  (albeit  increasing  the  number  of  LC-MALDI-
TOF/TOF MS analyses) as well as to provide quantitative information on PTMs, in which the ICPL 
peptide labelled samples can be coupled with enrichment techniques (as all peptides are now labelled) 
prior to MS analysis. 
 
5.3.2 Global pTyr analysis of R-IR-A/R-IR-B stimulated lysate 
The  improvement  in  quantitation  data  as  a  result  of  utilising  the  optimised  ICPL  peptide  labelling 
strategy provides a way to assess global pTyr changes in signalling cascades when combined with 
other  proteomic-based  strategies  for  pTyr  enrichment.    Strategies,  like  the  use  of  4G10-coupled 
stationary  phase  for  affinity  purification  and  HILIC,  with  EZYprep  DHB  coupled  with  LC-MALDI-
TOF/TOF  MS  analysis  can  be  coupled  with  the  ICPL  peptide  labelling  strategy  to  provide  the 
opportunity for a comprehensive global pTyr analysis of complex protein samples. 
 
To highlight the capability of this proposed global pTyr approach, the insulin-like growth factor system 
was selected, based on both the role the system has in developmental and patho-physiological states 
(including  cancer  and  diabetes)  and  the  existing  knowledge  regarding  receptor  and  downstream 
tyrosine phosphorylation.  In regards to insulin binding to the insulin receptor, previous research has 
shown that insulin binding to either IR-A or IR-B results in the activation of two signalling pathways 
(Akt/PKB and MAPK pathways), however under certain conditions such as cancer, insulin binding to IR-
A has been shown to improve cell survival and promote growth [387, 389-391].  Differences in insulin  
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binding affinity, activation of signalling cascades under certain physiological and patho-physiological 
sates  and  protein  expression  have  been  observed  between  IR-A  and  IR-B,  indicating  that  the  IR 
isoforms can be utilised for different cellular functions [401, 402].  As the IR receptor is a tyrosine kinase 
receptor, the initiation of different signalling cascades by these receptor isoforms may be due to the 
alterations  in  pTyr signalling, which  emphasises  the need  for  methods  to  provide  quantitative  and 
qualitative information regarding phosphorylation of the receptor and downstream signalling cascades. 
 
In order to determine pTyr signalling differences between insulin stimulated IR-A and IR-B, lysates 
collected from insulin-stimulated IGF-IR-deficient (R-ve) mouse embryo fibroblast lines engineered to 
express similar levels of human IR-A and IR-B (R-veIR-A and R-veIR-B), were digested and labelled with 
ICPL reagents 1-(12C61H4)-Nicotinoyloxy-succinamide 12C-Nic-Reagent [Mr = 105.0215 Da] for R-veIR-A 
and  1-(13C61H4)-Nicotinoyloxy-succinamide  13C-Nic-Reagent  [Mr  =  111.0419  Da]  for  R-veIR-B.    Both 
FACS and western blot analysis were utilised to confirm similar receptor copy number as well as similar 
activation of receptor and downstream signalling cascades, respectively.  Although the FACS analysis 
showed similar receptor expression levels numbers for both R-veIR-A and R-veIR-B cells, differences in 
the level of receptor phosphorylation were noted (Figure 4.4D), with the IR-B receptor showing a higher 
level of receptor tyrosine phosphorylation.  This is consistent with previously reported in vitro kinase 
activity of this receptor isoform [399, 403, 419, 442].  Visual inspection of western blot analysis of key 
downstream  signalling  proteins  (phospho-p90RSK,  phospho-Akt,  phospho-p44/p42,  MAP  Kinase 
[MAPK], and phospho-S6 ribosomal protein) show similar levels of downstream activation, irrespective 
of whether IR-A or IR-B is activated (Figure 4.4A).  However, although IR-B is known to show a higher 
level of phosphorylation, the results from Figure 4.4D are quite striking, with no evidence of IR-A 
phosphorylation on the 3Y region of the IR receptor.  As levels of phosphorylation of the IR-A are known 
to be lower than IR-B after insulin stimulation, the possibility of incomplete inhibition of tyrosine protein 
phosphatases may account for the dramatic difference seen in Figure 4.4D.  As the same lysis buffer 
(and consequently, the same phosphatase inhibitors) were utilised for R-veIR-A and R-veIR-B cells, the 
loss of pTyr in both lysates may have resulted in complete loss of signal in R-veIR-A and only partial loss 
in  the  R-veIR-B  lysate,  as  the  initial  pTyr  levels  would  have  been  higher  with  IR-B.    Incomplete 
phosphatase inhibition may also account for the minor differences in levels of downstream signalling 
proteins between IR-A and IR-B.  Despite the differences in receptor phosphorylation observed, the 
results from Figure 4.4A and Figure 4.4B (pTyr specific blot using 4G10) provided sufficient evidence of 
stimulation (resulting in an increase in tyrosine phosphorylation) upon insulin binding compared with the 
unstimulated control for both R-veIR-A and R-veIR-B lysate.  
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Upon labelling, ICPL labelled peptides from protein digests of lysates were combined and pTyr peptides 
enriched using HILIC followed by 4G10 affinity purification prior to EZYprep DHB LC-MALDI-TOF/TOF 
MS  analysis.    After  HILIC  and  pTyr  enrichment  using  4G10,  the  remaining  four  fractions,  HFT 
(Hydrophobic Flow Through), HE (Hydrophobic Eluate), HIE (Hydrophilic Eluate) and HIFT (Hydrophilic 
Flow Through) were analysed for labelled phosphopeptides.  As HFT was comprised of flow-through (or 
non-bound)  fractions  after  4G10  pTyr  enrichment,  it  was  anticipated  that  the  majority  of  non-
phosphorylated peptides would be identified in this fraction.  In contrast, it was anticipated that pTyr 
peptides would be found in the pTyr enriched fractions, HE and HIE.  Also, despite the increased 
sample complexity of the HIFT (Hydrophilic flow-through) compared with the HE HIE (Eluted hydrophilic 
fraction), the fraction was expected to provide pSer and pThr phosphopeptides. 
 
Unfortunately, despite fractionation to enrich pTyr phosphopeptides, no conclusive MS/MS data could 
be obtained from any fractions to identify and characterise phosphopeptides and thus provide any 
information regarding pTyr expression.  IPA database analysis of the proteins identified and shown to 
be significantly regulated were involved in cytoskeleton re-organisation, particularly actin and filament 
organisation.  These proteins were only identified in the HFT and HIFT fractions.  Many of the proteins 
identified, such as actin cytoplasmic 1, Heat shock proteins and annexins were also identified in the 
previous  analyses  carried  out  for  the  ICPL  labelling  optimisation  experiments  (Table  4.1).    The 
identification of these proteins in the ICPL control labelled samples (5.3.1) and the HFT and HIFT 
fractions indicate these proteins to be the most abundant proteins in the sample.  The high complexity of 
these  flow-through  fractions,  particularly  HFT,  meant  the  effectiveness  of  phosphorylated  peptide 
identification would be low, particularly compared with the pTyr enriched fractions HE and HIE.   
 
The results in Table 4.2 show that the proposed phosphoproteomic method for the global quantitation, 
identification  and  characterisation  of  pTyr  was  unsuccessful  in  conclusively  identifying  and 
characterising pSer, pThr or pTyr in insulin stimulated lysate.  In light of this, a number of aspects to the 
method can be optimised and/or modified to improve phosphopeptide recovery for subsequent analysis 
using  MS.    Improvements  in  the  sample  preparation  (including  labelling strategy),  phosphopeptide 
enrichment and subsequent MS analysis will ensure phosphopeptide identification and characterisation.  
Of  the  alterations  proposed,  the  most  imperative  of  these  involves  optimisation  of  the  sample 
preparation prior to MS analysis.  
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Unless sufficient precautions are taken, a substantial component of the phosphoproteome is susceptible 
to loss upon cell lysis, which is due to the activation of various protein proteases and phosphatases.  
The addition of protease and phosphatase inhibitors as well as sample handling at low temperatures 
(i.e. 4°C) minimises the degradation effects, particularly if used in all initial steps until complete protein 
inactivation (e.g. reduction and alkylation followed by digestion or treatment with denaturing buffers 
such as SDS following reduction)  [59, 220].  The addition of protein kinase inhibitors to minimise 
phosphorylation of sites with no biological significance and lysis buffers compatible with downstream 
processing must also be considered.  The western blot analysis in Figure 3.4D showed a striking 
difference between phosphorylation at three well-characterised tyrosine residues of the IR-A and IR-B 
isoforms, which may be due to incomplete inhibition of protein tyrosine phosphatases.  As such, an 
increased concentration of freshly made inhibitors may minimise loss due to sample handling. 
 
Improvements  in  sample  handling  prior  to  MS  analysis  will  minimise  instances  of  phosphorylated 
proteins/peptides being lost, to subsequently increase phosphorylation site characterisation.  However, 
certain aspects of the proposed pTyr global approach that requires significant optimisation concerns 
both the enrichment and quantitation strategies utilised.  The enrichment strategies utilised in this study, 
both  HILIC  and  pTyr  enrichment  using  a  4G10  column,  were  chosen  as  both  have  been  utilised 
successfully in phosphoproteome analyses [58, 80, 229, 306, 358].  HILIC, when coupled with IMAC, 
was shown to improve phosphopeptide selectivity when utilised as a first-stage enrichment tool [58, 80].  
This is due to multiple aspects, including the compatibility of buffers used for HILIC and IMAC as well as 
the improvement of the binding efficiencies of phosphorylated peptides to the IMAC resin after HILIC 
enrichment.  Although the HILIC-IMAC strategy enriches all phosphorylation (pSer, pThr and pTyr), the 
low  abundance  of  pTyr  compared  with  pSer  and  pThr  provided  a  rationale  to  replace  the  IMAC 
enrichment with an enrichment strategy based solely on pTyr enrichment to improve pTyr proteome 
coverage.  The ability to pre-fractionate phosphopeptides from non-phosphorylated peptides (on the 
basis  that  phosphopeptides  would  be  more  hydrophilic  than  the  majority  of  non-phosphorylated 
peptides) prior to 4G10 enrichment was thought to minimise non-specific binding of non-phosphorylated 
peptides.  This is important as the non-specificity of pTyr Abs in general as well as 4G10 for peptides 
with a higher number of tyrosine residues has been observed previously [225, 358]. 
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The inability to identify any phosphopeptides after HILIC-4G10 enrichment can be attributed to the low 
amount of starting material and multiple sample handling steps prior to MS analysis.  Many previously 
reported  strategies  for  pTyr  as well  as  global  phosphoproteome  analyses  (including  the strategies 
involving  HILIC  enrichment)  commenced  with  large  starting  material,  in  some  cases  processing 
miligrams at a time [58, 80, 191, 229, 243, 264, 294, 443-445].  In contrast, the global strategy proposed 
here was utilised for the analysis of pTyr from a low amount of starting material (40.3 µg from digested 
R-veIR-A and R-veIR-B stimulated lysates), which after ICPL peptide labelling was combined (resulting in 
80.6 µg starting material), was desalted using RP-cleanup and pTyr phosphopeptides were enriched 
using the HILIC-4G10 method.  This starting amount was determined on the basis of the modified ICPL 
peptide  labelling  requirements,  such  that  increasing  the  amount  of  sample  to  be  labelled  would 
significantly increase the costs associated with the process (as more label would be required). Label-
based strategies can be limited by cost and although pre-fractionation or sample down-scaling can 
improve label quantity issues, detection and adequate quantification of low abundant proteins/peptides 
(such as pTyr proteins/peptides) can become compromised [169, 209, 445].  Despite the drawbacks of 
label-based  starting  material  limitations,  a  recent  study  successfully  identified,  quantified,  and 
characterised phosphorylation using similar starting materials coupled with ICPL peptide labelling and 
phosphopeptide enrichment [439].  In that study, 50 µg of protein extracts were digested with trypsin, 
peptides were labelled using ICPL and 40 µg were desalted using RP-cleanup and phosphopeptides 
enriched using TiO2 enrichment.  However, of the phosphopeptides reported in the supplementary data 
in that study, none were pTyr peptides, emphasising the need for larger amounts of starting material to 
improve pTyr recovery and identification.  The HILIC-4G10 enrichment method utilised in the proposed 
global  strategy  may  be  beneficial  for  larger  amounts  of  starting  material  (or  batch  processing)  to 
compensate for sample losses that occurs with increased sample handling.  Additionally, the use of a 
mixture of pTyr specific-Abs (instead of solely 4G10) may improve pTyr recovery as other pTyr-specific 
Abs will likely cover more of the pTyr proteome.  However, increasing the starting material will increase 
the  costs  associated  if  a  label-based  quantitation  strategy  is  utilised.    As  such,  alteration  of  the 
quantitation strategy will allow for increased sample amounts to be analysed. 
 
In  terms  of  protein  quantitation  in  proteomics,  label-based  and  label-free  techniques  have  been 
simultaneously  developed,  as  outlined  in  Figure  5.4.    Quantitation  using  MS  is  achieved  by 
measurement of an intact ion in the MS spectrum or the signal of one or several fragment ions in the 
MS/MS signal.  Quantities determined by MS (using either the MS or MS/MS signal) are always based 
on signal comparisons [169, 209].  
- 139 - 
 
 
Figure  5.4:  A  summary  of  the  proteomic  workflows  that  can  be  utilised  for 
protein and/or PTM quantitation [Adapted from [446, 447]].   
The  green  and  red  box  corresponds  to  two  biological  states  and  the  horizontal  line 
indicates  the  point  at  which  the  samples  are  combined.  The  boxes  that  are  dashed 
indicate potential sources of experimental error, which affects quantitation read-outs. 
 
Label-based strategies  utilise  isotopic  references  (the  measurement  of  each  peptide  related  to  an 
isotopically labelled peptide with the same molecular structure), whilst label-free strategies utilise global 
references, which require the total ion count of peptides is used to derive quantitative information using 
appropriate normalisations [169, 448].  All label-free based strategies involve the following fundamental 
steps: sample preparation (including extraction and digestion), sample separation by 1D or 2D LC and 
analysis (typically by ESI based MS instruments) [449].  Quantitation in label-free strategies is based on 
the spectral count of a particular protein or comparison of peak intensity of the same peptide [169, 449].  
The  spectral  count  approach,  which  is  one  of  the  early  methods  to  determine  relative  protein 
abundance, involves comparing the number of identified MS/MS spectra from the same protein in each 
of the multiple LC-MS/MS analyses [449, 450].  The approach is based on the premise that an increase 
in protein abundance typically results in an increase of the number of detected (and subsequently 
identified) peptides from that protein.  The approach has been widely applied in a number of proteomic 
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screening of phosphotyrosine-binding proteins in mammalian cells [451, 452].  Despite the effectiveness 
of the approach, the availability of software and high resolution MS instruments allowing the quantitation 
based on the total ion intensity of the peptides has seen a shift away from the spectral counting method 
[169]. 
 
Label-free quantitation software typically involves data normalisation of the entire LC chromatographic 
run using global internal standards or normalisation of the sum of all ion intensities, time alignment, 
peak detection, peak quantitation based on ion intensity, peak matching, identification and statistical 
analysis [169, 449].  Label-free quantitation methods are particularly attractive as they require only 
minimal sample modification and handling and are therefore the most compatible method for biological 
experiments  [169].    Both  label-based  and  label-free  techniques  have  their  own  advantages  and 
disadvantages (for an excellent table summary review, refer to [169]).  As shown in Figure 5.4, different 
strategies have varying levels of potential sources of experimental variation (leading to quantitation 
errors downstream), as highlighted by the dashed boxes for each method.  It should be noted that 
although the metabolic labelling strategy (e.g. SILAC) has no dashed boxes, cell culture conditions must 
be monitored to prevent inter-conversion between arginine and proline, which could negatively affect 
quantification accuracy  [209].  As such, no proteomics-based quantitation strategy is  immune from 
experimental errors. 
 
Label-free techniques offer clear advantages over label-based strategies in terms of decreased sample 
handling, acquisition times, sensitivity thresholds and have been shown to cover a larger dynamic 
range, which may be more applicable to the analysis of tyrosine phosphorylation as it makes up an 
extremely small component of the proteome [209, 221, 225, 227, 330, 358, 439].  However, label-free 
techniques are limited to particular high-resolution MS configurations (including Orbitrap or Q-TOF MS) 
and require appropriate software, as well as stable HPLC systems (routinely UHPLC systems) for high 
reproducibility between replicate analyses [169].  MS configurations, like QQQ, Q-TOF and also 3D IT 
can be utilised for specific mass spectrometric scanning modes used for quantitation, such as multiple 
reaction monitoring (MRM) or selected reaction monitoring (SRM).  MRM allows selective detection and 
quantification of targeted molecules in complex mixtures [169, 453, 454].  It involves the application of 
m/z filters for a specific parent and one or several fragment ions from all incoming ions.  The use of 
these filters produces spectra only from ions that match the expected parent m/z as well the unique 
fragment ions to that parent ion.  This MRM approach has been applied for the investigation of the 
temporal dynamics of 226 phosphorylation sites at different time points following EGF stimulation of  
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HMECs.  As only pre-selected phosphopeptides are monitored in MRM mode, the reproducibility in 
phosphopeptide identification improved significantly between exploratory mode and monitoring mode 
[455].    The  major  disadvantage  of  the  MRM  approach  is  that  this  scanning  mode  needs  to  be 
established for every new targeted molecule [169].  Although a database that records peptides that 
provide unique fragment ions to allow detection using MRM has been developed  [456], the MRM 
strategy is not the method of choice for exploratory quantitative proteomics. 
 
In regards to quantitation by sample ion intensity, in order to ensure that ion intensity is reflective of the 
molecular  concentration  of  a  peptide  in  a  sample,  the  ionisation  process  must  be  stable  and 
reproducible  [169,  457,  458].  In  ESI  instruments,  at  flow  rates  higher  than  1  µl/min,  hydrophobic 
peptides have a higher desolvation efficiency than hydrophilic peptides and ion suppression effects are 
more  pronounced  [459].    This  results  in  irregular  ion  intensities  that  do  not  reflect  molecular 
concentration [169].  As such, the majority of LC-MS/MS configurations will utilise LC flow rates less 
than 0.5 µL/min, as spectral intensities have been shown to correlate well with sample molecular 
concentration [169].  The effects of the ionisation process on signal intensity is even more pronounced 
using MALDI due to the variable ionisation efficiency of peptides within a sample.  This is due to the 
ionisation process in MALDI, involving proton transfer from the matrix to the analyte  [169].  As the 
number  of  protons  available  for  ionising  compounds  is  limited  to  the  amount  of  matrix  present, 
compounds with a high proton affinity will pull protons away from other compounds present in the 
sample, resulting in pronounced ion-suppression effects, particularly for phosphopeptides [112, 116, 
150, 169, 256].  Compounding these known ion suppression of samples using MALDI is the fact that 
poor matrix heterogeneity of analyte/matrix crystallisation results in poor peak intensity reproducibility 
[457, 458, 460, 461].  Despite the negative effects that MALDI can have on compound signal intensity, 
recent  label-free  strategies  have  successfully  utilised  LC-MALDI-TOF/TOF  MS  analysis  as  a 
quantitative  strategy  [458,  460-462].    To  overcome  potential  ion  suppression  and  poor  intensity 
reproducibility,  label-free  quantitation  using  LC-MALDI  requires  well  controlled  signal  acquisition 
conditions, such as increasing the shot count per raster (up to 5000 shots over the raster position) [461].  
This resulted in the determination of differentially expressed proteins between analysed samples [461].  
Another study evaluating the quantitative reproducibility of MALDI signal intensity found a significant 
correlation between spiked peptide concentration and intensity in the range of 5 to 20 fmol/µL [458].  
Yet, despite this, the known ion suppression effects of phosphopeptides will further complicate the 
ability to successfully quantify phosphorylation using label-free LC-MALDI. The improvements in peptide 
ionisation  when  labelled  with  ICPL  will  minimise  this  ion  suppression  and  ensure  phosphopeptide 
intensity will be reflective of molecular concentration between samples.  Furthermore, an increase in  
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shot number per raster position will significantly decrease MS/MS information that can be obtained from 
a LC-MALDI analysis, as the sample amount is finite. Multiple LC-MALDI-TOF/TOF MS analyses would 
be required; one for label-free quantitation and one for peptide identification. However, this approach 
increases sample acquisition times compared with LC-ESI-MS/MS analysis. 
 
Although the implementation of integrated LC and MS systems with the appropriate software for label-
free quantitation becoming more affordable and mainstream, a large number of laboratories are not 
equipped with both the hardware and software required for label-free protein quantitation, including our 
laboratory at the time of writing.  As such, label-based strategies are utilised as they can provide 
effective quantitation using multiple MS configurations.  In addition, comparative analyses of samples 
using label-based strategies (such as iTRAQ and ICPL) and label-free analyses have shown significant 
correlation between the quantitative strategies [439, 463], highlighting label-based techniques as an 
appropriate quantitation strategy for proteomic analyses.  Although the developments and availability of 
label-free  quantitation  over  recent  times  in  terms  of both  hardware  (e.g.  the  development  of  next 
generation  MS  configurations  with  high  resolution  and  mass  accuracy  and  UHPLC  systems)  and 
software has improved, quantitative phosphoproteomic strategies being reported utilise label-based, 
label-free or a combination of both strategies [439, 464-468].  As with the complementary nature of ESI 
and MALDI MS methods for phosphopeptide identification and characterisation, at the present time no 
one quantitative strategy is capable for providing global expression changes.  The proposed ICPL 
labelling strategy coupled with pTyr enrichment followed by EZYprep LC-MALDI-TOF/TOF MS analysis 
still offers the potential to be an effective global phosphoproteomic approach for pTyr identification, 
quantitation and characterisation.  
143 
 
Chapter 5: Concluding Remarks: 
The study presented in this thesis targeted the limitations associated with tyrosine phosphoproteome 
identification, quantitation and characterisation.  The methods developed in this thesis were designed to 
provide both a targeted and global pTyr enrichment strategy, allowing the analysis of pTyr samples 
across  multiple  MS  platforms,  with  a  particular  focus  on  MALDI-TOF/TOF  MS  analysis.    The 
development of the Pro-GP/Cov-P approach provides an easy targeted pTyr strategy to phosphosite 
characterisation  on  proteins  of  interest.  The  low  degree  of  sample  handling  coupled  with  the 
compatibility of the approach with both ESI and MALDI MS makes this an attractive, cost effective 
strategy  for  most  laboratories.    The  ability  of  this  approach  to  identify  and  characterise  pTyr 
phosphorylation on EGF-stimulated EGFR highlighted the approach as an alternative strategy to the 
more sensitive LC-MALDI-TOF/TOF MS and LC-ESI-IT-MS/MS analyses. 
 
A  drawback  of  the  Pro-GP  approach  is  the  limited  capacity  of  the  Pro-GP/Cov-P  beads  for  pTyr 
enrichment of complex samples. This point highlighted the requirement for the development of a global 
pTyr method that is able to provide quantitative as well as qualitative information.  The EZYprep DHB 
method takes advantage of the atypical matrix DHB and PA for MALDI phosphopeptide ionisation to 
provide homogeneous sample/matrix crystallisation for coupling off-line to LC-MALDI-TOF/TOF MS.  
This approach improved pTyr identification and characterisation of EGF-stimulated EGFR compared 
with Pro-GP due to the ability to pre-fractionate the complex sample over multiple raster positions.  
Furthermore,  comparison  with  LC-ESI-IT-MS/MS  using  CID  and  ETD  fragmentation  showed  that 
EZYprep  DHB  LC-MALDI-TOF/TOF  MS  identified  more  phosphopeptides  than  LC-ESI-IT-MS/MS 
analysis.  However, the comparison also highlighted the complimentarily between EZYprep DHB LC-
MALDI-TOF/TOF MS and LC-ESI-IT-MS/MS, which adds further support to the use a multi-dimensional 
strategy to provide complete coverage of the pTyr phosphoproteome. 
 
The  advantages  of  the  EZYprep  DHB  LC-MALDI-TOF/TOF  MS  approach  for  phosphopeptide 
identification  and  characterisation  made  the  approach  suitable  for  use  as  part  of  a  global  pTyr 
methodology.  This global analysis coupled ICPL labelling, phosphoproteome enrichment, namely HILIC 
and pTyr enrichment using 4G10 Ab, with EZYprep LC-MALDI-TOF/TOF MS analysis.  The optimisation 
of the ICPL labelling such that all peptides generated from complex protein sample digests improved 
overall quantitation efficiency, providing more accurate quantitation per protein identified.  Despite this, 
limitations  at  the  level  of  starting  material  hindered  the  ability  of  the  global  HILIC/pTyr  4G10  Ab  
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enrichment to conclusively identify, quantify and characterise the pTyr phosphoproteome involved in 
insulin signalling through either the IR-A or IR-B receptor isoforms and downstream cascades.  In order 
for this approach to be successful for exhaustive pTyr phosphorylation analysis of complex protein 
samples, an increase in the amount of starting material and/or alteration of the enrichment protocols 
used (e.g. TiO2 as a replacement to HILIC) should be considered. 
 
These targeted and global pTyr methods have joined the explosive growth of pTyr phosphoproteomic-
based methods for quantitation, identification and characterisation of phosphorylation sites on cellular 
proteins, as highlighted on the timeline (Figure 5.5). 
 
Figure  5.5:  A  Timeline  of  key  milestones  in  the  analysis  of  the 
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The past decade has seen an explosion in the types of methods for phopshoproteome 
analysis from the more conventional 1- and 2-DE and Edman sequencing.  These new 
methods (particularly the global strategies) utilise MS for identification, quantitation and 
characterisation.    These  include  β-elimination  [472]  or  phosphoamidate  modification 
[473], the use of pTyr Abs for protein and/or peptide  [229, 253, 358, 444], IMAC  [50], 
SCX [33], TiO2 [280] and HILIC [58, 80] enrichment strategies to quantitative strategies 
in  addition  to  enrichment,  including  Absolute  Quantitation  (AQUA)  [474,  475],  SILAC 
[294],  iTRAQ  [191],  ICPL  [439]  and  multiple  reaction  monitoring  (MRM)  [455].  
Advancements  in  MS  have  additionally  seen  the  use  of  ETD  [305]  and  label-free 
analyses [465, 467] for phosphoproteome quantitation and characterisation. 
 
Currently, phosphoproteome method development is in a state of flux, with the number of  reported 
global  phosphoproteomic-based  methods  increasing  significantly  since  2005  [209].    This  can  be 
attributed to the inability of any one method to fully characterise the phosphoproteome, despite the 
increasing knowledge base of phosphoproteome signalling.  This was highlighted with the comparative 
analysis of the EGFR using EZYprep MALDI-TOF/TOF MS and LC-ESI-IT-MS/MS, which was shown to 
be complementary.  Furthermore, this complementarity extends to the varying quantitative strategies 
such as differences between label-based and label-free quantitative results.  In regards to pTyr analysis, 
the  low  abundance  of  this  PTM  extends  the  dynamic  range  required  to  be  detected  for  global 
characterisation, which would require the use of multiple MS configurations.  A greater understanding of 
the dynamic range of tyrosine phosphorylation along with more effective enrichment strategies will 
ultimately improve our understanding.  Methods successfully characterising the phosphoproteome will 
most likely use label-free strategies as it reduces the issues with low abundance pTyr quantitation. 
 
The  onset  of  the  large  number  of  phosphoproteomic  methods  has  resulted  in  an  increase  in  the 
identification  and  characterisation  of  phosphorylation  sites  throughout  the  mammalian  proteome.  
Further analysis of these sites to confirm their presence in in situ and in vivo settings as well as the 
determination of the function of these modifications in cellular signalling is imperative in order to gain a 
full  understanding  of  transduction  pathways  in  normal  and  patho-physiological  states.    Method 
development for the quantitation of low abundance pTyr must remain a focus to ensure absolute and 
reliable quantitation in pTyr proteins in cells.  Methods such as the use of high resolution capillary 
isoelectric  focusing  to  resolve  (and  subsequently  immobilise)  protein  isoforms  and  individual 
phosphorylation forms, which is followed by probing with phospho-specific Abs, has been shown to 
quantify cell signalling in a small number of cells (<25) [476].  High resolution methods such as this one 
coupled  with  MS-based  strategies  will  provide  the  selectivity  and  sensitivity  required  for  pTyr 
characterisation.     
146 
 
6 Reference List 
[1] Wilkins, M. R., Pasquali, C., Appel, R. D., Ou, K., et al., From proteins to proteomes: large scale 
protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (N Y) 
1996, 14, 61-65. 
[2] Issaq, H. J., Conrads, T. P., Janini, G. M., Veenstra, T. D., Methods for fractionation, separation and 
profiling of proteins and peptides. Electrophoresis 2002, 23, 3048-3061. 
[3] O'Farrell, P. H., High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975, 250, 
4007-4021. 
[4] Vanrobaeys, F., Van Coster, R., Dhondt, G., Devreese, B., Van Beeumen, J., Profiling of myelin 
proteins by 2D-gel electrophoresis and multidimensional liquid chromatography coupled to MALDI TOF-
TOF mass spectrometry. J Proteome Res 2005, 4, 2283-2293. 
[5] Aldred, S., Grant, M. M., Griffiths, H. R., The use of proteomics for the assessment of clinical 
samples in research. Clin Biochem 2004, 37, 943-952. 
[6] Futcher, B., Latter, G. I., Monardo, P., McLaughlin, C. S., Garrels, J. I., A sampling of the yeast 
proteome. Mol Cell Biol 1999, 19, 7357-7368. 
[7] Patton, W. F., Schulenberg, B., Steinberg, T. H., Two-dimensional gel electrophoresis; better than a 
poke in the ICAT? Curr Opin Biotechnol 2002, 13, 321-328. 
[8] Young, D. S., Tracy, R. P., Clinical applications of two-dimensional electrophoresis. J Chromatogr A 
1995, 698, 163-179. 
[9] Mann, M., Jensen, O. N., Proteomic analysis of post-translational modifications.  Nat Biotechnol 
2003, 21, 255-261. 
[10] Unlu, M., Morgan, M. E., Minden, J. S., Difference gel electrophoresis: a single gel method for 
detecting changes in protein extracts. Electrophoresis 1997, 18, 2071-2077. 
[11] Marouga, R., David, S., Hawkins, E., The development of the DIGE system: 2D fluorescence 
difference gel analysis technology. Anal Bioanal Chem 2005, 382, 669-678. 
[12]  Patton,  W.  F.,  Proteome  analysis.  II.  Protein  subcellular  redistribution:  linking  physiology  to 
genomics via the proteome and separation technologies involved. J Chromatogr B Biomed Sci Appl 
1999, 722, 203-223. 
[13] Schmidt,  A., Kellermann, J., Lottspeich, F., A novel strategy for quantitative proteomics using 
isotope-coded protein labels. Proteomics 2005, 5, 4-15. 
[14] Gygi, S. P., Corthals, G. L., Zhang, Y., Rochon, Y., Aebersold, R., Evaluation of two-dimensional 
gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A 2000, 97, 9390-
9395. 
[15]  Ong,  S.  E.,  Pandey,  A.,  An  evaluation  of  the  use  of  two-dimensional  gel  electrophoresis  in 
proteomics. Biomol Eng 2001, 18, 195-205. 
[16] Hamdan, M., Righetti, P. G., Modern strategies for protein quantification in proteome analysis: 
advantages and limitations. Mass Spectrom Rev 2002, 21, 287-302. 
[17] Wu, W. W., Wang, G., Baek, S. J., Shen, R. F., Comparative study of three proteomic quantitative 
methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res 2006, 5, 
651-658. 
[18] Grant, S. G., O'Dell, T. J., Multiprotein complex signaling and the plasticity problem. Curr Opin 
Neurobiol 2001, 11, 363-368. 
[19]  Milligan,  G.,  White,  J.  H.,  Protein-protein  interactions  at  G-protein-coupled  receptors.  Trends 
Pharmacol Sci 2001, 22, 513-518. 
[20] Kabbani, N., Proteomics of membrane receptors and signaling. Proteomics 2008, 8, 4146-4155. 
[21] Bisle, B., Schmidt, A., Scheibe, B., Klein, C., et al., Quantitative profiling of the membrane proteome 
in a halophilic archaeon. Mol Cell Proteomics 2006, 5, 1543-1558. 
[22] Macher, B. A., Yen, T. Y., Proteins at membrane surfaces-a review of approaches. Mol Biosyst 
2007, 3, 705-713.  
147 
 
[23] Pluder, F., Morl, K., Beck-Sickinger, A. G., Proteome analysis to study signal transduction of G 
protein-coupled receptors. Pharmacol Ther 2006, 112, 1-11. 
[24] Issaq, H. J., Chan, K. C., Blonder, J., Ye, X., Veenstra, T. D., Separation, detection and quantitation 
of peptides by liquid chromatography and capillary electrochromatography. J Chromatogr A 2009, 1216, 
1825-1837. 
[25] Westermeier, R., Naven, T., Hopker, H., Proteomics in Practice: A guide to successful experimental 
design, Wiley-VCH, Weinheim 2008. 
[26] Boersema, P. J., Mohammed, S., Heck, A. J., Hydrophilic interaction liquid chromatography (HILIC) 
in proteomics. Anal Bioanal Chem 2008, 391, 151-159. 
[27]  Nordborg,  A.,  Hilder,  E.  F.,  Recent  advances  in  polymer  monoliths  for  ion-exchange 
chromatography. Anal Bioanal Chem 2009, 394, 71-84. 
[28] Nesterenko, E. P., Nesterenko, P. N., Paull, B., Zwitterionic ion-exchangers in ion chromatography: 
A review of recent developments. Anal Chim Acta 2009, 652, 3-21. 
[29] Alberts, B., Johnson, A., Lewis, J., Raff, M., et al., Molecular Biology of the Cell, Garland Science, 
New York 2002. 
[30]  Nesterenko,  P.  N.,  Jones,  P.,  Recent  developments  in  the  high-performance  chelation  ion 
chromatography of trace metals. J Sep Sci 2007, 30, 1773-1793. 
[31] Jungbauer, A., Hahn, R., Ion-exchange chromatography. Methods Enzymol 2009, 463, 349-371. 
[32] Ballif, B. A., Villen, J., Beausoleil, S. A., Schwartz, D., Gygi, S. P., Phosphoproteomic analysis of 
the developing mouse brain. Mol Cell Proteomics 2004, 3, 1093-1101. 
[33] Beausoleil, S. A., Jedrychowski, M., Schwartz, D., Elias, J. E., et al., Large-scale characterization of 
HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 2004, 101, 12130-12135. 
[34]  Nuhse,  T.  S.,  Stensballe,  A.,  Jensen,  O.  N.,  Peck,  S.  C.,  Large-scale  analysis  of  in  vivo 
phosphorylated  membrane  proteins  by  immobilized  metal  ion  affinity  chromatography  and  mass 
spectrometry. Mol Cell Proteomics 2003, 2, 1234-1243. 
[35] Gauci, S., Helbig, A. O., Slijper, M., Krijgsveld, J., et al., Lys-N and trypsin cover complementary 
parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 2009, 81, 4493-4501. 
[36] Taouatas, N., Altelaar, A. F., Drugan, M. M., Helbig, A. O., et al., Strong cation exchange-based 
fractionation  of  Lys-N-generated  peptides  facilitates  the  targeted  analysis  of  post-translational 
modifications. Mol Cell Proteomics 2009, 8, 190-200. 
[37] Dai, J., Wang, L. S., Wu, Y. B., Sheng, Q. H., et al., Fully automatic separation and identification of 
phosphopeptides by continuous pH-gradient anion exchange online coupled with reversed-phase liquid 
chromatography mass spectrometry. J Proteome Res 2009, 8, 133-141. 
[38] Kunji, E. R., Harding, M., Butler, P. J., Akamine, P., Determination of the molecular mass and 
dimensions of membrane proteins by size exclusion chromatography. Methods 2008, 46, 62-72. 
[39] Hackenberg, H., Klingenberg, M., Molecular weight and hydrodynamic parameters of the adenosine 
5'-diphosphate--adenosine 5'-triphosphate carrier in Triton X-100. Biochemistry 1980, 19, 548-555. 
[40] Kotaria, R., Mayor, J. A., Walters, D. E., Kaplan, R. S., Oligomeric state of wild-type and cysteine-
less yeast mitochondrial citrate transport proteins. J Bioenerg Biomembr 1999, 31, 543-549. 
[41] Lin, C. S., Hackenberg, H., Klingenberg, E. M., The uncoupling protein from brown adipose tissue 
mitochondria is a dimer. A hydrodynamic study. FEBS Lett 1980, 113, 304-306. 
[42]  Larmann,  J.  P.,  Jr.,  Lemmo,  A.  V.,  Moore,  A.  W.,  Jr.,  Jorgenson,  J.  W.,  Two-dimensional 
separations of peptides and proteins by comprehensive liquid chromatography-capillary electrophoresis. 
Electrophoresis 1993, 14, 439-447. 
[43]  Opiteck,  G.  J.,  Ramirez,  S.  M.,  Jorgenson,  J.  W.,  Moseley,  M.  A.,  3rd,  Comprehensive  two-
dimensional high-performance liquid chromatography for the isolation of overexpressed proteins and 
proteome mapping. Anal Biochem 1998, 258, 349-361. 
[44] Zhang, Z., Smith, D. L., Smith, J. B., Multiple separations facilitate identification of protein variants 
by mass spectrometry. Proteomics 2001, 1, 1001-1009. 
[45] Thompson, N. E., Foley, K. M., Stalder, E. S., Burgess, R. R., Identification, production, and use of 
polyol-responsive monoclonal antibodies for immunoaffinity chromatography. Methods Enzymol 2009, 
463, 475-494.  
148 
 
[46] Urh, M., Simpson, D., Zhao, K., Affinity chromatography: general methods. Methods Enzymol 2009, 
463, 417-438. 
[47] PetfoodIndustry.com, Watt Publishing 2010, p. Utilised Figure outlining the DONtest WB Affinity 
Column. 
[48] Seward, R. J., Perlman, D. H., Berg, E. A., Hu, J., Costello, C. E., pp. 1-2. 
[49] Brill, L. M., Salomon, A. R., Ficarro, S. B., Mukherji, M., et al., Robust phosphoproteomic profiling of 
tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and 
tandem mass spectrometry. Anal Chem 2004, 76, 2763-2772. 
[50] Ficarro, S. B., McCleland, M. L., Stukenberg, P. T., Burke, D. J., et al., Phosphoproteome analysis 
by mass spectrometry and its application to Saccharomyces cerevisiae. Nat Biotechnol 2002, 20, 301-
305. 
[51]  Stensballe,  A.,  Jensen,  O.  N.,  Phosphoric  acid  enhances  the  performance  of  Fe(III)  affinity 
chromatography  and  matrix-assisted  laser  desorption/ionization  tandem  mass  spectrometry  for 
recovery, detection and sequencing of phosphopeptides. Rapid Commun Mass Spectrom 2004, 18, 
1721-1730. 
[52] Hart, S. R., Waterfield, M. D., Burlingame, A. L., Cramer, R., Factors governing the solubilization of 
phosphopeptides retained on ferric NTA IMAC beads and their analysis by MALDI TOFMS. J Am Soc 
Mass Spectrom 2002, 13, 1042-1051. 
[53] Zhang, X., Ye, J., Jensen, O. N., Roepstorff, P., Highly efficient phosphopeptide enrichment by 
calcium  phosphate  precipitation  combined  with  subsequent  serial  immobilized  metal  ion  affinity 
chromatography (IMAC) enrichment. Mol Cell Proteomics 2007. 
[54] Li, S., Dass, C., Iron(III)-immobilized metal ion affinity chromatography and mass spectrometry for 
the purification and characterization of synthetic phosphopeptides. Anal Biochem 1999, 270, 9-14. 
[55] Feng, S., Ye, M., Zhou, H., Jiang, X., et al., Immobilized zirconium ion affinity chromatography for 
specific enrichment of phosphopeptides in phosphoproteome analysis. Mol Cell Proteomics 2007. 
[56]  Sykora,  C.,  Hoffmann,  R.,  Hoffmann,  P.,  Enrichment  of  multiphosphorylated  peptides  by 
immobilized metal affinity chromatography using Ga(III)- and Fe(III)-complexes. Protein Pept Lett 2007, 
14, 489-496. 
[57]  Li,  Y.,  Lin,  H.,  Deng,  C.,  Yang,  P.,  Zhang,  X.,  Highly  selective  and  rapid  enrichment  of 
phosphorylated peptides using gallium oxide-coated magnetic microspheres for MALDI-TOF-MS and 
nano-LC-ESI-MS/MS/MS analysis. Proteomics 2008, 8, 238-249. 
[58]  Albuquerque,  C.  P.,  Smolka,  M.  B.,  Payne,  S.  H.,  Bafna,  V.,  et  al.,  A  multidimensional 
chromatography technology for in-depth phosphoproteome analysis. Mol Cell Proteomics 2008, 7, 1389-
1396. 
[59]  Thingholm,  T.  E.,  Jensen,  O.  N.,  Larsen,  M.  R.,  Analytical  strategies  for  phosphoproteomics. 
Proteomics 2009, 9, 1451-1468. 
[60] Thingholm, T. E., Jensen, O. N., Robinson, P. J., Larsen, M. R., SIMAC (sequential elution from 
IMAC), a phosphoproteomics strategy for the rapid separation of monophosphorylated from multiply 
phosphorylated peptides. Mol Cell Proteomics 2008, 7, 661-671. 
[61]  Block,  H.,  Maertens,  B.,  Spriestersbach,  A.,  Brinker,  N.,  et  al.,  Immobilized-metal  affinity 
chromatography (IMAC): a review. Methods Enzymol 2009, 463, 439-473. 
[62] Arnold, F. H., Metal-affinity separations: a new dimension in protein processing. Biotechnology (N 
Y) 1991, 9, 151-156. 
[63] Roullier, V., Clarke, S., You, C., Pinaud, F., et al., High-affinity labeling and tracking of individual 
histidine-tagged proteins in live cells using Ni2+ tris-nitrilotriacetic acid quantum dot conjugates. Nano 
Lett 2009, 9, 1228-1234. 
[64] You, C., Bhagawati, M., Brecht, A., Piehler, J., Affinity capturing for targeting proteins into micro and 
nanostructures. Anal Bioanal Chem 2009, 393, 1563-1570. 
[65] Wilchek, M., Bayer, E. A., The avidin-biotin complex in bioanalytical applications. Anal Biochem 
1988, 171, 1-32. 
[66] Wilchek, M., Knudsen, K. L., Miron, T., Improved method for preparing N-hydroxysuccinimide ester-
containing polymers for affinity chromatography. Bioconjug Chem 1994, 5, 491-492.  
149 
 
[67] Wilchek, M., Miron, T., Kohn, J., Affinity chromatography. Methods Enzymol 1984, 104, 3-55. 
[68] McCue, J. T., Theory and use of hydrophobic interaction chromatography in protein purification 
applications. Methods Enzymol 2009, 463, 405-414. 
[69] Frank, H. S., Evans, M. W., Free volume and entropy in condensed systems III. Entropy in binary 
liquid  mixtures;  partial  molal  entropy  in  dilute solutions;  structure and  thermodynamics  in aqueous 
electrolytes. J. Chem. Phys. 1945, 13, 507-532. 
[70] Lesk, A. M., Hydrophobicity--getting into hot water. Biophys Chem 2003, 105, 179-182. 
[71] Ben-Naim, A., Hydrophobic hydrophilic phenomena in biochemical processes. Biophys Chem 2003, 
105, 183-193. 
[72] The Effect of Ion Pair Reagent on Reversed-Phase Selectivity 
of Polypeptide Separations, Sigma-Aldrich, Bellefonte 2002. 
[73] Guo, D. C., Mant, C. T., Hodges, R. S., Effects of ion-pairing reagents on the prediction of peptide 
retention in reversed-phase high-performance liquid chromatography. J Chromatogr 1987, 386, 205-
222. 
[74] Shibue, M., Mant, C. T., Hodges, R. S., Effect of anionic ion-pairing reagent concentration (1-60 
mM) on reversed-phase liquid chromatography elution behaviour of peptides. J Chromatogr A 2005, 
1080, 58-67. 
[75] Roses, M., Subirats, X., Bosch, E., Retention models for ionizable compounds in reversed-phase 
liquid chromatography: effect of variation of mobile phase composition and temperature. J Chromatogr 
A 2009, 1216, 1756-1775. 
[76] Chakraborty, A. B., Berger, S. J., Optimization of reversed-phase peptide liquid chromatography 
ultraviolet mass spectrometry analyses using an automated blending methodology. J Biomol Tech 2005, 
16, 327-335. 
[77] Hancock, W. S., Bishop, C. A., Prestidge, R. L., Harding, D. R., Hearn, M. T., Reversed-phase, 
high-pressure liquid chromatography of peptides and proteins with ion-pairing reagents. Science 1978, 
200, 1168-1170. 
[78] McCalley, D. V., Effect of buffer on peak shape of peptides in reversed-phase high performance 
liquid chromatography. J Chromatogr A 2004, 1038, 77-84. 
[79] Larsen, M. R., Cordwell, S. J., Roepstorff, P., Graphite powder as an alternative or supplement to 
reversed-phase material for desalting and concentration of peptide mixtures prior to matrix-assisted 
laser desorption/ionization-mass spectrometry. Proteomics 2002, 2, 1277-1287. 
[80] McNulty, D. E., Annan, R. S., Hydrophilic interaction chromatography reduces the complexity of the 
phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 
2008, 7, 971-980. 
[81] Mitulovic, G., Mechtler, K., HPLC techniques for proteomics analysis--a short overview of latest 
developments. Brief Funct Genomic Proteomic 2006, 5, 249-260. 
[82] Washburn, M. P., Wolters, D., Yates, J. R., 3rd, Large-scale analysis of the yeast proteome by 
multidimensional protein identification technology. Nat Biotechnol 2001, 19, 242-247. 
[83]  Wolters,  D.  A.,  Washburn,  M.  P.,  Yates,  J.  R.,  3rd,  An  automated  multidimensional  protein 
identification technology for shotgun proteomics. Anal Chem 2001, 73, 5683-5690. 
[84]  Cooks,  R.,  Rockwood,  A.,  The  "Thompson":  A  suggested  unit  for  mass  spectrometry.  Rapid 
Commun Mass Spectrom 1991, 5, 93. 
[85]  Kinter,  M.,  Sherman,  N.  E.,  Protein  Sequencing  and  Identification  Using  Tandem  Mass 
Spectrometry, John Wiley & Sons, New York 2000. 
[86] Siuzdak, G., The Expanding Role of Mass Spectrometry in Biotechnology, MCC Press, San Diego 
2006. 
[87] Wong, P., Cooks, R., Ion Trap Mass Spectrometry. Curr. Sep. 1997, 16, 85. 
[88] Hillenkamp, F., Peter-Katalinic, J., MALDI MS - A practical guide to Instrumentation, Methods and 
Applications, Wiley-VCH Verlag GmbH & Co,, Weinheim 2007. 
[89] Han, X., Aslanian, A., Yates, J. R., 3rd, Mass spectrometry for proteomics. Curr Opin Chem Biol 
2008, 12, 483-490.  
150 
 
[90] Salzano, A. M., Crescenzi, M., Mass spectrometry for protein identification and the study of post 
translational modifications. Ann Ist Super Sanita 2005, 41, 443-450. 
[91] Yamashita, M., Fenn, J. B., Electrospray ion source. Another variation on the free-jet theme. J. 
Phys. Chem. 1984, 88 4451-4459. 
[92] Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., Whitehouse, C. M., Electrospray ionization for 
mass spectrometry of large biomolecules. Science 1989, 246, 64-71. 
[93] Tang, K., Page, J. S., Smith, R. D., Charge competition and the linear dynamic range of detection in 
electrospray ionization mass spectrometry. J Am Soc Mass Spectrom 2004, 15, 1416-1423. 
[94] Wahl, J. H., Goodlett, D. R., Udseth, H. R., Smith, R. D., Use of small-diameter capillaries for 
increasing  peptide  and  protein  detection  sensitivity  in  capillary  electrophoresis-mass  spectrometry. 
Electrophoresis 1993, 14, 448-457. 
[95] Shevchenko, A., Wilm, M., Vorm, O., Mann, M., Mass spectrometric sequencing of proteins silver-
stained polyacrylamide gels. Anal Chem 1996, 68, 850-858. 
[96] Wilm, M., Shevchenko, A., Houthaeve, T., Breit, S., et al., Femtomole sequencing of proteins from 
polyacrylamide gels by nano-electrospray mass spectrometry. Nature 1996, 379, 466-469. 
[97] March, R. E., Hughes, R. J., Quadrupole Storage Mass Spectrometry. John Wiley & Sons: New 
York, 1989, 7. 
[98] Paul, W., Steinwedel, H., A New Mass Spectrometer without a Magnetic Field. Z. Naturforsch 1953, 
8a, 448-450. 
[99] Stafford, G. C., Ion Trap Mass Spectrometry: A Personal Perspective. J Am Soc Mass Spectrom 
2002, 13, 589-596. 
[100] Stafford, G. C., Kelley, P. E., Syka, J. E. P., Reynolds, W. E., Todd, J. F. J., Recent Improvements 
In and Analytical Applications 
of Advanced Ion Trap Technology. Int. J. Mass Spectrom. Ion Proc. 1984, 60, 85-98. 
[101] Aebersold, R., Goodlett, D. R., Mass spectrometry in proteomics. Chem Rev 2001, 101, 269-295. 
[102] Aebersold, R., Mann, M., Mass spectrometry-based proteomics. Nature 2003, 422, 198-207. 
[103] Yang, Y., Zhang, S., Howe, K., Wilson, D. B., et al., A comparison of nLC-ESI-MS/MS and nLC-
MALDI-MS/MS  for  GeLC-based  protein  identification  and  iTRAQ-based  shotgun  quantitative 
proteomics. J Biomol Tech 2007, 18, 226-237. 
[104] Kuzyk, M. A., Ohlund, L. B., Elliott, M. H., Smith, D., et al., A comparison of MS/MS-based, stable-
isotope-labeled,  quantitation  performance  on  ESI-quadrupole  TOF  and  MALDI-TOF/TOF  mass 
spectrometers. Proteomics 2009, 9, 3328-3340. 
[105] Liu, Z., Schey, K. L., Fragmentation of multiply-charged intact protein ions using MALDI TOF-TOF 
mass spectrometry. J Am Soc Mass Spectrom 2008, 19, 231-238. 
[106] Spahr, C. S., Susin, S. A., Bures, E. J., Robinson, J. H., et al., Simplification of complex peptide 
mixtures for proteomic analysis: reversible biotinylation of cysteinyl peptides. Electrophoresis 2000, 21, 
1635-1650. 
[107] Koc, E. C., Burkhart, W., Blackburn, K., Moyer, M. B., et al., The large subunit of the mammalian 
mitochondrial ribosome. Analysis of the complement of ribosomal proteins present. J Biol Chem 2001, 
276, 43958-43969. 
[108] Guzzetta, A., IonSource.Com 2000-2009, p. HPLC Tube diammeters and Volumes. 
[109] Simpson, R. (Ed.), Purifying Proteins for Proteomics: a laboratory manual, Cold Spring Harbour 
Laboratory Press, Cold Spring Harbour, New York 2004. 
[110] van der Heijden, R., Powepoint Presentation, Bruker Daltonics, NL 2009. 
[111] Hillenkamp, F., Karas, M., Beavis, R. C., Chait, B. T., Matrix-assisted laser desorption/ionization 
mass spectrometry of biopolymers. Anal Chem 1991, 63, 1193A-1203A. 
[112]  Karas,  M.,  Hillenkamp,  F.,  Laser  desorption  ionization  of  proteins  with  molecular  masses 
exceeding 10,000 daltons. Anal Chem 1988, 60, 2299-2301. 
[113] Yates, J. R., 3rd, Mass spectrometry and the age of the proteome. J Mass Spectrom 1998, 33, 1-
19. 
[114] Tanaka, K., Waki, H., Ido, Y., Akita, S., et al., Protein and polymer analyses up to m/z 100 000 by 
laser ionisation time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 1988, 2, 151-153.  
151 
 
[115] Laboratory, M. L.-N. H. M. F., in: (MALDI), M.-A. L. D. I. (Ed.), National Science Foundation, 
Tallahasse, p. Figure used to generate my own interpretation of the MALDI process. 
[116] Karas, M., Gluckmann, M., Schafer, J., Ionization in matrix-assisted laser desorption/ionization: 
singly charged molecular ions are the lucky survivors. J Mass Spectrom 2000, 35, 1-12. 
[117] Knochenmuss, R., Zenobi, R., MALDI ionization: the role of in-plume processes. Chem Rev 2003, 
103, 441-452. 
[118] Ehring, H., Karas, M., Hillenkamp, F., Role of photoionisation and photochemistry in ionisation 
processes of organic molecules and relevance for matrix-assisted laser desorption ionisation mass 
spectrometry. Org Mass Spectrom 1992, 27, 472-480. 
[119] Karas, M., Bachmann, D., Bahr, U., Hillenkamp, F., Matrix-assisted ultraviolet laser desorption of 
non-volatile compounds. Int J Mass Spectrom Ion Proc 1987, 78, 53-68. 
[120] Knochenmuss, R., A quantitative model of ultraviolet matrix-assisted laser desorption/ionization. J 
Mass Spectrom 2002, 37, 867-877. 
[121] Knochenmuss, R., A quantitative model of ultraviolet matrix-assisted laser desorption/ionization 
including analyte ion generation. Anal Chem 2003, 75, 2199-2207. 
[122] Bahr, U., Rohling, U., Lautz, C., Strupat, K., et al., A charge detector for time-of-flight mass 
analysis of high mass ions produced by matrix-assisted laser desorption/ionization (MALDI). Int J Mass 
Spectrom Ion Proc 1996, 153, 9. 
[123] Gobom, J., Schuerenberg, M., Mueller, M., Theiss, D., et al., Alpha-cyano-4-hydroxycinnamic acid 
affinity sample preparation. A protocol for MALDI-MS peptide analysis in proteomics. Anal Chem 2001, 
73, 434-438. 
[124] Beavis, R. C., Chait, B. T., Cinnamic acid derivatives as matrices for ultraviolet laser desorption 
mass spectrometry of proteins. Rapid Commun Mass Spectrom 1989, 3, 432-435. 
[125] Kjellstrom, S., Jensen, O. N., Phosphoric acid as a matrix additive for MALDI MS analysis of 
phosphopeptides and phosphoproteins. Anal Chem 2004, 76, 5109-5117. 
[126] Gevaert, K., Vandekerckhove, J., Protein identification methods in proteomics.  Electrophoresis 
2000, 21, 1145-1154. 
[127] Pandey, A., Mann, M., Proteomics to study genes and genomes. Nature 2000, 405, 837-846. 
[128] Schuerenberg, M., Luebbert, C., Eickhoff, H., Kalkum, M., et al., Prestructured MALDI-MS sample 
supports. Anal Chem 2000, 72, 3436-3442. 
[129] Suckau, D., Resemann, A., Schuerenberg, M., Hufnagel, P., et al., A novel MALDI LIFT-TOF/TOF 
mass spectrometer for proteomics. Anal Bioanal Chem 2003, 376, 952-965. 
[130] Brown, R. S., Lennon, J. J., Mass resolution improvement by incorporation of pulsed ion extraction 
in a matrix-assisted laser desorption/ionization linear time-of-flight mass spectrometer. Anal Chem 1995, 
67, 1998-2003. 
[131] Juhasz, P., Roskey, M. T., Smirnov, I. P., Haff, L. A., et al., Applications of delayed extraction 
matrix-assisted laser desorption ionization time-of-flight mass spectrometry to oligonucleotide analysis. 
Anal Chem 1996, 68, 941-946. 
[132] Takach, E. J., Hines, W. M., Patterson, D. H., Juhasz, P., et al., Accurate mass measurements 
using MALDI-TOF with delayed extraction. J Protein Chem 1997, 16, 363-369. 
[133] Jensen, O. N., Podtelejnikov, A., Mann, M., Delayed extraction improves specificity in database 
searches by matrix-assisted laser desorption/ionization peptide maps. Rapid Commun Mass Spectrom 
1996, 10, 1371-1378. 
[134] Mamyrin, B., Karataev, V., Schmikk, D., Zagulin, B., The mass reflectron, a new nonmagnetic 
time-of-flight mass spectrometer with high resolution. Sov. Phys. JTEP 1973, 37, 45-48. 
[135]  Chaurand,  P.,  Luetzenkirchen,  F.,  Spengler,  B.,  Peptide  and  protein  identification  by  matrix-
assisted  laser  desorption  ionization  (MALDI)  and  MALDI-post-source  decay  time-of-flight  mass 
spectrometry. J Am Soc Mass Spectrom 1999, 10, 91-103. 
[136] Jespersen, S., Chaurand, P., van Strien, F. J., Spengler, B., van der Greef, J., Direct sequencing 
of neuropeptides in biological tissue by MALDI-PSD mass spectrometry. Anal Chem 1999, 71, 660-666.  
152 
 
[137]  Chong,  P.  K.,  Burja,  A.  M.,  Radianingtyas,  H.,  Fazeli,  A.,  Wright,  P.  C.,  Proteome  and 
transcriptional analysis of ethanol-grown Sulfolobus solfataricus P2 reveals ADH2, a potential alcohol 
dehydrogenase. J Proteome Res 2007, 6, 3985-3994. 
[138]  Drummelsmith,  J.,  Winstall,  E.,  Bergeron,  M.  G.,  Poirier,  G.  G.,  Ouellette,  M.,  Comparative 
proteomics  analyses  reveal  a  potential  biomarker  for  the  detection  of  vancomycin-intermediate 
Staphylococcus aureus strains. J Proteome Res 2007, 6, 4690-4702. 
[139] Gagne, J. P., Ethier, C., Gagne, P., Mercier, G., et al., Comparative proteome analysis of human 
epithelial ovarian cancer. Proteome Sci 2007, 5, 16. 
[140] Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., et al., Quantitative analysis of complex protein 
mixtures using isotope-coded affinity tags. Nat Biotechnol 1999, 17, 994-999. 
[141] Julka, S., Regnier, F., Quantification in proteomics through stable isotope coding: a review. J 
Proteome Res 2004, 3, 350-363. 
[142] Kassie, F., Anderson, L. B., Higgins, L., Pan, Y., et al., Chemopreventive agents modulate the 
protein  expression  profile  of  4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone  plus  benzo[a]pyrene-
induced lung tumors in A/J mice. Carcinogenesis 2008, 29, 610-619. 
[143] Melanson, J. E., Avery, S. L., Pinto, D. M., High-coverage quantitative proteomics using amine-
specific isotopic labeling. Proteomics 2006, 6, 4466-4474. 
[144]  Pierce,  A.,  Unwin,  R.  D.,  Evans,  C.  A.,  Griffiths,  S.,  et  al.,  Eight-channel  iTRAQ  enables 
comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics 2008, 7, 853-863. 
[145] Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., et al., Multiplexed protein quantitation 
in  Saccharomyces  cerevisiae  using  amine-reactive  isobaric  tagging  reagents.  Mol  Cell  Proteomics 
2004, 3, 1154-1169. 
[146] Stahl, S., Reinders, Y., Asan, E., Mothes, W., et al., Proteomic analysis of cathepsin B- and L-
deficient mouse brain lysosomes. Biochim Biophys Acta 2007, 1774, 1237-1246. 
[147] Williamson, A. J., Smith, D. L., Blinco, D., Unwin, R. D., et al., Quantitative proteomics analysis 
demonstrates post-transcriptional regulation of embryonic stem cell differentiation to hematopoiesis. Mol 
Cell Proteomics 2008, 7, 459-472. 
[148] Young, J. B., Li, L., Impulse-driven heated-droplet deposition interface for capillary and microbore 
LC-MALDI MS and MS/MS. Anal Chem 2007, 79, 5927-5934. 
[149] Zhao, Y., Giorgianni, F., Desiderio, D. M., Fang, B., Beranova-Giorgianni, S., Toward a global 
analysis of the human pituitary proteome by multiple gel-based technology. Anal Chem 2005, 77, 5324-
5331. 
[150] Knochenmuss, R., Stortelder, A., Breuker, K., Zenobi, R., Secondary ion-molecule reactions in 
matrix-assisted laser desorption/ionization. J Mass Spectrom 2000, 35, 1237-1245. 
[151] Kratzer, R., Eckerskorn, C., Karas, M., Lottspeich, F., Suppression effects in enzymatic peptide 
ladder sequencing using ultraviolet - matrix assisted laser desorption/ionization - mass spectormetry. 
Electrophoresis 1998, 19, 1910-1919. 
[152] Zhang, X., Shi, L., Shu, S., Wang, Y., et al., An improved method of sample preparation on 
AnchorChip  targets  for  MALDI-MS  and  MS/MS  and  its  application  in  the  liver  proteome  project. 
Proteomics 2007, 7, 2340-2349. 
[153] Arndt Asperger, Deininger, S.-O., Macht, M., Bruker Daltonics 2004. 
[154] Carranza, P., Hartmann, I., Lehner, A., Stephan, R., et al., Proteomic profiling of Cronobacter 
turicensis 3032, a food-borne opportunistic pathogen. Proteomics 2009, 9, 3564-3579. 
[155] Kouvonen, P., McDonnell, L. A., Heeren, R. M., Corthals, G. L., Nitromatrix provides improved LC-
MALDI signals and more protein identifications. Proteomics 2009, 9, 1662-1671. 
[156] Li, N., Wang, N., Zheng, J., Liu, X. M., et al., Characterization of human tear proteome using 
multiple proteomic analysis techniques. J Proteome Res 2005, 4, 2052-2061. 
[157] Scheurer, S. B., Roesli, C., Neri, D., Elia, G., A comparison of different biotinylation reagents, 
tryptic digestion procedures, and mass spectrometric techniques for 2-D peptide mapping of membrane 
proteins. Proteomics 2005, 5, 3035-3039.  
153 
 
[158] Tuerk, R. D., Auchli, Y., Thali, R. F., Scholz, R., et al., Tracking and quantification of 32P-labeled 
phosphopeptides  in  liquid  chromatography  matrix-assisted  laser  desorption/ionization  mass 
spectrometry. Anal Biochem 2009, 390, 141-148. 
[159] Wall, D. B., Berger, S. J., Finch, J. W., Cohen, S. A., et al., Continuous sample deposition from 
reversed-phase  liquid  chromatography  to  tracks  on  a  matrix-assisted  laser  desorption/ionization 
precoated target for the analysis of protein digests. Electrophoresis 2002, 23, 3193-3204. 
[160] Young, J. B., Li, L., An impulse-driven liquid-droplet deposition interface for combining LC with 
MALDI MS and MS/MS. J Am Soc Mass Spectrom 2006, 17, 325-334. 
[161] Paradela, A., Albar, J. P., Advances in the analysis of protein phosphorylation. J Proteome Res 
2008, 7, 1809-1818. 
[162] Hilger, M., Bonaldi, T., Gnad, F., Mann, M., Systems-wide analysis of a phosphatase knock-down 
by quantitative proteomics and phosphoproteomics. Mol Cell Proteomics 2009, 8, 1908-1920. 
[163] Paradela, A., Marcilla, M., Navajas, R., Ferreira, L., et al., Evaluation of isotope-coded protein 
labeling (ICPL) in the quantitative analysis of complex proteomes. Talanta 2010, 80, 1496-1502. 
[164]  Schmelzle,  K.,  White,  F.  M.,  Phosphoproteomic  approaches  to  elucidate  cellular  signaling 
networks. Curr Opin Biotechnol 2006, 17, 406-414. 
[165]  Witze,  E.  S.,  Old,  W.  M.,  Resing,  K.  A.,  Ahn,  N.  G.,  Mapping  protein  post-translational 
modifications with mass spectrometry. Nat Methods 2007, 4, 798-806. 
[166] Kim, Y. J., Zhan, P., Feild, B., Ruben, S. M.,  He, T., Reproducibility assessment of relative 
quantitation strategies for LC-MS based proteomics. Anal Chem 2007, 79, 5651-5658. 
[167] Mueller, L. N., Brusniak, M. Y., Mani, D. R., Aebersold, R., An assessment of software solutions 
for the analysis of mass spectrometry based quantitative proteomics data. J Proteome Res 2008, 7, 51-
61. 
[168] Turtoi, A., Mazzucchelli, G. D., De Pauw, E., Isotope coded protein label quantification of serum 
proteins--comparison with the label-free LC-MS and validation using the MRM approach. Talanta 2010, 
80, 1487-1495. 
[169] Wilm, M., Quantitative proteomics in biological research. Proteomics 2009, 9, 4590-4605. 
[170] Mirgorodskaya, O. A., Kozmin, Y. P., Titov, M. I., Korner, R., et al., Quantitation of peptides and 
proteins by matrix-assisted laser desorption/ionization mass spectrometry using (18)O-labeled internal 
standards. Rapid Commun Mass Spectrom 2000, 14, 1226-1232. 
[171] Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B., et al., Stable isotope labeling by 
amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol 
Cell Proteomics 2002, 1, 376-386. 
[172] Schnolzer, M., Jedrzejewski, P., Lehmann, W. D., Protease-catalyzed incorporation of 18O into 
peptide fragments and its application for protein sequencing by electrospray and matrix-assisted laser 
desorption/ionization mass spectrometry. Electrophoresis 1996, 17, 945-953. 
[173] Shevchenko, A., Chernushevich, I., Ens, W., Standing, K. G., et al., Rapid 'de novo' peptide 
sequencing by  a  combination  of  nanoelectrospray,  isotopic  labeling  and  a  quadrupole/time-of-flight 
mass spectrometer. Rapid Commun Mass Spectrom 1997, 11, 1015-1024. 
[174] Stewart, II, Thomson, T., Figeys, D., 18O labeling: a tool for proteomics. Rapid Commun Mass 
Spectrom 2001, 15, 2456-2465. 
[175]  Yao,  X.,  Freas,  A.,  Ramirez,  J.,  Demirev,  P.  A.,  Fenselau,  C.,  Proteolytic  18O  labeling  for 
comparative proteomics: model studies with two serotypes of adenovirus. Anal Chem 2001, 73, 2836-
2842. 
[176] Smolka, M., Zhou, H., Aebersold, R., Quantitative protein profiling using two-dimensional gel 
electrophoresis, isotope-coded affinity tag labeling, and mass spectrometry. Mol Cell Proteomics 2002, 
1, 19-29. 
[177] Smolka, M. B., Zhou, H., Purkayastha, S., Aebersold, R., Optimization of the isotope-coded affinity 
tag-labeling procedure for quantitative proteome analysis. Anal Biochem 2001, 297, 25-31. 
[178] Fontana, S., De Leo, G., Sedic, M., Pavelic, S., Alessandro, R., Proteomics in antitumor research. 
Drug Discovery Today: Technologies 2006, 3, 441-449.  
154 
 
[179]  Leitner,  A.,  Lindner, W.,  Current chemical  tagging  strategies  for  proteome  analysis  by  mass 
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 813, 1-26. 
[180]  Han,  D.  K.,  Eng,  J.,  Zhou,  H.,  Aebersold,  R.,  Quantitative  profiling  of  differentiation-induced 
microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat Biotechnol 2001, 19, 
946-951. 
[181] Patton, W. F., Detection technologies in proteome analysis.  J Chromatogr B Analyt Technol 
Biomed Life Sci 2002, 771, 3-31. 
[182] Zhou, H., Ranish, J. A., Watts, J. D., Aebersold, R., Quantitative proteome analysis by solid-phase 
isotope tagging and mass spectrometry. Nat Biotechnol 2002, 20, 512-515. 
[183] Gevaert, K., Goethals, M., Martens, L., Van Damme, J., et al., Exploring proteomes and analyzing 
protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol 
2003, 21, 566-569. 
[184] Brancia, F. L., Oliver, S. G., Gaskell, S. J., Improved matrix-assisted laser desorption/ionization 
mass  spectrometric  analysis  of  tryptic  hydrolysates  of  proteins  following  guanidination  of  lysine-
containing peptides. Rapid Commun Mass Spectrom 2000, 14, 2070-2073. 
[185] Krause, E., Wenschuh, H., Jungblut, P. R., The dominance of arginine-containing peptides in 
MALDI-derived tryptic mass fingerprints of proteins. Anal Chem 1999, 71, 4160-4165. 
[186] Beardsley, R. L., Reilly, J. P., Optimization of guanidination procedures for MALDI mass mapping. 
Anal Chem 2002, 74, 1884-1890. 
[187] Brancia, F. L., Bereszczak, J. Z., Piatkowska, E., Delneri, D., Development of novel guanidino-
labelling  derivatisation  (GLaD)  reagents  for  liquid  chromatography/matrix-assisted  laser 
desorption/ionisation analysis. Rapid Commun Mass Spectrom 2007, 21, 3069-3076. 
[188]  Brancia,  F.  L.,  Butt,  A.,  Beynon,  R.  J.,  Hubbard,  S.  J.,  et  al.,  A  combination  of  chemical 
derivatisation  and  improved  bioinformatic  tools  optimises  protein  identification  for  proteomics. 
Electrophoresis 2001, 22, 552-559. 
[189] Hu, J., Qian, J., Borisov, O., Pan, S., et al., Optimized proteomic analysis of a mouse model of 
cerebellar dysfunction using amine-specific isobaric tags. Proteomics 2006, 6, 4321-4334. 
[190] Zhang, Y., Ficarro, S. B., Li, S., Marto, J. A., Optimized Orbitrap HCD for quantitative analysis of 
phosphopeptides. J Am Soc Mass Spectrom 2009, 20, 1425-1434. 
[191] Zhang, Y., Wolf-Yadlin, A., Ross, P. L., Pappin, D. J., et al., Time-resolved mass spectrometry of 
tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic 
modules. Mol Cell Proteomics 2005, 4, 1240-1250. 
[192] Ow, S. Y., Salim, M., Noirel, J., Evans, C., et al., iTRAQ underestimation in simple and complex 
mixtures: "the good, the bad and the ugly". J Proteome Res 2009, 8, 5347-5355. 
[193] Chen, C. H., Review of a current role of mass spectrometry for proteome research. Anal Chim 
Acta 2008, 624, 16-36. 
[194] Colzani, M., Schutz, F., Potts, A., Waridel, P., Quadroni, M., Relative protein quantification by 
isobaric SILAC with immonium ion splitting (ISIS). Mol Cell Proteomics 2008, 7, 927-937. 
[195]  Goshe,  M.  B.,  Smith,  R.  D.,  Stable  isotope-coded  proteomic  mass  spectrometry.  Curr  Opin 
Biotechnol 2003, 14, 101-109. 
[196]  Ong,  S.  E.,  Foster,  L.  J.,  Mann,  M.,  Mass  spectrometric-based  approaches  in  quantitative 
proteomics. Methods 2003, 29, 124-130. 
[197] Schmidt, F., Hustoft, H. K., Strozynski, M., Dimmler, C., et al., Quantitative proteome analysis of 
cisplatin-induced apoptotic Jurkat T cells by stable isotope labeling with amino acids in cell culture, 
SDS-PAGE, and LC-MALDI-TOF/TOF MS. Electrophoresis 2007, 28, 4359-4368. 
[198] Schmidt, F., Strozynski, M., Salus, S. S., Nilsen, H., Thiede, B., Rapid determination of amino acid 
incorporation by stable isotope labeling with amino acids in cell culture (SILAC). Rapid Commun Mass 
Spectrom 2007, 21, 3919-3926. 
[199] Blagoev, B., Kratchmarova, I., Ong, S. E., Nielsen, M., et al., A proteomics strategy to elucidate 
functional protein-protein interactions applied to EGF signaling. Nat Biotechnol 2003, 21, 315-318.  
155 
 
[200] Boeri Erba, E., Bergatto, E., Carbodi, S., Silengo, L., et al., Systematic analysis of the epidermal 
growth factor receptor by mass spectrometry reveals stimulation-dependent multisite phosphorylation. 
Mol Cell Proteomics 2005, 4, 1107-1121. 
[201] Dohnal, I., Veis, J., Grosstessner-Hain, K., Roitinger, E., et al.,  
17th International Mass Spectrometry Conference  Prague, 2006 2006. 
[202] Gruhler, A., Olsen, J. V., Mohammed, S., Mortensen, P., et al., Quantitative phosphoproteomics 
applied to the yeast pheromone signaling pathway. Mol Cell Proteomics 2005, 4, 310-327. 
[203] Kruger, M., Kratchmarova, I., Blagoev, B., Tseng, Y. H., et al., Dissection of the insulin signaling 
pathway via quantitative phosphoproteomics. Proc Natl Acad Sci U S A 2008, 105, 2451-2456. 
[204] Nguyen, V., Cao, L., Lin, J. T., Hung, N., et al., A new approach for quantitative phosphoproteomic 
dissection of signaling pathways applied to T cell receptor activation. Mol Cell Proteomics 2009. 
[205] Platt, M. D., Salicioni, A. M., Hunt, D. F., Visconti, P. E., Use of differential isotopic labeling and 
mass spectrometry to analyze capacitation-associated changes in the phosphorylation status of mouse 
sperm proteins. J Proteome Res 2009, 8, 1431-1440. 
[206] Trinkle-Mulcahy, L., Boulon, S., Lam, Y. W., Urcia, R., et al., Identifying specific protein interaction 
partners using quantitative mass spectrometry and bead proteomes. J Cell Biol 2008, 183, 223-239. 
[207] Yamauchi, E., Taniguchi, H.,  
17th International Mass Spectrometry Conference  Prague, 2006 2006, pp. Abstract No. ThP-207  
[208]  Zhang,  G.,  Spellman,  D.  S.,  Skolnik,  E.  Y.,  Neubert,  T.  A.,  Quantitative  phosphotyrosine 
proteomics of EphB2 signaling by stable isotope labeling with amino acids in cell culture (SILAC).  J 
Proteome Res 2006, 5, 581-588. 
[209]  Nita-Lazar,  A.,  Saito-Benz,  H.,  White,  F.  M.,  Quantitative  phosphoproteomics  by  mass 
spectrometry: past, present, and future. Proteomics 2008, 8, 4433-4443. 
[210] Kellermann, J., 2D PAGE: Sample Preparation and Fractionation - ICPL—Isotope-Coded Protein 
Label, Humana Press 2008. 
[211]  Sarioglu,  H.,  Brandner,  S.,  Jacobsen,  C.,  Meindl,  T.,  et  al.,  Quantitative  analysis  of  2,3,7,8-
tetrachlorodibenzo-p-dioxin-induced proteome alterations in 5L rat hepatoma cells using isotope-coded 
protein labels. Proteomics 2006, 6, 2407-2421. 
[212]  Schmidt,  A.,  Bisle,  B.,  Kislinger,  T.,  Quantitative  peptide  and  protein  profiling  by  mass 
spectrometry. Methods Mol Biol 2009, 492, 21-38. 
[213] SERVA, SERVA Electrophoresis 2009, pp. ICPL 4-plex reagent chemical structure. 
[214] Brunner, A., Keidel, E. M., Dosch, D., Kellermann, J., Lottspeich, F., ICPLQuant - A software for 
non-isobaric isotopic labeling proteomics. Proteomics 2010, 10, 315-326. 
[215] Farley, A. R., Link, A. J., Identification and quantification of protein posttranslational modifications. 
Methods Enzymol 2009, 463, 725-763. 
[216] Creasy, D. M., Cottrell, J. S., Unimod: Protein modifications for mass spectrometry. Proteomics 
2004, 4, 1534-1536. 
[217] Cohen, P., The role of protein phosphorylation in human health and disease. The Sir Hans Krebs 
Medal Lecture. Eur J Biochem 2001, 268, 5001-5010. 
[218]  Hubbard,  M.  J.,  Cohen,  P.,  On  target  with  a  new  mechanism  for  the  regulation  of  protein 
phosphorylation. Trends Biochem Sci 1993, 18, 172-177. 
[219] Larsen, M. R., Roepstorff, P., Mass spectrometric identification of proteins and characterization of 
their post-translational modifications in proteome analysis. Fresenius J Anal Chem 2000, 366, 677-690. 
[220] Reinders, J., Sickmann, A., State-of-the-art in phosphoproteomics. Proteomics 2005, 5, 4052-
4061. 
[221] Hunter, T., THE CROONIAN LECTURE 1997. The 
phosphorylation of proteins on tyrosine: 
its role in cell growth and disease. Phil.Trans. R. Soc. Lond. B 1998, 353, 583-605. 
[222] Goyal, P., Behring, A., Kumar, A., Siess, W., Identifying and characterizing a novel protein kinase 
STK35L1 and deciphering its orthologs and close-homologs in vertebrates. PLoS One 2009, 4, e6981. 
[223]  Manning,  G.,  Whyte,  D.  B.,  Martinez,  R.,  Hunter,  T.,  Sudarsanam,  S.,  The  protein  kinase 
complement of the human genome. Science 2002, 298, 1912-1934.  
156 
 
[224] Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., et al., The sequence of the human genome. 
Science 2001, 291, 1304-1351. 
[225]  Ding,  S.  J.,  Qian,  W.  J.,  Smith,  R.  D.,  Quantitative  proteomic  approaches  for  studying 
phosphotyrosine signaling. Expert Rev Proteomics 2007, 4, 13-23. 
[226] Hunter, T., Tyrosine phosphorylation in cell signaling and disease. Keio J Med 2002, 51, 61-71. 
[227] Hunter,  T., Sefton, B. M., Transforming gene product of Rous sarcoma virus phosphorylates 
tyrosine. Proc Natl Acad Sci U S A 1980, 77, 1311-1315. 
[228] Zhang, H., Zha, X., Tan, Y., Hornbeck, P. V., et al., Phosphoprotein analysis using antibodies 
broadly reactive against phosphorylated motifs. J Biol Chem 2002, 277, 39379-39387. 
[229] Rush, J., Moritz, A., Lee, K. A., Guo, A., et al., Immunoaffinity profiling of tyrosine phosphorylation 
in cancer cells. Nat Biotechnol 2005, 23, 94-101. 
[230] Kalume, D. E., Molina, H., Pandey, A., Tackling the phosphoproteome: tools and strategies. Curr 
Opin Chem Biol 2003, 7, 64-69. 
[231] Steen, H., Kuster, B., Fernandez, M., Pandey, A., Mann, M., Detection of tyrosine phosphorylated 
peptides by precursor ion scanning quadrupole TOF mass spectrometry in positive ion mode. Anal 
Chem 2001, 73, 1440-1448. 
[232] Kaufmann, H., Bailey, J. E., Fussenegger, M., Use of antibodies for detection of phosphorylated 
proteins separated by two-dimensional gel electrophoresis. Proteomics 2001, 1, 194-199. 
[233]  Chitteti,  B.  R.,  Peng,  Z.,  Proteome  and  phosphoproteome  dynamic  change  during  cell 
dedifferentiation in Arabidopsis. Proteomics 2007, 7, 1473-1500. 
[234] Chitteti, B. R., Peng, Z., Proteome and phosphoproteome differential expression under salinity 
stress in rice (Oryza sativa) roots. J Proteome Res 2007, 6, 1718-1727. 
[235] Clarke, S. J., Khaliulin, I., Das, M., Parker, J. E., et al., Inhibition of mitochondrial permeability 
transition pore opening by ischemic preconditioning is probably mediated by reduction of oxidative 
stress rather than mitochondrial protein phosphorylation. Circ Res 2008, 102, 1082-1090. 
[236] Eymann, C., Becher, D., Bernhardt, J., Gronau, K., et al., Dynamics of protein phosphorylation on 
Ser/Thr/Tyr in Bacillus subtilis. Proteomics 2007, 7, 3509-3526. 
[237] Steinberg, T. H., Agnew, B. J., Gee, K. R., Leung, W. Y., et al., Global quantitative phosphoprotein 
analysis using Multiplexed Proteomics technology. Proteomics 2003, 3, 1128-1144. 
[238] Su, H. C., Hutchison, C. A., 3rd, Giddings, M. C., Mapping phosphoproteins in Mycoplasma 
genitalium and Mycoplasma pneumoniae. BMC Microbiol 2007, 7, 63. 
[239] Tan, F., Li, G., Chitteti, B. R., Peng, Z., Proteome and phosphoproteome analysis of chromatin 
associated proteins in rice (Oryza sativa). Proteomics 2007, 7, 4511-4527. 
[240] Wolschin, F., Wienkoop, S., Weckwerth, W., Enrichment of phosphorylated proteins and peptides 
from complex mixtures using metal oxide/hydroxide affinity chromatography (MOAC). Proteomics 2005, 
5, 4389-4397. 
[241] Essner, R., Huynh, Y., Nguyen, T., Morton, D. L., Hoon, D. S., Functional interleukin 4 receptor 
and interleukin 2 receptor common gamma-chain on human non-small cell lung cancers: novel targets 
for immune therapy. J Thorac Cardiovasc Surg 2000, 119, 10-20. 
[242] Jaso-Friedmann, L., Leary, J. H., 3rd, Evans, D. L., Monoclonal antibody binding to a receptor on 
nonspecific  cytotoxic cells (NCC)  increases  the  expression  of  proto-oncogene kinases  and  protein 
kinase C. Cell Signal 1995, 7, 463-470. 
[243] Lim, Y. P., Diong, L. S., Qi, R., Druker, B. J., Epstein, R. J., Phosphoproteomic fingerprinting of 
epidermal growth factor signaling and anticancer drug action in human tumor cells. Mol Cancer Ther 
2003, 2, 1369-1377. 
[244] Yan, G., Xiao, C., He, G., Yin, X., et al., Global phosphoproteomic effects of natural tyrosine 
kinase inhibitor, genistein, on signaling pathways. Proteomics 2010, 10, 976-986. 
[245] Young, A. V., Hehn, B. M., Sanghera, J. S., Pelech, S. L., Shah, R. M., The activation of MAP 
kinase during vertical palatal shelf development in hamster. Growth Dev Aging 1997, 61, 27-38. 
[246] Berwick, D. C., Tavare, J. M., Identifying protein kinase substrates: hunting for the organ-grinder's 
monkeys. Trends Biochem Sci 2004, 29, 227-232.  
157 
 
[247] Ignatoski, K. M., Immunoprecipitation and western blotting of phosphotyrosine-containing proteins. 
Methods Mol Biol 2001, 124, 39-48. 
[248] Izaguirre, G., Aguirre, L., Ji, P., Aneskievich, B., Haimovich, B., Tyrosine phosphorylation of alpha-
actinin in activated platelets. J Biol Chem 1999, 274, 37012-37020. 
[249] Jaso-Friedmann, L., Leary, J. H., 3rd, Evans, D. L., Pathways of signaling in nonspecific cytotoxic 
cells:  effects  of  protein  kinase  and  phosphatase  inhibitors  and  evidence  for  membrane  tyrosine 
phosphorylation. Cell Immunol 1994, 153, 142-153. 
[250] Maguire, P. B., Wynne, K. J., Harney, D. F., O'Donoghue, N. M., et al., Identification of the 
phosphotyrosine proteome from thrombin activated platelets. Proteomics 2002, 2, 642-648. 
[251] Xu, K. P., Yu, F. S., Cross talk between c-Met and epidermal growth factor receptor during retinal 
pigment epithelial wound healing. Invest Ophthalmol Vis Sci 2007, 48, 2242-2248. 
[252] Gronborg, M., Kristiansen, T. Z., Stensballe, A., Andersen, J. S., et al., A mass spectrometry-
based proteomic approach for identification of serine/threonine-phosphorylated proteins by enrichment 
with phospho-specific antibodies: identification of a novel protein, Frigg, as a protein kinase A substrate. 
Mol Cell Proteomics 2002, 1, 517-527. 
[253] Steen, H., Kuster, B., Fernandez, M., Pandey, A., Mann, M., Tyrosine phosphorylation mapping of 
the epidermal growth factor receptor signaling pathway. J Biol Chem 2002, 277, 1031-1039. 
[254] Kersten, B., Agrawal, G. K., Durek, P., Neigenfind, J., et al., Plant phosphoproteomics: an update. 
Proteomics 2009, 9, 964-988. 
[255] Porath, J., Carlsson, J., Olsson, I., Belfrage, G., Metal chelate affinity chromatography, a new 
approach to protein fractionation. Nature 1975, 258, 598-599. 
[256]  McLachlin,  D.  T.,  Chait,  B.  T.,  Analysis  of  phosphorylated  proteins  and  peptides  by  mass 
spectrometry. Curr Opin Chem Biol 2001, 5, 591-602. 
[257] Hochuli, E., Dobeli, H., Schacher, A., New metal chelate adsorbent selective for proteins and 
peptides containing neighbouring histidine residues. J Chromatogr 1987, 411, 177-184. 
[258]  Andersson,  L.,  Porath,  J.,  Isolation  of  phosphoproteins  by  immobilized  metal  (Fe3+)  affinity 
chromatography. Anal Biochem 1986, 154, 250-254. 
[259] Ficarro, S. B., Salomon, A. R., Brill, L. M., Mason, D. E., et al., Automated immobilized metal 
affinity chromatography/nano-liquid chromatography/electrospray ionization mass spectrometry platform 
for profiling protein phosphorylation sites. Rapid Commun Mass Spectrom 2005, 19, 57-71. 
[260]  Kocher,  T.,  Allmaier,  G.,  Wilm,  M.,  Nanoelectrospray-based  detection  and  sequencing  of 
substoichiometric amounts of phosphopeptides in complex mixtures. J Mass Spectrom 2003, 38, 131-
137. 
[261] Larsen, M. R., Thingholm, T. E., Jensen, O. N., Roepstorff, P., Jorgensen, T. J., Highly selective 
enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol 
Cell Proteomics 2005, 4, 873-886. 
[262] Li, X., Gerber, S. A., Rudner, A. D., Beausoleil, S. A., et al., Large-scale phosphorylation analysis 
of alpha-factor-arrested Saccharomyces cerevisiae. J Proteome Res 2007, 6, 1190-1197. 
[263]  Muszynska,  G.,  Andersson,  L.,  Porath,  J.,  Selective  adsorption  of  phosphoproteins  on  gel-
immobilized ferric chelate. Biochemistry 1986, 25, 6850-6853. 
[264] Zheng, H., Hu, P., Quinn, D. F., Wang, Y. K., Phosphotyrosine proteomic study of interferon alpha 
signaling  pathway  using  a  combination  of  immunoprecipitation  and  immobilized  metal  affinity 
chromatography. Mol Cell Proteomics 2005, 4, 721-730. 
[265] Pinkse, M. W., Uitto, P. M., Hilhorst, M. J., Ooms, B., Heck, A. J., Selective isolation at the 
femtomole level of phosphopeptides from proteolytic digests using 2D-NanoLC-ESI-MS/MS and titanium 
oxide precolumns. Anal Chem 2004, 76, 3935-3943. 
[266] Torta, F., Fusi, M., Casari, C. S., Bottani, C. E., Bachi, A., Titanium Dioxide Coated MALDI plate 
for on target Analysis of Phosphopeptides. J Proteome Res 2009. 
[267] Lin, B., Li, T., Zhao, Y., Huang, F. K., et al., Preparation of a TiO2 nanoparticle-deposited capillary 
column by liquid phase deposition and its application in phosphopeptide analysis. J Chromatogr A 2008, 
1192, 95-102.  
158 
 
[268] Raijmakers, R., Kraiczek, K., de Jong, A. P., Mohammed, S., Heck, A. J., Exploring the human 
leukocyte  phosphoproteome  using  a  microfluidic  reversed-phase-TiO2-reversed-phase  high-
performance  liquid  chromatography  phosphochip  coupled  to  a  quadrupole  time-of-flight  mass 
spectrometer. Anal Chem, 82, 824-832. 
[269] Cantin, G. T., Shock, T. R., Park, S. K., Madhani, H. D., Yates, J. R., 3rd, Optimizing TiO2-based 
phosphopeptide enrichment for automated multidimensional liquid chromatography coupled to tandem 
mass spectrometry. Anal Chem 2007, 79, 4666-4673. 
[270] Collins, M. O., Yu, L., Choudhary, J. S., Analysis of protein phosphorylation on a proteome-scale. 
Proteomics 2007, 7, 2751-2768. 
[271] Kweon, H. K., Hakansson, K., Selective zirconium dioxide-based enrichment of phosphorylated 
peptides for mass spectrometric analysis. Anal Chem 2006, 78, 1743-1749. 
[272] Chen, C. T., Chen, Y. C., Fe3O4/TiO2 core/shell nanoparticles as affinity probes for the analysis 
of phosphopeptides using TiO2 surface-assisted laser desorption/ionization mass spectrometry. Anal 
Chem 2005, 77, 5912-5919. 
[273]  Mazanek,  M.,  Roitinger,  E.,  Hudecz,  O.,  Hutchins,  J.  R.,  et  al.,  A  new  acid  mix  enhances 
phosphopeptide enrichment on titanium- and zirconium dioxide for mapping of phosphorylation sites on 
protein complexes. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878, 515-524. 
[274] Alpert, A. J., Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids 
and other polar compounds. J Chromatogr 1990, 499, 177-196. 
[275] Alpert, A. J., Electrostatic repulsion hydrophilic interaction chromatography for isocratic separation 
of charged solutes and selective isolation of phosphopeptides. Anal Chem 2008, 80, 62-76. 
[276] Guo, Y., Gaiki, S., Retention behavior of small polar compounds on polar stationary phases in 
hydrophilic interaction chromatography. J Chromatogr A 2005, 1074, 71-80. 
[277]  Naidong,  W.,  Bioanalytical  liquid  chromatography  tandem  mass  spectrometry  methods  on 
underivatized  silica  columns  with  aqueous/organic  mobile  phases.  J  Chromatogr  B  Analyt  Technol 
Biomed Life Sci 2003, 796, 209-224. 
[278] Boersema, P. J., Divecha, N., Heck, A. J., Mohammed, S., Evaluation and optimization of ZIC-
HILIC-RP as an alternative MudPIT strategy. J Proteome Res 2007, 6, 937-946. 
[279] Gilar, M., Olivova, P., Daly, A. E., Gebler, J. C., Orthogonality of separation in two-dimensional 
liquid chromatography. Anal Chem 2005, 77, 6426-6434. 
[280]  Olsen,  J.  V.,  Blagoev,  B.,  Gnad,  F.,  Macek,  B.,  et  al.,  Global,  in  vivo,  and  site-specific 
phosphorylation dynamics in signaling networks. Cell 2006, 127, 635-648. 
[281] Chong, P. K., Lee, H., Kong, J. W., Loh, M. C., et al., Phosphoproteomics, oncogenic signaling 
and cancer research. Proteomics 2008, 8, 4370-4382. 
[282] Blume-Jensen, P., Hunter, T., Oncogenic kinase signalling. Nature 2001, 411, 355-365. 
[283] Krishnamoorthy, S., Receptor tyrosine kinase (RTK) mediated tyrosine phosphor-proteome from 
Drosophila S2 (ErbB1) cells reveals novel signaling networks. PLoS One 2008, 3, e2877. 
[284] Chiarugi, P., Cirri, P., Redox regulation of protein tyrosine phosphatases during receptor tyrosine 
kinase signal transduction. Trends Biochem Sci 2003, 28, 509-514. 
[285]  Cans,  C.,  Mangano,  R.,  Barila,  D.,  Neubauer,  G.,  Superti-Furga,  G.,  Nuclear  tyrosine 
phosphorylation: the beginning of a map. Biochem Pharmacol 2000, 60, 1203-1215. 
[286] Robinson, D. R., Wu, Y. M., Lin, S. F., The protein tyrosine kinase family of the human genome. 
Oncogene 2000, 19, 5548-5557. 
[287]  Cooper,  J.  A.,  Sefton,  B.  M.,  Hunter,  T.,  Detection  and  quantification  of  phosphotyrosine  in 
proteins. Methods Enzymol 1983, 99, 387-402. 
[288] Matsumoto, M., Oyamada, K., Takahashi, H., Sato, T., et al., Large-scale proteomic analysis of 
tyrosine-phosphorylation induced by T-cell receptor or B-cell receptor activation reveals new signaling 
pathways. Proteomics 2009, 9, 3549-3563. 
[289]  Frackelton,  A.  R.,  Jr.,  Posner,  M.,  Kannan,  B.,  Mermelstein,  F.,  Generation  of  monoclonal 
antibodies against phosphotyrosine and their use for affinity purification of phosphotyrosine-containing 
proteins. Methods Enzymol 1991, 201, 79-92.  
159 
 
[290]  Glenney,  J.  R.,  Isolation  of  tyrosine-phosphorylated  proteins  and  generation  of  monoclonal 
antibodies. Methods Enzymol 1991, 201, 92-100. 
[291]  Kamps,  M.  P.,  Generation  and  use  of  anti-phosphotyrosine  antibodies  for  immunoblotting. 
Methods Enzymol 1991, 201, 101-110. 
[292] White, M. F., Backer, J. M., Preparation and use of anti-phosphotyrosine antibodies to study 
structure and function of insulin receptor. Methods Enzymol 1991, 201, 65-79. 
[293] Pandey, A., Podtelejnikov, A. V., Blagoev, B., Bustelo, X. R., et al., Analysis of receptor signaling 
pathways by mass spectrometry: identification of vav-2 as a substrate of the epidermal and platelet-
derived growth factor receptors. Proc Natl Acad Sci U S A 2000, 97, 179-184. 
[294] Blagoev, B., Ong, S. E., Kratchmarova,  I., Mann, M., Temporal analysis of phosphotyrosine-
dependent signaling networks by quantitative proteomics. Nat Biotechnol 2004, 22, 1139-1145. 
[295] Kim, J. E., White, F. M., Quantitative analysis of phosphotyrosine signaling networks triggered by 
CD3 and CD28 costimulation in Jurkat cells. J Immunol 2006, 176, 2833-2843. 
[296] Steen, H., Pandey, A., Andersen, J. S., Mann, M., Analysis of tyrosine phosphorylation sites in 
signaling molecules by a phosphotyrosine-specific immonium ion scanning method. Sci STKE 2002, 
2002, pl16. 
[297]  Thelemann,  A.,  Petti,  F.,  Griffin,  G.,  Iwata,  K.,  et  al.,  Phosphotyrosine signaling  networks  in 
epidermal growth factor overexpressing squamous carcinoma cells. Mol Cell Proteomics 2005, 4, 356-
376. 
[298] Kettman, J. R., Frey, J. R., Lefkovits, I., Proteome, transcriptome and genome: top down or bottom 
up analysis? Biomol Eng 2001, 18, 207-212. 
[299] De Corte, V., Demol, H., Goethals, M., Van Damme, J., et al., Identification of Tyr438 as the major 
in vitro c-Src phosphorylation site in human gelsolin: a mass spectrometric approach. Protein Sci 1999, 
8, 234-241. 
[300] Kalo, M. S., Pasquale, E. B., Multiple in vivo tyrosine phosphorylation sites in EphB receptors. 
Biochemistry 1999, 38, 14396-14408. 
[301] Schmelzle, K., Kane, S., Gridley, S., Leinhard, G., White, F. M., Temporal dynamics of tyrosine 
phosphorylation in insulin signalling. Diabetes 2006, 55, 2171-2179. 
[302] Salomon, A. R., Ficarro, S. B., Brill, L. M., Brinker, A., et al., Profiling of tyrosine phosphorylation 
pathways in human cells using mass spectrometry. Proc Natl Acad Sci U S A 2003, 100, 443-448. 
[303] Wiesner, J., Premsler, T., Sickmann, A., Application of electron transfer dissociation (ETD) for the 
analysis of posttranslational modifications. Proteomics 2008, 8, 4466-4483. 
[304] Mikesh, L. M., Ueberheide, B., Chi, A., Coon, J. J., et al., The utility of ETD mass spectrometry in 
proteomic analysis. Biochim Biophys Acta 2006, 1764, 1811-1822. 
[305] Molina, H., Horn, D. M., Tang, N., Mathivanan, S., Pandey, A., Global proteomic profiling of 
phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U 
S A 2007, 104, 2199-2204. 
[306] Condina, M. R., Gustafsson, J. O., Klingler-Hoffmann, M., Bagley, C. J., et al., EZYprep LC-
coupled  MALDI-TOF/TOF  MS:  An  improved  matrix  spray  application  for  phosphopeptide 
characterisation. Proteomics 2010, 10, 2516-2530. 
[307] Leinenbach, A., Hartmer, R., Lubeck, M., Kneissl, B., et al., Proteome analysis of Sorangium 
cellulosum employing 2D-HPLC-MS/MS and improved database searching strategies for CID and ETD 
fragment spectra. J Proteome Res 2009, 8, 4350-4361. 
[308] Hennrich, M. L., Boersema, P. J., van den Toorn, H., Mischerikow, N., et al., Effect of chemical 
modifications  on  peptide  fragmentation  behavior  upon  electron  transfer  induced  dissociation.  Anal 
Chem 2009, 81, 7814-7822. 
[309]  Chen,  W.  Q.,  Graf,  C.,  Zimmel,  D.,  Rovina,  P.,  et  al.,  Ceramide  kinase  profiling  by  mass 
spectrometry reveals a conserved phosphorylation pattern downstream of the catalytic site. J Proteome 
Res, 9, 420-429. 
[310]  Steen,  H.,  Kuster,  B.,  Mann,  M.,  Quadrupole  time-of-flight  versus  triple-quadrupole  mass 
spectrometry for the determination of phosphopeptides by precursor ion scanning. J Mass Spectrom 
2001, 36, 782-790.  
160 
 
[311] Zubarev, R., Kelleher NL, McLafferty FW, ECD of multiply charged protein cations. A non-ergodic 
process. J Am Chem Soc. 1998, 120, 3265–3266. 
[312] Syka, J. E., Coon, J. J., Schroeder, M. J., Shabanowitz, J., Hunt, D. F., Peptide and protein 
sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci U S A 2004, 
101, 9528-9533. 
[313] Hartmer, R., Ledertheil , T., Brekenfeld, A., Proceedings of the 53rd ASMS Conference on Mass 
Spectrometry and Allied Topics, San Antonio, TX 2005. 
[314] Coon, J. J., Shabanowitz, J., Hunt, D. F., Syka, J. E., Electron transfer dissociation of peptide 
anions. J Am Soc Mass Spectrom 2005, 16, 880-882. 
[315] Coon, J. J., Syka, J. E., Shabanowitz, J., Hunt, D. F., Tandem mass spectrometry for peptide and 
protein sequence analysis. Biotechniques 2005, 38, 519, 521, 523. 
[316]  Coon,  J.  J.,  Ueberheide,  B.,  Syka,  J.  E.,  Dryhurst,  D.  D.,  et  al.,  Protein  identification  using 
sequential ion/ion reactions and tandem mass spectrometry. Proc Natl Acad Sci U S A 2005, 102, 9463-
9468. 
[317] Pitteri, S. J., Chrisman, P. A., Hogan, J. M., McLuckey, S. A., Electron transfer ion/ion reactions in 
a three-dimensional quadrupole ion trap: reactions of doubly and triply protonated peptides with SO2*. 
Anal Chem 2005, 77, 1831-1839. 
[318] Pitteri,  S. J., Chrisman, P. A., McLuckey, S. A., Electron-transfer ion/ion reactions of doubly 
protonated peptides: effect of elevated bath gas temperature. Anal Chem 2005, 77, 5662-5669. 
[319] Loughrey Chen, S., Huddleston, M. J., Shou, W., Deshaies, R., et al., Mass spectrometry-based 
methods for phosphorylation site mapping of hyperphosphorylated proteins applied to Net1, a regulator 
of exit from mitosis in yeast. Mol Cell Proteomics 2002, 1, 186-196. 
[320] Garaguso, I., Borlak, J., Matrix layer sample preparation: an improved MALDI-MS peptide analysis 
method for proteomic studies. Proteomics 2008, 8, 2583-2595. 
[321] Bodnar, W. M., Blackburn, R. K., Krise, J. M., Moseley, M. A., Exploiting the complementary 
nature of LC/MALDI/MS/MS and LC/ESI/MS/MS for increased proteome coverage.  J Am Soc Mass 
Spectrom 2003, 14, 971-979. 
[322] Hansen, K. C., Schmitt-Ulms, G., Chalkley, R. J., Hirsch, J., et al., Mass spectrometric analysis of 
protein  mixtures  at  low  levels using cleavable  13C-isotope-coded  affinity  tag  and  multidimensional 
chromatography. Mol Cell Proteomics 2003, 2, 299-314. 
[323]  Kratchmarova,  I.,  Blagoev,  B.,  Haack-Sorensen,  M.,  Kassem,  M.,  Mann,  M.,  Mechanism  of 
divergent growth factor effects in mesenchymal stem cell differentiation. Science 2005, 308, 1472-1477. 
[324] Atsriku, C., Britton, D. J., Held, J. M., Schilling, B., et al., Systematic mapping of posttranslational 
modifications in human estrogen receptor alpha, with emphasis on novel phosphorylation sites. Mol Cell 
Proteomics 2008, 8, 467-480. 
[325] Morandell, S., Stasyk, T., Skvortsov, S., Ascher, S., Huber, L. A., Quantitative proteomics and 
phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. 
Proteomics 2008, 8, 4383-4401. 
[326] Alonso, A., Sasin, J., Bottini, N., Friedberg, I., et al., Protein tyrosine phosphatases in the human 
genome. Cell 2004, 117, 699-711. 
[327]  Guthridge,  M.  A.,  Stomski,  F.  C.,  Barry,  E.  F.,  Winnall,  W.,  et  al.,  Site-specific  serine 
phosphorylation of the IL-3 receptor is required for hemopoietic cell survival. Mol Cell 2000, 6, 99-108. 
[328] Levy-Toledano, S., Maclouf, J., Rosa, J. P., Gallet, C., et al., Abnormal tyrosine phosphorylation 
linked to a defective interaction between ADP and its receptor on platelets. Thromb Haemost 1998, 80, 
463-468. 
[329] Mann, M., Ong, S. E., Gronborg, M., Steen, H., et al., Analysis of protein phosphorylation using 
mass spectrometry: deciphering the phosphoproteome. Trends Biotechnol 2002, 20, 261-268. 
[330] Marcus, K., Immler, D., Sternberger, J., Meyer, H. E., Identification of platelet proteins separated 
by two-dimensional gel electrophoresis and analyzed by matrix assisted laser desorption/ionization-time 
of flight-mass spectrometry and detection of tyrosine-phosphorylated proteins. Electrophoresis 2000, 
21, 2622-2636.  
161 
 
[331]  Bonewald,  L.  F.,  Bibbs,  L.,  Kates,  S.  A.,  Khatri,  A.,  et  al.,  Study  on  the  synthesis  and 
characterization of peptides containing phosphorylated tyrosine. J Pept Res 1999, 53, 161-169. 
[332] Cohen, S. L., Chait, B. T., Influence of matrix solution conditions on the MALDI-MS analysis of 
peptides and proteins. Anal Chem 1996, 68, 31-37. 
[333] Janeck, K., Wenschuh, H., Bienert, M., Krause, E.,  Phosphopeptide analysis by positive and 
negative  ion  matrix-assisted  laser  desorption/ionization  mass  spectrometry.  Rapid  Commun  Mass 
Spectrom 2001, 15, 1593-1599. 
[334] Antignani, A., Youle, R. J., The cytokine, granulocyte-macrophage colony-stimulating factor (GM-
CSF), can deliver Bcl-XL as an extracellular fusion protein to protect cells from apoptosis and retain 
differentiation induction. J Biol Chem 2007, 282, 11246-11254. 
[335]  Dhar-Mascareno,  M.,  Chen,  J.,  Zhang,  R.  H.,  Carcamo,  J.  M.,  Golde,  D.  W.,  Granulocyte-
macrophage colony-stimulating factor signals for increased glucose transport via phosphatidylinositol 3-
kinase- and hydrogen peroxide-dependent mechanisms. J Biol Chem 2003, 278, 11107-11114. 
[336] Guthridge, M. A., Lopez, A. F., Phosphotyrosine/phosphoserine binary switches: a new paradigm 
for the regulation of PI3K signalling and growth factor pleiotropy? Biochem Soc Trans 2007, 35, 250-
252. 
[337] Chen, V. C., Chou, C. C., Hsieh, H. Y., Perreault, H., Khoo, K. H., Targeted identification of 
phosphorylated peptides by off-line HPLC-MALDI-MS/MS using LC retention time prediction. J Mass 
Spectrom 2008, 43, 1649-1658. 
[338] Kim, E. A., Noh, Y. T., Ryu, M. J., Kim, H. T., et al., Phosphorylation and transactivation of Pax6 
by homeodomain-interacting protein kinase 2. J Biol Chem 2006, 281, 7489-7497. 
[339] Vitorino, R., Alves, R., Barros, A., Caseiro, A., et al., Finding new posttranslational modifications in 
salivary proline-rich proteins. Proteomics, 10, 3732-3742. 
[340] Dashtiev, M., Frankevich, V., Zenobi, R., Kinetic energy of free electrons affects MALDI positive 
ion yield via capture cross-section. J Phys Chem A 2006, 110, 926-930. 
[341] Callesen, A. K., Mohammed, S., Bunkenborg, J., Kruse, T. A., et al., Serum protein profiling by 
miniaturized solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. 
Rapid Commun Mass Spectrom 2005, 19, 1578-1586. 
[342] Kussmann, M., Lassing, U., Sturmer, C. A., Przybylski, M., Roepstorff, P., Matrix-assisted laser 
desorption/ionization mass spectrometric peptide mapping of the neural cell adhesion protein neurolin 
purified by sodium dodecyl sulfate polyacrylamide gel electrophoresis or acidic precipitation. J Mass 
Spectrom 1997, 32, 483-493. 
[343] Laugesen, S., Roepstorff, P., Combination of two matrices results in improved performance of 
MALDI MS for peptide mass mapping and protein analysis. J Am Soc Mass Spectrom 2003, 14, 992-
1002. 
[344] Schiller, J., Suss, R., Fuchs, B., Muller, M., et al., The suitability of different DHB isomers as 
matrices for the MALDI-TOF MS analysis of phospholipids: which isomer for what purpose? Eur Biophys 
J 2007, 36, 517-527. 
[345] Soltwisch, J., Berkenkamp, S., Dreisewerd, K., A binary matrix of 2,5-dihydroxybenzoic acid and 
glycerol  produces  homogenous  sample  preparations  for  matrix-assisted  laser  desorption/ionization 
mass spectrometry. Rapid Commun Mass Spectrom 2008, 22, 59-66. 
[346] Xu, S., Ye, M., Xu, D., Li, X., et al., Matrix with high salt tolerance for the analysis of peptide and 
protein samples by desorption/ionization time-of-flight mass spectrometry. Anal Chem 2006, 78, 2593-
2599. 
[347] Vorm, O., Roepstorff, P., Mann, M., Improved resolution and very high sensitivity in MALDI TOF of 
matrix surfaces made by fast evaporation. Anal Chem 1994, 66, 3281-3287. 
[348]  Thomas,  H.,  Havlis,  J.,  Peychl,  J.,  Shevchenko,  A.,  Dried-droplet  probe  preparation  on 
AnchorChip targets for navigating the acquisition of matrix-assisted laser desorption/ionization time-of-




[349]  Penno,  M.  A.,  Ernst,  M.,  Hoffmann,  P.,  Optimal  preparation  methods  for  automated  matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry profiling of low molecular weight 
proteins and peptides. Rapid Commun Mass Spectrom 2009, 23, 2656-2662. 
[350] Ekstrom, S., Nilsson, J., Helldin, G., Laurell, T., Marko-Varga, G., Disposable polymeric high-
density nanovial arrays for matrix assisted laser desorption/ionization-time of flight-mass spectrometry: 
II. Biological applications. Electrophoresis 2001, 22, 3984-3992. 
[351] Ericson, C., Phung, Q. T., Horn, D. M., Peters, E. C., et al., An automated noncontact deposition 
interface for liquid chromatography matrix-assisted laser desorption/ionization mass spectrometry. Anal 
Chem 2003, 75, 2309-2315. 
[352] Hofmann, S., Gluckmann, M., Kausche, S., Schmidt, A., et al., Rapid and sensitive identification of 
major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. Mol 
Cell Proteomics 2005, 4, 1888-1897. 
[353]  Laurell,  T.,  Nilsson,  J.,  Marko-Varga,  G.,  Silicon  microstructures  for  high-speed  and  high-
sensitivity protein identifications. J Chromatogr B Biomed Sci Appl 2001, 752, 217-232. 
[354] Miliotis, T., Kjellstrom, S., Nilsson, J., Laurell, T., et al., Capillary liquid chromatography interfaced 
to matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using an on-line coupled 
piezoelectric flow-through microdispenser. J Mass Spectrom 2000, 35, 369-377. 
[355] Miliotis, T., Kjellstrom, S., Onnerfjord, P., Nilsson, J., et al., Protein identification platform utilizing 
micro dispensing technology interfaced to matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry. J Chromatogr A 2000, 886, 99-110. 
[356]  Preisler,  J.,  Hu,  P.,  Rejtar,  T.,  Karger,  B.  L.,  Capillary  electrophoresis--matrix-assisted  laser 
desorption/ionization time-of-flight mass spectrometry using a vacuum deposition interface. Anal Chem 
2000, 72, 4785-4795. 
[357] Preisler, J., Hu, P., Rejtar, T., Moskovets, E., Karger, B. L., Capillary array electrophoresis-MALDI 
mass spectrometry using a vacuum deposition interface. Anal Chem 2002, 74, 17-25. 
[358] Condina, M. R., Guthridge, M. A., McColl, S. R., Hoffmann, P., A sensitive magnetic bead method 
for the detection and identification of tyrosine phosphorylation in proteins by MALDI-TOF/TOF MS. 
Proteomics 2009, 9, 3047-3057. 
[359] Oyama, M., Kozuka-Hata, H., Tasaki, S., Semba, K., et al., Temporal perturbation of tyrosine 
phosphoproteome dynamics reveals the system-wide regulatory networks. Mol Cell Proteomics 2009, 8, 
226-231. 
[360] Tong, J., Taylor, P., Peterman, S. M., Prakash, A., Moran, M. F., Epidermal growth factor receptor 
phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and 
phosphorylations at Ser1039 and Thr1041. Mol Cell Proteomics 2009, 8, 2131-2144. 
[361] Johns, T. G., Stockert, E., Ritter, G., Jungbluth, A. A., et al., Novel monoclonal antibody specific 
for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in 
cells containing amplification of the EGFR gene. Int J Cancer 2002, 98, 398-408. 
[362] Santon, J. B., Cronin, M. T., MacLeod, C. L., Mendelsohn, J., et al., Effects of epidermal growth 
factor receptor concentration on tumorigenicity of A431 cells in nude mice. Cancer Res 1986, 46, 4701-
4705. 
[363]  Schmidt,  M.,  Maurer-Gebhard,  M.,  Groner,  B.,  Kohler,  G.,  et  al.,  Suppression  of  metastasis 
formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant 
EGF receptors. Oncogene 1999, 18, 1711-1721. 
[364] Wels, W., Beerli, R., Hellmann, P., Schmidt, M., et al., EGF receptor and p185erbB-2-specific 
single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor 
proteins. Int J Cancer 1995, 60, 137-144. 
[365] Wels, W., Harwerth, I. M., Mueller, M., Groner, B., Hynes, N. E., Selective inhibition of tumor cell 
growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 1992, 
52, 6310-6317. 
[366] Wiegant, F. A., Blok, F. J., Defize, L. H., Linnemans, W. A., et al., Epidermal growth factor 
receptors associated to cytoskeletal elements of epidermoid carcinoma (A431) cells. J Cell Biol 1986, 
103, 87-94.  
163 
 
[367] Bae, Y. S., Kang, S. W., Seo, M. S., Baines, I. C., et al., Epidermal growth factor (EGF)-induced 
generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 
1997, 272, 217-221. 
[368] Du, Y., Danjo, K., Robinson, P. A., Crabtree, J. E., In-Cell Western analysis of Helicobacter pylori-
induced phosphorylation of extracellular-signal related kinase via the transactivation of the epidermal 
growth factor receptor. Microbes Infect 2007, 9, 838-846. 
[369]  Palumbo,  A.  M.,  Reid,  G.  E.,  Evaluation  of  gas-phase  rearrangement  and  competing 
fragmentation reactions on protein phosphorylation site assignment using collision induced dissociation-
MS/MS and MS3. Anal Chem 2008, 80, 9735-9747. 
[370] Schulze, W. X., Deng, L., Mann, M., Phosphotyrosine interactome of the ErbB-receptor kinase 
family. Mol Syst Biol 2005, 1, 1-13. 
[371] Guo, L., Kozlosky, C. J., Ericsson, L. H., Daniel, T. O., et al., Studies of ligand-induced site-
specific phosphorylation of epidermal growth factor receptor. J Am Soc Mass Spectrom 2003, 14, 1022-
1031. 
[372]  Gembitsky,  D.  S.,  Lawlor,  K.,  Jacovina,  A.,  Yaneva,  M.,  Tempst,  P.,  A  prototype  antibody 
microarray platform to monitor changes in protein tyrosine phosphorylation. Mol Cell Proteomics 2004, 
3, 1102-1118. 
[373]  Pandey,  A.,  Fernandez,  M.  M.,  Steen,  H.,  Blagoev,  B.,  et  al.,  Identification  of  a  novel 
immunoreceptor tyrosine-based activation motif-containing molecule, STAM2, by mass spectrometry 
and its involvement in growth factor and cytokine receptor signaling pathways. J Biol Chem 2000, 275, 
38633-38639. 
[374] Kooijman, R., Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor 
Rev 2006, 17, 305-323. 
[375] Adams, T. E., Epa, V. C., Garrett, T. P., Ward, C. W., Structure and function of the type 1 insulin-
like growth factor receptor. Cell Mol Life Sci 2000, 57, 1050-1093. 
[376] Denley, A., Wallace, J. C., Cosgrove, L. J., Forbes, B. E., The insulin receptor isoform exon 11- 
(IR-A) in cancer and other diseases: a review. Horm Metab Res 2003, 35, 778-785. 
[377] Hanke, S., Mann, M., The phosphotyrosine interactome of the insulin receptor family and its 
substrates IRS-1 and IRS-2. Mol Cell Proteomics 2009, 8, 519-534. 
[378] Vincent, A. M., Feldman, E. L., Control of cell survival by IGF signaling pathways. Growth Horm 
IGF Res 2002, 12, 193-197. 
[379] Pollak, M., Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8, 
915-928. 
[380]  Pollak,  M.,  Targeting  insulin  and  insulin-like  growth  factor  signalling  in  oncology.  Curr  Opin 
Pharmacol 2008, 8, 384-392. 
[381] Pollak, M. N., Schernhammer, E. S., Hankinson, S. E., Insulin-like growth factors and neoplasia. 
Nat Rev Cancer 2004, 4, 505-518. 
[382] Olefsky, J. M., The insulin receptor. A multifunctional protein. Diabetes 1990, 39, 1009-1016. 
[383] Ullrich, A., Bell, J. R., Chen, E. Y., Herrera, R., et al., Human insulin receptor and its relationship to 
the tyrosine kinase family of oncogenes. Nature 1985, 313, 756-761. 
[384] Mosthaf, L., Grako, K., Dull, T. J., Coussens, L., et al., Functionally distinct insulin receptors 
generated by tissue-specific alternative splicing. EMBO J 1990, 9, 2409-2413. 
[385] Seino, S., Bell, G. I., Alternative splicing of human insulin receptor messenger RNA. Biochem 
Biophys Res Commun 1989, 159, 312-316. 
[386] Moller, D. E., Yokota, A., Caro, J. F., Flier, J. S., Tissue-specific expression of two alternatively 
spliced insulin receptor mRNAs in man. Mol Endocrinol 1989, 3, 1263-1269. 
[387]  Frasca,  F.,  Pandini,  G.,  Scalia,  P.,  Sciacca,  L.,  et  al.,  Insulin  receptor  isoform  A,  a  newly 
recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999, 
19, 3278-3288. 
[388] Vella, V., Pandini, G., Sciacca, L., Mineo, R., et al., A novel autocrine loop involving IGF-II and the 




[389] Denley, A., Cosgrove, L. J., Booker, G. W., Wallace, J. C., Forbes, B. E., Molecular interactions of 
the IGF system. Cytokine Growth Factor Rev 2005, 16, 421-439. 
[390] Sciacca, L., Costantino, A., Pandini, G., Mineo, R., et al., Insulin receptor activation by IGF-II in 
breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999, 18, 2471-2479. 
[391] Sciacca, L., Mineo, R., Pandini, G., Murabito, A., et al., In IGF-I receptor-deficient leiomyosarcoma 
cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform 
A. Oncogene 2002, 21, 8240-8250. 
[392] Jensen, M., Hansen, B., De Meyts, P., Schaffer, L., Urso, B., Activation of the insulin receptor by 
insulin and a synthetic peptide leads to divergent metabolic and mitogenic signaling and responses. J 
Biol Chem 2007, 282, 35179-35186. 
[393] Kurtzhals, P., Schaffer, L., Sorensen, A., Kristensen, C., et al., Correlations of receptor binding 
and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000, 49, 
999-1005. 
[394] Feener, E. P., Backer, J. M., King, G. L., Wilden, P. A., et al., Insulin stimulates serine and 
tyrosine phosphorylation in the juxtamembrane region of the insulin receptor. J Biol Chem 1993, 268, 
11256-11264. 
[395] Issad, T., Tavare, J. M., Denton, R. M., Analysis of insulin receptor phosphorylation sites in intact 
rat liver cells by two-dimensional phosphopeptide mapping. Predominance of the tris-phosphorylated 
form of the kinase domain after stimulation by insulin. Biochem J 1991, 275 ( Pt 1), 15-21. 
[396] Kohanski, R. A., Insulin receptor autophosphorylation. II. Determination of autophosphorylation 
sites by chemical sequence analysis and identification of the juxtamembrane sites. Biochemistry 1993, 
32, 5773-5780. 
[397] Tornqvist, H. E., Pierce, M. W., Frackelton, A. R., Nemenoff, R. A., Avruch, J., Identification of 
insulin receptor tyrosine residues autophosphorylated in vitro. J Biol Chem 1987, 262, 10212-10219. 
[398] Forbes, B. E., Martin, L., Hoffmann, P., Wallace, J., NHMRC, The University of Adelaide 2010. 
[399] Denley, A., Bonython, E. R., Booker, G. W., Cosgrove, L. J., et al., Structural determinants for 
high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of 
the IR. Mol Endocrinol 2004, 18, 2502-2512. 
[400] McClain, D. A., Different ligand affinities of the two human insulin receptor splice variants are 
reflected in parallel changes in sensitivity for insulin action. Mol Endocrinol 1991, 5, 734-739. 
[401] Yamaguchi, Y., Flier, J. S., Benecke, H., Ransil, B. J., Moller, D. E., Ligand-binding properties of 
the two isoforms of the human insulin receptor. Endocrinology 1993, 132, 1132-1138. 
[402] Yamaguchi, Y., Flier, J. S., Yokota, A., Benecke, H., et al., Functional properties of two naturally 
occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology 1991, 
129, 2058-2066. 
[403] Kellerer, M., Lammers, R., Ermel, B., Tippmer, S., et al., Distinct alpha-subunit structures of 
human insulin receptor A and B variants determine differences in tyrosine kinase activities. Biochemistry 
1992, 31, 4588-4596. 
[404] Lew, E. D., Furdui, C. M., Anderson, K. S., Schlessinger, J., The precise sequence of FGF 
receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci Signal 
2009, 2, ra6. 
[405] Greene, M. W., Morrice, N., Garofalo, R. S., Roth, R. A., Modulation of human insulin receptor 
substrate-1 tyrosine phosphorylation by protein kinase Cdelta. Biochem J 2004, 378, 105-116. 
[406]  Hojlund,  K.,  Wrzesinski,  K.,  Larsen,  P.  M.,  Fey,  S.  J.,  et  al.,  Proteome  analysis  reveals 
phosphorylation of ATP synthase beta -subunit in human skeletal muscle and proteins with potential 
roles in type 2 diabetes. J Biol Chem 2003, 278, 10436-10442. 
[407] Kim, J. A., Yeh, D. C., Ver, M., Li, Y., et al., Phosphorylation of Ser24 in the pleckstrin homology 
domain  of  insulin  receptor  substrate-1  by  Mouse  Pelle-like  kinase/interleukin-1  receptor-associated 
kinase: cross-talk between inflammatory signaling and insulin signaling that may contribute to insulin 
resistance. J Biol Chem 2005, 280, 23173-23183. 
[408]  Ibarrola,  N.,  Molina,  H.,  Iwahori,  A.,  Pandey,  A.,  A  novel  proteomic  approach  for  specific 
identification of tyrosine kinase substrates using [13C]tyrosine. J Biol Chem 2004, 279, 15805-15813.  
165 
 
[409]  Temporini,  C.,  Dolcini,  L.,  Abee,  A.,  Calleri,  E.,  et  al.,  Development  of  an  integrated 
chromatographic  system  for  on-line  digestion  and  characterization  of  phosphorylated  proteins.  J 
Chromatogr A 2008, 1183, 65-75. 
[410] Furdui, C. M., Lew, E. D., Schlessinger, J., Anderson, K. S., Autophosphorylation of FGFR1 
kinase is mediated by a sequential and precisely ordered reaction. Mol Cell 2006, 21, 711-717. 
[411] Denley, A., Brierley, G. V., Carroll, J. M., Lindenberg, A., et al., Differential activation of insulin 
receptor isoforms by insulin-like growth factors is determined by the C domain. Endocrinology 2006, 
147, 1029-1036. 
[412] Li, G., Barrett, E. J., Wang, H., Chai, W., Liu, Z., Insulin at physiological concentrations selectively 
activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial 
cells. Endocrinology 2005, 146, 4690-4696. 
[413] Lynn, M. A., Rupnow, H. L., Kleinhenz, D. J., Kanner, W. A., et al., Fatty acids differentially 
modulate  insulin-stimulated  endothelial  nitric  oxide  production  by  an  Akt-independent  pathway.  J 
Investig Med 2004, 52, 129-136. 
[414] Montagnani, M., Chen, H., Barr, V. A., Quon, M. J., Insulin-stimulated activation of eNOS is 
independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem 2001, 276, 30392-
30398. 
[415] Montagnani, M., Golovchenko, I., Kim, I., Koh, G. Y., et al., Inhibition of phosphatidylinositol 3-
kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 2002, 277, 1794-1799. 
[416] Zeng, G., Nystrom, F. H., Ravichandran, L. V., Cong, L. N., et al., Roles for insulin receptor, PI3-
kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular 
endothelial cells. Circulation 2000, 101, 1539-1545. 
[417] Zeng, G., Quon, M. J., Insulin-stimulated production of nitric oxide is inhibited by wortmannin. 
Direct measurement in vascular endothelial cells. J Clin Invest 1996, 98, 894-898. 
[418] Anfossi, G., Massucco, P., Mattiello, L., Piretto, V., et al., Insulin exerts opposite effects on platelet 
function at physiological and supraphysiological concentrations. Thromb Res 1996, 82, 57-68. 
[419] Denley, A., Carroll, J. M., Brierley, G. V., Cosgrove, L., et al., Differential activation of insulin 
receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol 2007, 
27, 3569-3577. 
[420] Tao, W. A., Aebersold, R., Advances in quantitative proteomics via stable isotope tagging and 
mass spectrometry. Curr Opin Biotechnol 2003, 14, 110-118. 
[421] Druker, B. J., Mamon, H. J., Roberts, T. M., Oncogenes, growth factors, and signal transduction. N 
Engl J Med 1989, 321, 1383-1391. 
[422]  Liao,  P.  C.,  Leykam,  J.,  Andrews,  P.  C.,  Gage,  D.  A.,  Allison,  J.,  An  approach  to  locate 
phosphorylation sites in a phosphoprotein: mass mapping by combining specific enzymatic degradation 
with matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem 1994, 219, 9-20. 
[423]  Beck,  A.,  Deeg,  M.,  Moeschel,  K.,  Schmidt,  E.  K.,  et  al.,  Alkaline  liquid 
chromatography/electrospray ionization skimmer collision-induced dissociation mass spectrometry for 
phosphopeptide screening. Rapid Commun Mass Spectrom 2001, 15, 2324-2333. 
[424] Ding, J., Burkhart, W., Kassel, D. B., Identification of phosphorylated peptides from complex 
mixtures using negative-ion orifice-potential stepping and capillary liquid chromatography/electrospray 
ionization mass spectrometry. Rapid Commun Mass Spectrom 1994, 8, 94-98. 
[425]  Neubauer,  G.,  Mann,  M.,  Mapping  of  phosphorylation  sites  of  gel-isolated  proteins  by 
nanoelectrospray tandem mass spectrometry: potentials and limitations. Anal Chem 1999, 71, 235-242. 
[426] Nabetani, T., Miyazaki, K., Tabuse, Y., Tsugita, A., Analysis of acidic peptides with a matrix-
assisted laser desorption/ionization mass spectrometry using positive and negative ion modes with 
additive monoammonium phosphate. Proteomics 2006, 6, 4456-4465. 
[427] Xu, C. F., Lu, Y., Ma, J., Mohammadi, M., Neubert, T. A., Identification of phosphopeptides by 
MALDI Q-TOF MS in positive and negative ion modes after methyl esterification. Mol Cell Proteomics 
2005, 4, 809-818.  
166 
 
[428]  Asara,  J.  M.,  Allison,  J.,  Enhanced  detection  of  phosphopeptides  in  matrix-assisted  laser 
desorption/ionization mass spectrometry using ammonium salts. J Am Soc Mass Spectrom 1999, 10, 
35-44. 
[429] Gorman, J. J., Ferguson, B. L., Nguyen, T. B., Use of 2,6-dihydroxyacetophenone for analysis of 
fragile peptides, disulphide bonding and small proteins by matrix-assisted laser desorption/ionization. 
Rapid Commun Mass Spectrom 1996, 10, 529-536. 
[430] Hou, J., Xie, Z., Xue, P., Cui, Z., et al., Enhanced MALDI-TOF MS analysis of phosphopeptides 
using an optimized DHAP/DAHC matrix. J Biomed Biotechnol 2010, 759690. 
[431] Yang, X., Wu, H., Kobayashi, T., Solaro, R. J., van Breemen, R. B., Enhanced ionization of 
phosphorylated peptides during MALDI TOF mass spectrometry. Anal Chem 2004, 76, 1532-1536. 
[432] Murray, K. K., DNA sequencing by mass spectrometry. J Mass Spectrom 1996, 31, 1203-1215. 
[433] Tholey, A., Ionic liquid matrices with phosphoric acid as matrix additive for the facilitated analysis 
of phosphopeptides by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun 
Mass Spectrom 2006, 20, 1761-1768. 
[434]  Amado,  F.,  Domingues,  P.,  Graça  Santana-Marques,  M.,  Ferrer-Correia,  A.,  Tomer,  K., 
Discrimination  effects  and sensitivity  variations  in  matrix-assisted  laser desorption/ionization.  Rapid 
Communications in Mass Spectrometry 1997, 11, 1347 - 1352. 
[435]  Bienvenut,  W.  V.,  Deon,  C.,  Pasquarello,  C.,  Campbell,  J.  M.,  et  al.,  Matrix-assisted  laser 
desorption/ionization-tandem mass spectrometry with high resolution and sensitivity for identification 
and characterization of proteins. Proteomics 2002, 2, 868-876. 
[436]  Krutchinsky,  A.  N.,  Zhang,  W.,  Chait,  B.  T.,  Rapidly  switchable  matrix-assisted  laser 
desorption/ionization  and  electrospray  quadrupole-time-of-flight  mass  spectrometry  for  protein 
identification. J Am Soc Mass Spectrom 2000, 11, 493-504. 
[437]  Wattenberg,  A.,  Organ,  A.  J.,  Schneider,  K.,  Tyldesley,  R.,  et  al.,  Sequence  dependent 
fragmentation  of  peptides  generated  by  MALDI  quadrupole  time-of-flight  (MALDI  Q-TOF)  mass 
spectrometry and its implications for protein identification. J Am Soc Mass Spectrom 2002, 13, 772-783. 
[438] Kim, J., Camp, D. G., 2nd, Smith, R. D., Improved detection of multi-phosphorylated peptides in 
the presence of phosphoric acid in liquid chromatography/mass spectrometry. J Mass Spectrom 2004, 
39, 208-215. 
[439] Fleron, M., Greffe, Y., Musmeci, D., Massart, A. C., et al., Novel post-digest isotope coded protein 
labeling method for phospho- and glycoproteome analysis. J Proteomics. 
[440] Leroy, B., Rosier, C., Erculisse, V., Leys, N., et al., Differential proteomic analysis using isotope-
coded protein-labeling strategies: comparison, improvements and application to simulated microgravity 
effect on Cupriavidus metallidurans CH34. Proteomics 2010, 10, 2281-2291. 
[441]  Munchbach,  M.,  Quadroni,  M.,  Miotto,  G.,  James,  P.,  Quantitation  and  facilitated  de  novo 
sequencing of proteins by isotopic N-terminal labeling of peptides with a fragmentation-directing moiety. 
Anal Chem 2000, 72, 4047-4057. 
[442] Kosaki, A., Pillay, T. S., Xu, L., Webster, N. J., The B isoform of the insulin receptor signals more 
efficiently than the A isoform in HepG2 cells. J Biol Chem 1995, 270, 20816-20823. 
[443] Harsha, H. C., Pandey, A., Phosphoproteomics in cancer. Mol Oncol 2010. 
[444] Rikova, K., Guo, A., Zeng, Q., Possemato, A., et al., Global survey of phosphotyrosine signaling 
identifies oncogenic kinases in lung cancer. Cell 2007, 131, 1190-1203. 
[445] Tedford, N. C., Hall, A. B., Graham, J. R., Murphy, C. E., et al., Quantitative analysis of cell 
signaling and drug action via mass spectrometry-based systems level phosphoproteomics. Proteomics 
2009, 9, 1469-1487. 
[446] Bantscheff, M., Schirle, M., Sweetman, G., Rick, J., Kuster, B., Quantitative mass spectrometry in 
proteomics: a critical review. Anal Bioanal Chem 2007, 389, 1017-1031. 
[447] Ong, S. E., Mann, M., Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 
2005, 1, 252-262. 
[448] Silva, J. C., Gorenstein, M. V., Li, G. Z., Vissers, J. P., Geromanos, S. J., Absolute quantification 
of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics 2006, 5, 144-156.  
167 
 
[449] Zhu, W., Smith, J. W., Huang, C. M., Mass spectrometry-based label-free quantitative proteomics. 
J Biomed Biotechnol, 2010, 840518. 
[450] Liu, H., Sadygov, R. G., Yates, J. R., 3rd, A model for random sampling and estimation of relative 
protein abundance in shotgun proteomics. Anal Chem 2004, 76, 4193-4201. 
[451] Asara, J. M., Christofk, H. R., Freimark, L. M., Cantley, L. C., A label-free quantification method by 
MS/MS TIC compared to SILAC and spectral counting in a proteomics screen. Proteomics 2008, 8, 994-
999. 
[452] Rao, P. V., Reddy, A. P., Lu, X., Dasari, S., et al., Proteomic identification of salivary biomarkers of 
type-2 diabetes. J Proteome Res 2009, 8, 239-245. 
[453] Lange, V., Malmstrom, J. A., Didion, J., King, N. L., et al., Targeted quantitative analysis of 
Streptococcus pyogenes virulence factors by multiple reaction monitoring. Mol Cell Proteomics 2008, 7, 
1489-1500. 
[454] Lange, V., Picotti, P., Domon, B., Aebersold, R., Selected reaction monitoring for quantitative 
proteomics: a tutorial. Mol Syst Biol 2008, 4, 222. 
[455] Wolf-Yadlin, A., Hautaniemi, S., Lauffenburger, D. A., White, F. M., Multiple reaction monitoring for 
robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci U S A 2007, 
104, 5860-5865. 
[456] Mallick, P., Schirle, M., Chen, S. S., Flory, M. R., et al., Computational prediction of proteotypic 
peptides for quantitative proteomics. Nat Biotechnol 2007, 25, 125-131. 
[457] Bell, A. W., Deutsch, E. W., Au, C. E., Kearney, R. E., et al., A HUPO test sample study reveals 
common problems in mass spectrometry-based proteomics. Nat Methods 2009, 6, 423-430. 
[458] Rocchiccioli, S., Citti, L., Boccardi, C., Ucciferri, N., et al., A gel-free approach in vascular smooth 
muscle cell proteome: perspectives for a better insight into activation. Proteome Sci, 8, 15. 
[459] Schmidt, A., Karas, M., Dulcks, T., Effect of different solution flow rates on analyte ion signals in 
nano-ESI MS, or: when does ESI turn into nano-ESI? J Am Soc Mass Spectrom 2003, 14, 492-500. 
[460] Neubert, H., Bonnert, T. P., Rumpel, K., Hunt, B. T., et al., Label-free detection of differential 
protein expression by LC/MALDI mass spectrometry. J Proteome Res 2008, 7, 2270-2279. 
[461] Hattan, S. J., Parker, K. C., Methodology utilizing MS signal intensity and LC retention time for 
quantitative analysis and precursor ion selection in proteomic LC-MALDI analyses. Anal Chem 2006, 
78, 7986-7996. 
[462] Fugmann, T., Neri, D., Roesli, C., DeepQuanTR: MALDI-MS-based label-free quantification of 
proteins in complex biological samples. Proteomics 2010, 10, 2631-2643. 
[463] Patel, V., Thalassinos, K., Slade, S., Connolly, J., et al., A comparison of labelling and label-free 
mass spectrometry-based proteomics approaches. J Proteome Res 2009, 8, 3752-3759. 
[464] Ge, F., Xiao, C. L., Bi, L. J., Tao, S. C., et al., Quantitative phosphoproteomics of proteasome 
inhibition in multiple myeloma cells. PLoS One, 5. 
[465]  Baker,  M.  A.,  Smith,  N.  D.,  Hetherington,  L.,  Taubman,  K.,  et  al.,  Label-free  quantitation  of 
phosphopeptide changes during rat sperm capacitation. J Proteome Res, 9, 718-729. 
[466] Lange, S., Sylvester, M., Schumann, M., Freund, C., Krause, E., Identification of phosphorylation-
dependent interaction partners of the adapter protein ADAP using quantitative mass spectrometry: 
SILAC vs (18)O-labeling. J Proteome Res, 9, 4113-4122. 
[467] Wu, H. Y., Tseng, V. S., Chen, L. C., Chang, H. Y., et al., Identification of tyrosine-phosphorylated 
proteins associated with lung cancer metastasis using label-free quantitative analyses. J Proteome Res, 
9, 4102-4112. 
[468] Zhang, Y., Wolf-Yadlin, A., White, F. M., Quantitative proteomic analysis of phosphotyrosine-
mediated cellular signaling networks. Methods Mol Biol 2007, 359, 203-212. 
[469] Bonilla, L., Means, G., Lee, K., Patterson, S., The evolution of tools for protein phosphorylation 
site analysis: from discovery to clinical application. Biotechniques 2008, 44, 671-679. 
[470] Ozlu, N., Akten, B., Timm, W., Haseley, N., et al., Phosphoproteomics. Wiley Interdiscip Rev Syst 
Biol Med, 2, 255-276. 
[471] Nita-Lazar, A., Quantitative analysis of phosphorylation-based protein signaling networks in the 
immune system by mass spectrometry. Wiley Interdiscip Rev Syst Biol Med.  
168 
 
[472] Oda, Y., Nagasu, T., Chait, B. T., Enrichment analysis of phosphorylated proteins as a tool for 
probing the phosphoproteome. Nat Biotechnol 2001, 19, 379-382. 
[473]  Zhou,  H.,  Watts,  J.  D.,  Aebersold,  R.,  A  systematic  approach  to  the  analysis  of  protein 
phosphorylation. Nat Biotechnol 2001, 19, 375-378. 
[474] Stemmann, O., Zou, H., Gerber, S. A., Gygi, S. P., Kirschner, M. W., Dual inhibition of sister 
chromatid separation at metaphase. Cell 2001, 107, 715-726. 
[475] Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W., Gygi, S. P., Absolute quantification of 
proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A 2003, 100, 
6940-6945. 
[476]  O'Neill,  R.  A.,  Bhamidipati,  A.,  Bi,  X.,  Deb-Basu,  D.,  et  al.,  Isoelectric  focusing  technology 












Condina, M. R., Gustafsson, J. O. R., Klingler-Hoffmann, M., Bagley, C. J., McColl, 
S. R., Hoffmann, P.  (2010) EZYprep LC-coupled MALDI-TOF/TOF MS: An 
improved matrix spray application for phosphopeptide characterisation. 





NOTE:  This publication is included in the print copy of the thesis 
held in the University of Adelaide Library. 
 








Tyrosine Phosphorylation Enrichment and Subsequent Analysis by 
MALDI-TOF/TOF MS/MS and LC-ESI-IT-MS/MS. 
 
Mark R. Condina1, Manuela Klingler-Hoffmann2, and Peter Hoffmann1* 
1Adelaide Proteomics Centre, School of Molecular and Biomedical Science, The University of Adelaide, 
SA 5005 Adelaide, Australia 
2Chemokine  Biology  Laboratory,  School  of  Molecular  and  Biomedical  Science,  The  University  of 
Adelaide, SA 5005 Adelaide, Australia 
3School of Medicine, The University of Adelaide, SA 5005 Adelaide, Australia 
  
- 212 - 
 
STATEMENT OF AUTHORSHIP FOR APPENDIX 7B 
 
Tyrosine Phosphorylation Enrichment and Subsequent Analysis by MALDI-TOF/TOF MS/MS and 
LC-ESI-IT-MS/MS. Current Protocols in Protein Science 2010, 62:13.11.1-13.11.26. 
 
Mark R. Condina (Candidate) 
Statement  of  contribution  (in  terms  of  the  conceptualization  of  the  work,  its  realisation  and  its 
documentation) 
 
Designed experimental methods, interpreted data, wrote manuscript 
 




Manuela Klingler-Hoffmann (co-author) 
Statement  of  contribution  (in  terms  of  the  conceptualization  of  the  work,  its  realisation  and  its 
documentation) 
 
Aided in method parameter suggestions and manuscript evaluation 
 
Certification that the statement of contribution is accurate and permission is given for the inclusion of the 
paper in the thesis 
 
Signed.................................................................................................................Date.................................  
- 213 - 
 
 
Peter Hoffmann (co-author) 
Statement  of  contribution  (in  terms  of  the  conceptualization  of  the  work,  its  realisation  and  its 
documentation) 
 
Supervised development of methods, helped in data interpretation and manuscript evaluation and acted 
as corresponding author 
 
Certification that the statement of contribution is accurate and permission is given for the inclusion of the 









Condina, M.R., Klingler-Hoffmann, M. and Hoffmann, P. (2010) Tyrosine 
Phosphorylation Enrichment and Subsequent Analysis by MALDI-TOF/TOF MS/MS 
and LC-ESI-IT-MS/MS. 






NOTE:  This publication is included in the print copy of the thesis 
held in the University of Adelaide Library. 
 
It is also available online to authorised users at: 
 
http://dx.doi.org/10.1002/0471140864.ps1311s62 
 